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Figure 1
ATGGGTTTCCGGCCAGTTAGCCAACGTTTGCGTGACATCAACCTGCAGGCCCTCGGC
AAGTTTTCCTGCCTTGCCCTGGTCCTCGGCCTGGAATCGGTAAGCCATCCGGCCGGC
CCGGTCCAGGCCCCCTCGTTCAGCCAGGGCACCGCCAGCCCGTCCTTCGCTACTCCG
CTCGGCCTCGACGGCCCGGCCCGCGCCAGGGCCGAGATGTGGAACGTCGGCCTGTC
CGGCGCCGTCAGCGTGCGTGACGAGTTGCGCTGGGTGTTTTGA
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Figure 2
MGFRPVSQRLRDINLQALGKFSCLALVLGLES V SHPAGPVQAPSFSQGTASPSFATPLGL
DGPARARAEMWNVGLSGAV SVRDELRWVF
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Figure 3
ATGGGGAACCTGCTCAGGAAAGGCCAGGTCGCGCTTGTCAGAATATTCAGCGGCGA
TGATCCGGTGCGTCTTCTCAGTTTGATGCTGGCGGCTTATCTGGGAATCAGTGCCTGT
ACCGTGCCAGCGTCCACAGCGGGCTGCTGTCAGCCCTCCGGCATAGGGCAATACCC
GGCGTCTGCCCTGCCCGCTGGCAGTGACTCCAACCTGACCCTGGACGCCGAGCCCGT
GATCGGTCGGACAGCGCTACCCACGAACCTGCAGCCACCGGCCCCGCGCTGGGTGT
TCTAG
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Figure 4
MGNLLRKGQ VALVRIFSGDDPVRLLSLMLAAYLGISACTVPAS TAGCCQPSGIGQYPAS
ALPAGSDSNLTLDAEPVIGRTALPTNLQPPAPRWVF
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METHODS OF DETECTING AND
CONTROLLING MUCOID PSEUDOMONAS
BIOFILM PRODUCTION
CROSS REFERENCE TO RELATED
APPLICATIONS
This application claims the benefit of the filing date of U.S.
Provisional Patent Application No. 60/787,497, filed Mar. 31,
2006, which is incorporated herein by reference in its entirety.
STATEMENT REGARDING
FEDERALLY-SPONSORED RESEARCH AND
DEVELOPMENT
Statement under MPEP 310. The U.S. government has a
paid-up license in this invention and the right in limited cir-
cumstances to require the patent owner to license others on
reasonable terms as provided for by the terms of
NNA04CC74G awarded by the National Aeronautics and
Space Administration (NASA).
Part of the work performed during development of this
invention utilized U.S. Government funds. The U.S. Govern-
ment has certain rights in this invention.
REFERENCE TO SEQUENCE LISTING
SUBMITTED ELECTRONICALLY
The content of the electronically submitted sequence list-
ing, file name: SegList.txt; Size: 69,132 bytes; and Date of
Creation: Jun. 8, 2009, filed herewith, is incorporated herein
by reference in its entirety.
NAMES OF THE PARTIES TO A JOINT
RESEARCH AGREEMENT
Not Applicable.
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to the identification and use
of positive regulators of alginate production in Pseudomonas
aeruginosa. One aspect of the invention provides composi-
tions and methods for the early detection and diagnosis of the
conversion to mucoidy of Pseudomonas aeruginosa. The
present invention also provides a molecular mechanism for
detecting the conversion from the nonmucoid to the mucoid
state, including molecular probes for the early detection of
this disease state.
2. Background Art
Cystic Fibrosis (CF) is the most common inheritable lethal
disease among Caucasians. The leading cause of high mor-
bidity and mortality in CF patients are the chronic respiratory
infections caused by Pseudomonas aeruginosa. Pseudomo-
nas aeruginosa is an aerobic, motile, gram-negative bacte-
rium with a simple metabolic demand that allows it to thrive
in diverse environments. P. aeruginosa normally inhabits
soil, water, and vegetation. Although it seldom causes disease
in healthy people, P. aeruginosa is an opportunistic pathogen
associated with fatal pneumonia in patients with CF, as well
as patients with compromised immune systems and chronic
infections such as non-cystic fibrosis bronchiectasis and uri-
nary tract infections.
In CF patients, the initially colonizing P. aeruginosa
strains are nonmucoid but in the CF lung, after a variable
period, often one or two years, they inevitably convert into the
2
mucoid form. Mucoid strains of P. aeruginosa grow as bio-
films in the airways of CF patients (Yu, H., and N. E. Head,
Front Biosci. 7:D442-57 (2002)). Biofilms refer to surface-
attached bacterial communities encased in a glycocalyx
5 matrix (Costerton, J. W., et al., Science 284:1318-22 (1999)).
Mucoid P. aeruginosa biofilms are microcolonies embedded
in a capsule composed of copious amounts of alginate, an
exopolysaccharide (Govan, J. R., and V. Deretic, Microbiol.
Rev. 60:539-74 (1996)) and are resistant to host defenses
io (Ramsey, D. M., and D. J. Wozniak, Mol. Microbiol. 56:309-
22 (2005)).
The emergence of mucoid strains of P. aeruginosa in CF
lungs signals the beginning of the chronic phase of infection
and is associated with further disease deterioration and poor
15 prognosis (Lyczak, J. B., et al., Clin. Microbiol. Rev. 15:194-
222 (2002)). The chronic phase of infection due to P. aerugi-
nosa is characterized by pulmonary exacerbations (fever,
elevated white blood cell count, increased sputum produc-
tion, and decreased pulmonary function) that require antimi-
20 crobial therapy (Miller, M. B., and Gilligan, P. H., J. Clin.
Microbiol. 41:4009-4015 (2003)). CF exacerbations are typi-
cally interspersed with intervening periods of relative quies-
cence, with each phase lasting various lengths of time (Miller,
M. B., and Gilligan, P. H., J. Clin. Microbiol. 41:4009-4015
25 (2003)). However, lung function continuously declines, the
infecting strains become increasingly resistant, and inevita-
bly, the patient succumbs to cardiopulmonary failure (Miller,
M. B., and Gilligan, P. H., J. Clin. Microbiol. 41:4009-4015
(2003)).
30 There is a growing consensus that the lung pathology that
occurs during chronic P. aeruginosa infection is due to a large
extent to the immune response directed against pseudomonal
biofilms (Miller, M. B., and Gilligan, P. H., J. Clin. Microbiol.
41:4009-4015 (2003)). High levels of cytokines and leuko-
35 cyte-derived proteases can be detected in airway fluid from
CF patients and are believed to be responsible for much of the
lung damage that occurs in this patient population (Miller, M.
B., and Gilligan, P. H., J. Clin. Microbiol. 41:4009-4015
(2003)). Alginate appears to protect P. aeruginosa from the
40 consequences of this inflammatory response as it scavenges
free radicals released by activated macrophages (Simpson, J.
A., et al., Free Rad. Biol. Med. 6:347-353 (1989)). The algi-
nate mucoid coating also leads to the inability of patients to
clear the infection, even under aggressive antibiotic therapies,
45 most probably because it provides a physical and chemical
barrier to the bacterium (Govan and Deretic, Microbiol. Rev.
60:539-574 (1996)).
Early aggressive antibiotic treatment of the initial coloniz-
ing non-mucoid P. aeruginosa population might prevent or at
50 least delay chronic pulmonary infection. However, questions
still remain as to whether such treatment should be performed
routinely or only during pulmonary exacerbation, and
whether the regimen could potentially lead to the emergence
of resistant strains (Ramsey and Wozniak, Mol. Microbiol.
55 56:309-322 (2005)). Since P. aeruginosa is inherently resis-
tantto many antibiotics at concentrations that canbe achieved
in vivo, with the exception of ciprofloxacin, those to which it
is sensitive need to be given intravenously (Wilson and Dowl-
ing, Thorax 53:213-219 (1998)). However, long-term,
6o aggressive antibiotic treatment is not without side effects.
Therefore, it would be more beneficial to place the emphasis
on aggressive treatment strategies before the in vivo switch to
mucoidy since once chronic infection is established, it is
rarely possible to eradicate it even with intensive, antibiotic
65 therapy. Thus, early detection of conversion to mucoidy in
patients is desired to allow aggressive therapy, thereby pre-
venting further disease deterioration.
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3
Synthesis of alginate and its regulation has been the object
of numerous studies (Govan, J. R., and V. Deretic, Microbiol.
Rev. 60:539-74 (1996); Ramsey, D. M., and D. J. Wozniak,
Mol. Microbiol. 56:309-22 (2005)). Alginate production is
positively and negatively regulated in wild-type cells.
Three tightly linked genes a1gU, mucA, and mucB have
been previously identified with a chromosomal region shown
by genetic means to represent the site where mutations cause
conversion to mucoidy (see U.S. Pat. Nos. 6,426,187, 6,083,
691, 5,591,838, and 5,573,910, incorporated herein by refer-
ence in their entireties).
Positive regulation centers on the activation of the alginate
biosynthetic operon (Govan, J. R., and V. Deretic, Microbiol.
Rev. 60:539-74 (1996)). Positive regulators include the alter-
native stress-related sigma factorAlgU (Martin, D. W., et al.,
Proc. Natl. Acad. Sci. 90:8377-81 (1993)), also called A1gT
(DeVries, C. A., and D. E. Ohman, J. Bacteriol. 176:6677-87
(1994)), and transcriptional activators A1gR andAlgB, which
belong to a bacterial two component signaling system. The
cognate kinase ofA1gB is KinB (Ma, S., et al., J. Biol. Chem.
272:17952-60 (1997)) whileAlgZ (Yu, H., et al., J. Bacteriol.
179:187-93 (1997)) may be the kinase that phosphorylates
A1gR. However, unlike a typical two-component system,
alginate overproduction is independent of phosphorylation of
A1gR or A1gB (Ma, S., et al., J. Bacteriol. 180:956-68
(1998)).
Negative regulation of alginate has focused on the post-
translational control of A1gU activity. In alginate regulation,
the master regulator is A1gU and the signal transducer is
MucA, a trans-inner membrane protein whose amino termi-
nus interacts with A1gU to antagonize the activity of A1gU,
and the carboxyl terminus with MucB, another negative regu-
lator of alginate biosynthesis. The algUmucABC cluster is
conserved among many Gram-negative bacteria. A1gU
belongs to the family of extracytoplasmic function (ECF)
sigma factors that regulate cellular functions in response to
extreme stress stimuli. The action of ECF sigma factors is
negatively controlled by MucA, MucB and MucC. This set of
proteins forms a signal transduction system that senses and
responds to envelope stress.
MucA is the anti-sigma factor that binds A19U and antago-
nizes its transcriptional activator activity (Schurr, M. J., et al.,
J. Bacteriol. 178:4997-5004 (1996)). Consequently, inactiva-
tion of mucA in P. aeruginosa strain PAOI results in the
mucoid phenotype (Alg+) (Martin, D. W., et al., Proc. Natl.
Acad. Sci. USA 90:8377-81 (1993); Mathee, K., et al., Micro-
biology 145:1349-57 (1999)). Clinical mucoid isolates of P.
aeruginosa carry recessive mutations in mucA (Anthony, M.,
et al., J. Clin. Microbiol. 40:2772-8 (2002); Boucher, J. C., et
al., Infect. Immun. 65:3838-46 (1997)). The transition from a
non-mucoid to mucoid variant occurs in concurrence with the
mucA22 allele after exposure to hydrogen peroxide, an oxi-
dant in neutrophils (Mathee, K., et al., Microbiology 145:
1349-57 (1999)).
MucB is located in the periplasm in association with the
periplasmic portion of MucA (Mathee, K., et al., J. Bacteriol.
179:3711-20 (1997); Rowen, D. W., and V. Deretic, Mol.
Microbiol. 36:314-27 (2000)). MucC is a mild negative regu-
lator whose action is in synergy with MucA or MucB
(Boucher, J. C., et al., Microbiology 143:3473-80 (1997)).
MucD is a negative regulator whose dual functions include
periplasmic serine protease and chaperone activities that are
thought to help remove misfolded proteins of the cell enve-
lope for quality control (Boucher, J. C., et al., J. Bacteriol
178:511-23 (1996); Yorgey, P., et al., Mol. Microbiol.
41:1063-76 (2001)).
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Overproduction of alginate is an important virulence factor
for bacterial biofilm formation in vivo. Alginate protects the
bacterium from oxidative stress by scavenging the reactive
oxygen species (Learn, D. B., et al., Infect. Immun. 55:1813-8
5 (1987); Simpson, J. A., et al., Free Radic. Biol. Med. 6:347-53
(1989)).
There is a significant and urgent need in hospitals and
clinical laboratories for a rapid, sensitive and accurate diag-
nostic test for detection of potential conversion to mucoidy of
io P. aeruginosa prior to the detection of the emergence of a
mucoid colony morphology on a growth plate in a laboratory.
BRIEF SUMMARY OF THE INVENTION
15 The present invention describes the identification and use
of mucE, a positive regulator of alginate production in P.
aeruginosa. Induction of mucE causes mucoid conversion in
P. aeruginosa.
One object of this invention is to provide compositions for
20 the early detection and diagnosis of the conversion to
mucoidy of Pseudomonas aeruginosa. The present invention
also provides molecular probes to detect the conversion from
the nonmucoid to the mucoid state, via Northern blot, RT-
PCR, or real-time RT-PCR, including diagnostic kits for the
25 early detection of this disease state.
Another object of this invention is to provide methods for
the early detection and diagnosis of the conversion to
mucoidy of Pseudomonas aeruginosa. One method for
detecting a cell converted to mucoidy involves obtaining a
30 cell sample suspected of conversion to mucoidy, contacting
messenger RNA from the cell sample with a mucE nucleic
acid segment, and detecting the presence of increased hybrid-
ized complexes, wherein the presence of increased hybrid-
ized complexes is indicative of conversion to mucoidy. A six
35 fold increase of mucE messenger RNA is sufficient to cause
conversion to mucoidy in mucA+ wild type cells. Thus, early
detection of conversion to mucoidy is possible by detecting
and measuring mucE expression as compared to the baseline
expression level of mucE in non-mucoid cells.
40 Early detection for the trend of increased expression of the
mucE message in various samples, including the sputum
samples from patients with cystic fibrosis, samples from
patients carrying endotracheal tubes, and urinary tract cath-
eters would provide an indication that the colonizing bacteria
45 has started to enter the biofilm mode of growth, thereby
requiring immediate administration of aggressive antibiotic
therapy.
A further embodiment of thi s invention are the use of MucE
antibodies and methods of using MucE antibodies for detect-
50 ing the conversion to mucoidy of P. aeruginosa.
A further embodiment of this invention is a method for
preventing the conversion to mucoidy of P. aeruginosa by
blocking mucE expression or MucE activity. Mucoid P.
aeruginosa biofilms can be formed via two means: the muta-
55 tions in mucA (see U.S. Pat. Nos. 6,426,187, 6,083,691, and
5,591,838), and increased expression of mucE. mucE acts
upstream of mucA, thus, the control of mucoidy mediated by
mucE occurs before the mucA mutation. Therefore, inhibi-
tion of MucE activity provides a means to prevent conversion
60 to mucoidy during the early stage of bacterial colonization.
In still further embodiments, the present invention con-
cerns a method for identifying new compounds that inhibit
mucE gene expression or MucE function, which may be
termed "candidate substances." Such compounds may
65 include anti-sense oligonucleotides or molecules that block
or repress the mucE promoter, or molecules that directly bind
to MucE to block the activity of MucE.
US 7,781,166 B2
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The present invention also provides for a method for
screening a candidate substance for preventing P. aeruginosa
conversion to mucoidy comprising contacting E. coli bacteria
with an effective amount of a candidate substance; and assay-
ing for reporter gene activity, wherein a decrease in the
expression of the reporter gene indicates inhibition of mucE
promoter activity.
Another object of the present invention is A1gW, a positive
regulator for alginate production, and the use of A1gW as a
potential drug target.
BRIEF DESCRIPTION OF THE
DRAWINGS/FIGURES
The following drawings form part of the present specifica-
tion and are included to further demonstrate certain aspects of
the present invention. The invention may be better understood
by reference to one or more of these drawings in combination
with the detailed description of specific embodiments pre-
sented herein.
FIG.1 shows the nucleotide sequence of mucE in P. aerugi-
nosa (SEQ ID NO: 1). The mucE gene is an unclassified ORE
(PA4033) in the genomes of PAOI and PA14. It encodes a
small peptide of 89 amino acids with a molecular mass of 9.5
kDa.
FIG. 2 shows the amino acid sequence of MucE in P.
aeruginosa (SEQ ID NO:2). MucE has a predicted N-tenni-
nal leader peptide of 36 amino acids, which is likely to direct
the native peptide of MucE to the inner membrane for pro-
cessing and export to the periplasm or outer membrane of P.
aeruginosa. The WVF at the C-terminus is the signal for
alginate induction.
FIG. 3 shows the nucleotide sequence of the homolog of
mucE in P. fluorescence Pf-5 (SEQ ID NO:3).
FIG. 4 shows the amino acid sequence of the homolog of
MucE in P. fluorescence Pf-5 (SEQ ID NO:4).
FIG. 5 shows the number of mariner transposon insertions
per TA site in the algU promoter region of four strains of P.
aeruginosa. FIG. 5A shows the frequency of the insertions in
each P. aeruginosa strain. FIG. 5B shows the sequence of the
a1gU promoter region (SEQ ID NO: 16) containing all TA
sites with an assigned number matching to FIG. 5A.
FIG. 6 shows the levels of alginate, A1gU and MucB in P.
aeruginosa mucoid mutants caused by induction of algUmu-
cABC in comparison with the wild type PAOI (B). FIG. 6A
shows the amounts of alginate (µg alginate/mg protein) that
were measured for 4-72 h. Asterisk indicates significant dif-
ferences at P<0.05 in comparison with the same time point in
PAOl . FIG. 6B is a Western blot analysis of the total protein
extracts from the same cells as above were probed by anti-
A1gU (Schurr, M. 7., et al., J. Bacteriol. 178:4997-5004
(1996)) and anti-MucB (Boucher, J. C., et al., J. Bacteriol.
178:511-23 (1996)) monoclonal antibodies. The genotype of
each mutant is shown. The number below each blot was the
ratio of internally normalized protein relative to the level of
PAOI at the same timepoint. The +oe superscriptused in FIG.
6A refers to the overexpression of the algU mucABC operon.
FIG. 7 shows the levels of alginate, the expression ofA1gU
and MucB in VE2 (PAOI mucE +Oe) as detected by Western
blots (FIG. 7A) and RT-PCR (FIG. 713). Bacterial cells were
grown under the same conditions as described in Methods,
and were subjected to the same treatments as in FIG. 6.
Asterisk in alginate production indicates significant differ-
ences compared with PAOI at the same time point as in FIG.
6. The ratio of internally normalizedAlgU and MucB to those
of PAOI is shown. in FIG. 7B indicates the RT minus
controls.
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FIG. 8 shows upregulation ofAlgU in VE13 (PAOI kinB-)
(FIG. 8A) in association with increased alginate production.
FIG. 813: Western blots showing the levels of A1gU and MucB
in various mutants after 24 h growth. FRD2 carries the a1gT18
5 suppressor mutant while FRD2-VEI is like VEl with the
insertion in the algU promoter. VE3-NMI to -NM4 are the
spontaneous nonmucoid mutants with suppressors inactivat-
ing a1gU. VE3NM3+algU: pUCP20—algU in trans. VE22:
cupB5 +Oe and VE24: oprL+ but with reduced expression of
10 oprL due to production of the antisense RNA.
FIG. 9 shows the regulatory cascade of alginate production
in P. aeruginosa. A1gU is the alginate-specific sigma factor,
whose activity is antagonized by anti-sigma factor, MucA.
MucA is an inner membrane protein with its C-terminus in the
15 periplasm, and its N-terminus interacting with A1gU in cyto-
plasm. The alginate operon consists of 12 genes encoding
biosynthetic enzymes, thus collectively termed "alginate
engine." The enzymes A1gI, A1g7, and A1gF are involved in
O-acetylation of alginate. A1gK is needed for formation of the
20 alginate polymer and A1gE for the export of alginate across
the membrane.
FIG. 10 is a map of the expression vector pUCP20-Gm-
mucE. The expression vector contains the coding region of
25 the mucE gene driven by a promoter derived from the gen-
tamicin (Gm) cassette of pFAC. This promoter is highly
expressive in P. aeruginosa. This construct can render the
nonmucoid PAOI mucoid while the control backbone vector
without mucE has no effect on the phenotype.
30 FIG. 11 shows an alignment of the mucE homologs iden-
tified from the completed andpartially completed genomes of
three species within the genus of Pseudomonas. The three
species are PA: Pseudomonas aeruginosa; PF: Pseudomonas
fluorescens; and PS: Pseudomonas syringae. The strains
35 shown are: PA-PAOI (SEQ ID NO: 23), Pseudomonas
aeruginosa PAOI (causes opportunistic infections in
humans); PA-PA14 (SEQ ID NO: 22), Pseudomonas aerugi-
nosa UCBPP PA14 (human clinical isolate); PA-2192 (SEQ
ID NO: 20), Pseudomonas aeruginosa 2192 (CF patient iso-
40 late); PA-C3719 (SEQ ID NO: 21), Pseudomonas aeruginosa
C3719 (unknown source but probably clinical origin); PS-
PPH (SEQ ID NO: 26), Pseudomonas syringae pv. phaseoli-
cola 1448A (causes halo blight on beans); PS-PTO (SEQ ID
NO: 27), Pseudomonas syringae pv. tomato DC3000 (bacte-
45 rial speck disease on tomato plants); PS-SB728 (SEQ ID NO:
28), Pseudomonas syringae pv. syringae B728a (brown spot
disease on beans); PF PF5 (SEQ ID NO: 24), Pseudomonas
fluorescens Pf-5 (Saprophyte) (the production of a number of
antibiotics as well as the production of siderophores by this
50 strain can inhibit phytopathogen growth); and PF-PFOI
(SEQ ID NO: 25), Pseudomonas fluorescens PfO-1 (micro-
organism of putrefaction and well adapted to soil environ-
ments).
FIG. 12 shows an alignment of the algW homologs iden-
55 tified from the completed and partially completed genomes of
three species within the genus of Pseudomonas. The three
species are PA: Pseudomonas aeruginosa; PF: Pseudomonas
fluorescens; and PS: Pseudomonas syringae. All these spe-
cies have the capacity to overproduce alginate. The strains
60 shown are the same as for FIG. 11, and include A1gW
homologs for PA-2192 (SEQ ID NO: 29), PA-C3719 (SEQ
ID NO: 30), PA-PA14 (SEQ ID NO: 31), PA-PAOI (SEQ ID
NO: 32), PF-PF5 (SEQ ID NO: 33), PF-PFOI (SEQ ID NO:
34), PS PPH (SEQ ID NO: 35), PS-PTO (SEQ ID NO: 36),
65 and PS-SB728 (SEQ ID NO: 37). The predicted functional
domains of A1gW include an N-terminal signal peptide
sequence at amino acids 1-27, a trypsin domain (peptidase
US 7,781,166 B2
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activity, serine at A1gW 227 is conserved) at amino acids 	 state, including via Northern blot, RT-PCR, or real-time RT-
114-260, and a PDZ domain at amino acids 270-380. 	 PCR, including diagnostic kits for the early detection of this
FIG. 13 shows the detection of N-terminal His-tag labeled 	 disease state.
MucE protein via Western Blot with anti-penta-his mono- 	 The present invention is also directed to algW and the use
clonal antibody and SDS-PAGE with Coomassie blue. 	 5 of A1gW as a potential drug target. Contrary to previous
FIG. 14 shows the sequence of mucE (SEQ ID NO: 2; 	 findings, A1gW is a positive regulator for alginate production.
amino acid sequence of mucE) and the phenotypes of the 	 The algW gene and A1gW protein, the algW homologs, and
different translational mucE-phoA fusions (SEQ ID NO: 17;	 the uses thereof as described above for the P. aeruginosa
nucleic acid sequence of the full-length mucE-phoA fusion). 	 mucE gene and MucE protein are also part of the present
The location of the mariner transposon bearing the aacCI io invention.
gene conferring Gm" in the chromosome of the mucoid 	 Another object of this invention are mucA mucoid mutants
mutants PAOI VE2 and PA14DR4 is shown. Different lengths 	 and the use of these mutants to screen for suppressors and
of mucE sequences were fused with phoA without the leader	 potential toxin genes. Mucoid mutants with mucA mutations
signal peptide sequence to demonstrate the effect of the signal
	 (see U.S. Pat. Nos. 6,426,187, 6,083,691, and 5,591,838)
sequence on translocation across the inner membrane to the 15 have been previously detected from clinical specimens. The
periplasm. 1. Negative control, no 5' leader peptide sequence	 presence of these mutations is a poor prognosticator and
(no sig phoA); 2. Positive control, the wild-type E. coli phoA	 represents the onset of chronic infection. Since the elevation
leader sequence restored in the construct by directly fusing it 	 of mucE can cause the emergence of mucoid P. aeruginosa
with phoA (Ec wt-phoA); 3. Full-length mucE-phoA; 4. 	 before mucA mutations occur, the involvement of mucE in
mucE with the predicted N-terminal leader sequence fused 20 alginate induction is upstream of mucA.
with phoA; 5. partial mucE N-terminal leader sequence fused	 Another object of this invention is to provide methods for
with phoA; 6. C-terminal mucE with ATG fused with phoA. 	 the early detection and diagnosis of the conversion to
The exact phoA fusion sites are as indicated in the mucE 	 mucoidy of Pseudomonas aeruginosa. One method for
sequence. The leader sequence of mucE with max cleavage	 detecting a cell converted to mucoidy involves obtaining a
site is between pos. 36 (P) and 37 (A) (box). 	 25 biological specimen suspected of conversion to mucoidy,
FIG. 15 shows an alignment of MucP (SEQ ID NO: 19) and	 contacting messenger RNA from the specimen with a mucE
the Escherichia coli orthologue RseP (SEQ ID NO: 18). 	 nucleic acid segment, and detecting the presence of increased
Identical amino acids are marked by an asterisk (*). The two	 hybridized complexes, wherein the presence of increased
terminal protease domains are shown in light gray and the two 	 hybridized complexes over baseline is indicative of conver-
PDZ domains are shown in medium gray. The overlapping 30 sion to mucoidy.
region containing both a portion of the protease domain and a 	 The biological specimen to be assayed for the presence of
portion of the PDZ domain is shown in dark gray. 	 mucoid P. aeruginosa can be prepared in a variety of ways,
depending on the source of the specimen. The specimen may
DETAILED DESCRIPTION OF THE INVENTION	 be obtained from the following: patients with debilitated
35 immune systems, sputum samples from patients with pneu-
Infections due to P. aeruginosa are recognized by the medi-	 monia, endotracheal samples from incubating patients under
cal community as particularly difficult to treat. In particular, 	 intensive care, samples from urinary catheters, samples from
the emergence of a mucoid phenotype of P. aeruginosa in CF	 wounds, and especially from patients suffering from cystic
lungs is associated with further disease deterioration and poor 	 fibrosis. Specimens may be a sample of human blood, spu-
prognosis. A patient's prognosis for recovery from an infec- 40 turn, wound exudate, endotracheal samples, respiratory
tion caused by mucoid P. aeruginosa is enhanced when the	 secretions, human tissues (e.g., lung) or a laboratory culture
diagnosis is made and appropriate treatment initiated as early	 thereof, and urine. Since alginate induction is synonymous
in the course of infection as possible before the number of 	 with biofilm formation in vivo, the increased expression of
bacteria in the host becomes overwhelming and much more 	 mucE may also be used to monitor the biofilm formation in a
difficult to bring under control. Thus, early detection of P. 45 confined environment during space travel (astronauts).
aeruginosa conversion to mucoidy in patients is particularly 	 A further embodiment of this invention is the use of MucE
desired to allow aggressive therapy, thereby preventing fur- 	 antibodies and methods of using MucE antibodies for detect-
ther disease deterioration.	 ing the conversion to mucoidy of P. aeruginosa via ELISA or
The present application describes the identification of a 	 other immunoassays.
positive regulator involved in alginate and biofilm production 50	 A further embodiment of this invention is a method for
in P. aeruginosa, termed mucE (SEQ ID NOs:1-2) (GenBank 	 preventing the conversion to mucoidy of P. aeruginosa. In
accession numbers DQ352561 (PAOI mucE) and DQ352562 	 particular, the present invention concerns methods for iden-
(PA14 mucE)). Induction of mucE causes mucoid conversion 	 tifying new compounds that inhibit mucE gene expression or
in P. aeruginosa.	 MucE function, which may be termed "candidate sub-
One object of this invention is to provide compositions for 55 stances." Such compounds may include anti-sense oligo-
the early detection and diagnosis of the conversion to 	 nucleotides or molecules that block or repress the mucE pro-
mucoidy of Pseudomonas aeruginosa in biological speci- 	 moter.
mens. By "early detection" is meant detecting P. aeruginosa	 Specifically, when the last three amino acids of MucE are
conversion to mucoidy using certain assay methods, includ- 	 changed from WVF to other combinations, the majority of
ing but not limited to, methods involving the use of a nucleic 6o altered signals are ineffective to induce mucoid biofilm pro-
acid probe or antibodies, 1 to 14 days, specifically 1 to 10	 duction, indicating the specificity of this signal in mucoid
days, more specifically 1 to 7 days, and most specifically 6 	 conversion. Thus, WVF is an important signal for mucoid
days, 5 days, 4 days, 3 days, 2 days, 24 hours, 18 hours, 12 	 biofilm formation in P. aeruginosa. This WVF signal plays a
hours or 8 hours before detecting the emergence of a mucoid 	 role in the bacterium's ability to overproduce alginate and
colony morphology on a growth plate in a laboratory. 	 65 enter a biofilm mode of growth via regulated proteolysis as
The present invention also provides molecular probes to 	 depicted in FIG. 9. The present invention provides for meth-
detect the conversion from the nonmucoid to the mucoid	 ods to employ the signal as a drug target. Diagnostic kits to
US 7,781,166 B2
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screen for the presence of the signal in patients with chronic 	 and recovery of the sequence and its component nucleotide
P. aeruginosa infections are contemplated. In addition, meth- 	 sequences by standard biochemical methods, for example,
ods to screen for compounds that inhibit the function of this 	 using a cloning vector. Such sequences are preferably pro-
signal are also contemplated. Such compounds will have a 	 vided in the form of an open reading frame uninterrupted by
specific anti-biofilm function. 	 5 internal nontranslated sequences. Genomic DNA containing
The present invention also provides for a method for 	 the relevant sequences could also be used. Sequences of non-
screening a candidate substance for preventing P. aeruginosa	 translated DNA may be present 5' or 3' from the open reading
conversion to mucoidy comprising contacting E. coli bacteria	 frame, where the same do not interfere with manipulation or
with an effective amount of a candidate substance; and assay-	 expression of the coding regions.
ing for reporter gene activity, wherein a decrease in the io 	 The term "nucleotide sequence" refers to a heteropolymer
expression of the reporter gene indicates inhibition of mucE	 of deoxyribonucleotides. DNA sequences encoding the pro-
promoter activity.	 teins of this invention can be assembled from fragments and
MucE homologs from other Pseudomonas species or	 short oligonucleotide linkers, or from a series of oligonucle-
strains are also contemplated (see FIG. 11). ThesePseudomo- 	otides, to provide a synthetic gene which is capable of being
nas species and strains include PA-PAOI, Pseudomonas 15 expressed in a recombinant transcriptional unit.
aeruginosa PAOI (causes opportunistic infections in	 The term "recombinant expression vector" refers to a rep-
humans); PA-PA14, Pseudomonas aeruginosa UCBPP PA14	 licable DNA construct used either to amplify or to express
(human clinical isolate); PA-2192, Pseudomonas aeruginosa	 DNA which encodes the recombinant proteins of the present
2192 (CF patient isolate); PA-C3719, Pseudomonas aerugi- 	invention and which includes a transcriptional unit compris-
nosa C3719 (unknown source but probably clinical origin); 20 ing an assembly of (1) a genetic element or elements having
PS-PPH, Pseudomonas syringae pv. phaseolicola 1448A	 a regulatory role in gene expression, for example, promoters
(causes halo blight on beans); PS-PTO, Pseudomonas syrin- 	or enhancers, (2) a structure or coding sequence which is
gae pv. tomato DC3000 (bacterial speck disease on tomato 	 transcribed into mRNA and translated into protein, and (3)
plants); PS-SB728, Pseudomonas syringae pv. syringae	 appropriate transcription and translation initiation and termi-
B728a (brown spot disease onbeans); PF-PF5, Pseudomonas 25 nation sequences. Structural elements intended for use in
fluorescens Pf-5 (Saprophyte) (the production of a number of 	 yeast expression systems preferably include a leader
antibiotics as well as the production of siderophores by this	 sequence enabling extracellular secretion of translated pro-
strain can inhibit phytopathogen growth); and PF-PFOI, 	 tein by a host cell. Alternatively, where recombinant protein is
Pseudomonas fluorescens PfO-1 (microorganism of putre-	 expressed without a leader or transport sequence, it may
faction and well adapted to soil environments). The mucE 30 include an N-terminal methionine residue. This residue may
homologs and the use thereof as described above for the P. 	 optionally by subsequently cleaved from the expressed
aeruginosa mucE gene and MucE protein are also part of the 	 recombinant protein to provide a final product.
present invention.	 As used herein, the term "expression vector" refers to a
Isolated polynucleotides comprising fragments containing 	 construct made up of genetic material (i.e., nucleic acids).
one or more mucE consensus regions are also contemplated. 35 Typically, a expression vector contains an origin of replica-
The consensus regions are shown in FIG. 11. 	 tion which is functional in bacterial host cells, e.g., Escheri-
By "isolated" polynucleotide is intended a nucleic acid 	 chia coli, and selectable markers for detecting bacterial host
molecule, DNA or RNA, circular or linear, which has been	 cells comprising the expression vector. Expression vectors of
removed from its native environment. For example, recom- 	 the present invention contain a promoter sequence and
binant DNA molecules contained in a vector are considered 40 include genetic elements as described herein arranged such
isolated for the purposes of the present invention. Further 	 that an inserted coding sequence can be transcribed and trans-
examples of isolated DNA molecules include recombinant	 lated in prokaryotes or eukaroytes. In certain embodiments
DNA molecules maintained in heterologous host cells or	 described herein, an expression vector is a closed circular
purified (partially or substantially) DNA molecules in solu- 	 DNA molecule.
tion.	 45	 The term "expression" refers to the biological production
The term "positive regulator" as used herein, means that 	 of a product encoded by a coding sequence. In most cases, a
the induction of expression and/or activity of such a gene	 DNA sequence, including the coding sequence, is transcribed
encoding a functional protein causes alginate overproduction. 	 to form a messenger-RNA (mRNA). The messenger-RNA is
Examples of positive regulators include a1gU, mucE, and 	 then translated to form a polypeptide product which has a
algW.	 5o relevant biological activity. Also, the process of expression
The term "negative regulator" as used herein, means that 	 may involve further processing steps to the RNA product of
the absence of such a gene encoding a functional protein 	 transcription, such as splicing to remove introns, and/or post-
causes alginate overproduction. Examples of negative regu- 	 translational processing of a polypeptide product.
lators include kinB, mucA, mucB, and mucD.	 The term "recombinant microbial expression system"
The term "recombinant," as used herein, means that a pro-  55 means a substantially homogeneous monoculture of suitable
tein is derived from recombinant (e.g., microbial) expression	 host microorganisms, for example, bacteria such as E. coli or
systems. The term "microbial" refers to recombinant proteins 	 yeast such as S. cerevisiae, which have stably integrated a
made in bacterial or fungal. (e.g., yeast) expression systems. 	 recombinant transcriptional unit into chromosomal DNA or
As a product, the term "recombinant microbial" defines a	 carry the recombinant transcriptional unit as a component of
protein produced in a microbial expression system which is 6o a resident plasmid. Generally, cells constituting the system
essentially free of native endogenous substances. Protein 	 are the progeny of a single ancestral transformant. Recombi-
expressed in most bacterial cultures, e.g., E. coli, will be free	 nant expression systems as defined herein will express heter-
of glycan.	 ologous protein upon induction of the regulatory elements
The term "DNA sequence" refers to a DNA polymer, in the 	 linked to the DNA sequence or synthetic gene to be
form of a separate fragment or as a component of a larger 65 expressed.
DNA construct. Preferably, the DNA sequences are in a quan- 	 One embodiment of the present invention is a method of
tity or concentration enabling identification, manipulation, 	 detecting conversion to mucoidy in Pseudomonas aerugi-
US 7,781,166 B2
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nosa in a biological specimen comprising detecting MucE
expression. A preferred embodiment is a method of detecting
conversion to mucoidy in Pseudomonas aeruginosa having
an active mucE gene product comprising the detection of the
mucE messenger RNA in a sample suspected of conversion to
mucoidy. In this case, the sequence encodes an active gene
product and the sequence is detected by hybridization with a
complementary oligonucleotide, to form hybridized com-
plexes. The presence of increased hybridized complexes is
indicative of conversion to mucoidy in Pseudomonas aerugi-
nosa. The complementary oligonucleotides may be
5'-TCAAAACACCCAGCGCAACTCGTCACG-3', (SEQ
ID NO:5) 5'-AGTAGCGAAGGACGGGCTGGCGGT-3',
(SEQ ID NO:6) or 5'-TTGGCTAACTGGCCGGAAAC-
CCAT-3' (SEQID NO:7).
A further embodiment of the present invention is the use of
MucE antibodies and methods of using MucE antibodies for
detecting the conversion to mucoidy of P. aeruginosa or for
inhibiting MucE function.
In still further embodiments, the present invention con-
cerns a method for identifying new compounds that inhibit
transcription from the mucE promoter, which may be termed
as "candidate substances." Such compounds may include
anti-sense oligonucleotides or molecules that encourage
repression of the mucE promoter. The present invention pro-
vides for a method for screening a candidate substance for
preventing P. aeruginosa conversion to mucoidy comprising:
contacting E. coli bacteria with an effective amount of a
candidate substance; and assaying for reporter gene activity,
wherein a decrease in the expression of the reporter gene
indicates inhibition of MucE promoter activity.
In additional embodiments, the present invention also con-
cerns a method for detecting mucoid Pseudomonas aerugi-
nosa bacterium in a biological sample. The method comprises
reacting a sample suspected of containing P. aeruginosa with
a detergent, EDTA, and a monoclonal antibody or fragment
thereof capable of specifically binding to MucE expressed by
P. aeruginosa, separating the sample from unbound mono-
clonal antibody; and detecting the presence or absence of
immune complexes formed between the monoclonal anti-
body and MucE.
Polynucleotides
The DNA sequences disclosed herein will also find utility
as probes or primers in nucleic acid hybridization embodi-
ments. Nucleotide sequences of between about 10 nucle-
otides to about 20 or to about 30 nucleotides, complementary
to SEQ ID NOs:1-4, will find particular utility, with even
longer sequences, e.g., 40, 50, 100, even up to full length,
being more preferred for certain embodiments. The ability of
such nucleic acid probes to specifically hybridize to mucE-
encoding sequences will enable them to be of use in a variety
of embodiments. For example, the probes can be used in a
variety of assays for detecting the presence of complementary
sequences in a given sample. However, other uses are envi-
sioned, including the use of the sequence information for the
preparation of mutant species primers, or primers for use in
preparing other genetic constructions.
Nucleic acid molecules having stretches of 10, 15, 20, 30,
50, or even of 100 nucleotides or so, complementary to SEQ
ID NOs:l and 3, will have utility as hybridization probes.
These probes will be useful in a variety of hybridization
embodiments, such as Southern and Northern blotting in
connection with analyzing the complex interaction of struc-
tural and regulatory genes in diverse microorganisms and in
clinical isolates from patients, including CF patients. The
total size of fragment, as well as the size of the complemen-
tary stretch(es), will ultimately depend on the intended use or
application of the particular nucleic acid segment. Smaller
fragments will generally find use in hybridization embodi-
ments, wherein the length of the complementary region may
5 be varied, such as between about 10 and about 100 nucle-
otides, according to the complementary sequences one
wishes to detect.
The use of a hybridization probe of about 10 nucleotides in
length allows the formation of a duplex molecule that is both
io stable and selective. Molecules having complementary
sequences over stretches greater than 10 bases in length are
generally preferred, though, in order to increase stability and
selectivity of the hybrid, and thereby improve the quality and
degree of specific hybrid molecules obtained. One will gen-
ie erally prefer to design nucleic acid molecules having gene-
complementary stretches of 15 to 20 nucleotides, or even
longer where desired. Such fragments may be readily pre-
pared by, for example, directly synthesizing the fragment by
chemical means, by application of nucleic acid reproduction
20 technology, such as the Polymerase Chain Reaction (PCR)
technology of U.S. Pat. No. 4,603,102 (herein incorporated
by reference) or by introducing selected sequences into
recombinant vectors for recombinant production.
Accordingly, the nucleotide sequences of the invention
25 may be used for their ability to selectively form duplex mol-
ecules with complementary stretches of homologous, or het-
erologous genes or cDNAs. Depending on the application
envisioned, one will desire to employ varying conditions of
hybridization to achieve varying degrees of selectivity of
30 probe towards target sequence. For applications requiring
high selectivity, one will typically desire to employ relatively
stringent conditions to form the hybrids, e.g., one will select
relatively low salt and/or high temperature conditions, such as
provided by 0.02 M-0.15 M NaCl at temperatures of 50° C. to
35 70° C. Such selective conditions tolerate little, if any, mis-
match between the probe and the template or target strand,
and would be particularly suitable for isolating functionally
related genes.
In certain instances, for example, where one desires to
40 prepare mutants employing a mutant primer strand hybrid-
ized to an underlying template or where one seeks to isolate
specific mutant mucE-encoding sequences from related spe-
cies, functional equivalents, or the like, less stringent hybrid-
ization conditions will typically be needed in order to allow
45 formation of the heteroduplex. In these circumstances, one
may desire to employ conditions such as 0.15 M-0.9 M salt, at
temperatures ranging from 20'C. to 55° C. Cross-hybridizing
species can thereby be readily identified as positively hybrid-
izing signals with respect to control hybridizations. In any
50 case, it is generally appreciated that conditions can be ren-
dered more stringent by the addition of increasing amounts of
formamide, which serves to destabilize the hybrid duplex in
the same manner as increased temperature. Thus, hybridiza-
tion conditions can be readily manipulated, and thus will
55 generally be a method of choice depending on the desired
results.
In certain embodiments, it will be advantageous to employ
nucleic acid sequences of the present invention in combina-
tion with an appropriate means, such as a label, for determin-
60 ing hybridization. A wide variety of appropriate indicator
means are known in the art, including fluorescent, radioac-
tive, enzymatic, biotinylated, and chemiluminescent labels,
which are capable of giving a detectable signal. Fluorophores,
luminescent compounds, radioisotopes and particles can also
65 be employed. In preferred embodiments, one will likely
desire to employ a fluorescent label or an enzyme tag, such as
urease, alkaline phosphatase or peroxidase, instead of radio-
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active or other environmental undesirable reagents. In the
case of enzyme tags, calorimetric indicator substrates are
known which can be employed to provide a means visible to
the human eye or spectrophotometrically, to identify specific
hybridization with complementary nucleic acid-containing
samples.
In general, it is envisioned that the hybridization probes
described herein will be useful both as reagents in solution
hybridization as well as in embodiments employing a solid
phase. In embodiments involving a solid phase, the test DNA
(or RNA) is adsorbed or otherwise affixed to a selected matrix
or surface. This fixed, single-stranded nucleic acid is then
subjectedto specific hybridization with selectedprobes under
desired conditions. The selected conditions will depend on
the particular circumstances based on the particular criteria
required (depending, for example, on the G+C contents, type
of target nucleic acid, source of nucleic acid, size of hybrid-
ization probe, etc.). Following washing of the hybridized
surface so as to remove nonspecifically bound probe mol-
ecules, specific hybridization is detected, or even quantified,
by means of the label.
Longer DNA segments will often find particular utility in
the recombinant production of peptides or proteins. DNA
segments which encode peptide antigens from about 15 to
about 50 amino acids in length, or more preferably, from
about 15 to about 30 amino acids in length are contemplated
to be particularly useful. DNA segments encoding peptides
will generally have a minimum coding length in the order of
about 45 to about 150, or to about 90 nucleotides.
The nucleic acid segments of the present invention, regard-
less of the length of the coding sequence itself, may be com-
bined with other DNA sequences, such as promoters, addi-
tional restriction enzyme sites, multiple cloning sites, other
coding segments, and the like, such that their overall length
may vary considerably. It is contemplated that a nucleic acid
fragment of almost any length may be employed, with the
total length preferably being limited by the ease of prepara-
tion and use in the intended recombinant DNA protocol. For
example, nucleic acid fragments may be prepared in accor-
dance with the present invention which are up to 10,000 base
pairs in length, with segments of 5,000, 3,000, 2,000 or 1,000
base pairs being preferred and segments of about 500 base
pairs in length being particularly preferred.
It will be understood that this invention is not limited to the
particular nucleic acid and amino acid sequences of SEQ ID
NOs:I and 3. Therefore, DNA segments prepared in accor-
dance with the present invention may also encode biologi-
cally functional equivalent proteins or peptides which have
variant amino acids sequences. Such sequences may arise as
a consequence of codon redundancy and functional equiva-
lency which are known to occur naturally within nucleic acid
sequences and the proteins thus encoded. Alternatively, func-
tionally equivalent proteins orpeptides maybe created via the
application of recombinant DNA technology, in which
changes in the protein structure may be engineered, based on
considerations of the properties of the amino acids being
exchanged.
Further embodiments of the invention include vectors
comprising polynucleotides, which comprise a nucleotide
sequence at least 95% identical, and more preferably at least
96%, 97%, 98% or 99% identical, to any of the nucleotide
sequences of the vectors comprising polynucleotides
described above.
Other embodiments of the invention include polynucle-
otides, which comprise a nucleotide sequence at least 95%
identical, and more preferably at least 96%, 97%, 98% or
14
99% identical, to any of the nucleotide sequences of the
polynucleotides described above.
As a practical matter, whether any particular vector or
polynucleotide is at least 95%, 96%, 97%, 98% or 99% iden-
5 tical to a nucleotide sequence according to the present inven-
tion, can be determined conventionally using known com-
puter programs such as the Bestfit program (Wisconsin
Sequence Analysis Package, Version 8 for Unix, Genetics
Computer Group, University Research Park 575 Science
io Drive, Madison, Wis. 53711). Bestfit uses the local homology
algorithm of Smith and Waterman, Advances in Applied
Mathematics 2:482-489 (1981), to find the best segment of
homology between two sequences. When using Bestfit or any
other sequence alignment program to determine whether a
15 particular sequence is, for instance, 95% identical to a refer-
ence sequence according to the present invention, the param-
eters are set, of course, such that the percentage of identity is
calculated over the full length of the reference nucleotide
sequence and that gaps in homology of up to 5% of the total
20 number of nucleotides in the reference sequence are allowed.
Codon Optimization
As used herein, the term "codon optimization" is defined as
modifying a nucleic acid sequence for enhanced expression
25 
in the cells of the vertebrate of interest, e.g., human, by
replacing at least one, more than one, or a significant number,
of codons of the native sequence with codons that are more
frequently or most frequently used in the genes of that verte-
brate. Various species exhibit particular bias for certain
30 codons of a particular amino acid.In one aspect, the present invention relates to polynucle-
otide expression constructs or vectors, and host cells com-
prising nucleic acid fragments of codon-optimized coding
regions which encode therapeutic polypeptides, and frag-
35 ments, variants, or derivatives thereof, and various methods
of using the polynucleotide expression constructs, vectors,
host cells to treat or prevent disease in a vertebrate.
As used herein the term "codon-optimized coding region"
means a nucleic acid coding region that has been adapted for
expression in the cells of a given vertebrate by replacing at
40 least one, ormore than one, or a significant number, of codons
with one or more codons that are more frequently used in the
genes of that vertebrate.
Deviations in the nucleotide sequence that comprise the
45 
codons encoding the amino acids of any polypeptide chain
allow for variations in the sequence coding for the gene. Since
each codon consists of three nucleotides, and the nucleotides
comprising DNA are restricted to four specific bases, there
are 64 possible combinations of nucleotides, 61 of which
50 
encode amino acids (the remaining three codons encode sig-
nals ending translation). Many amino acids are designated by
more than one codon. For example, the amino acids alanine
and proline are coded for by four triplets, serine and arginine
by six, whereas tryptophan and methionine are coded by just
one triplet. This degeneracy allows for DNA base composi-
55 tion to vary over a wide range without altering the amino acid
sequence of the proteins encoded by the DNA.
Consensus Sequences
The present invention is further directed to expressionplas-
60 mids that contain chimeric genes which express therapeutic
fusion proteins with specific consensus sequences, and frag-
ments, derivatives and variants thereof. A "consensus
sequence" is, e.g., an idealized sequence that represents the
amino acids most often present at each position of two or
65 more sequences which have been compared to each other. A
consensus sequence is a theoretical representative amino acid
sequence in which each amino acid is the one which occurs
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most frequently at that site in the different sequences which
occur in nature. The term also refers to an actual sequence
which approximates the theoretical consensus. A consensus
sequence can be derived from sequences which have, e.g.,
shared functional or structural purposes. It can be defined by
aligning as many known examples of a particular structural or
functional domain as possible to maximize the homology. A
sequence is generally accepted as a consensus when each
particular amino acid is reasonably predominant at its posi-
tion, and most of the sequences which form the basis of the
comparison are related to the consensus by rather few substi-
tutions, e.g., from 0 to about 100 substitutions. In general, the
wild-type comparison sequences are at least about 50%,75%,
80%, 90%, 95%, 96%, 97%, 98% or 99% identical to the
consensus sequence. Accordingly, polypeptides of the inven-
tion are about 50%, 75%, 80%, 85%, 90%, 91%, 92%, 93%,
94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the
consensus sequence.
A "consensus amino acid" is an amino acid chosen to
occupy a given position in the consensus protein. A system
which is organized to select consensus amino acids can be a
computer program, or a combination of one or more computer
programs with "by hand" analysis and calculation. When a
consensus amino acid is obtained for each position of the
aligned amino acid sequences, then these consensus amino
acids are "lined up" to obtain the amino acid sequence of the
consensus protein.
As mentioned above, modification and changes may be
made in the structure of the mucE coding region and still
obtain a molecule having like or otherwise desirable charac-
teristics. As used herein, the term "biological functional
equivalent" refers to such proteins. For example, certain
amino acids may be substituted for other amino acids in a
protein structure without appreciable loss of interactive bind-
ing capacity with structures such as, for example, antigen-
binding regions of antibodies or binding sites on substrate
molecules. Since it is the interactive capacity and nature of a
protein that defines that protein's biological functional activ-
ity, certain amino acid sequence substitutions can be made in
the DNA coding sequence and nevertheless obtain a protein
with like or even countervailing properties (e.g., antagonistic
v. agonistic). It is thus contemplated by the inventors that
various changes may be made in the DNA sequence of mucE
(or MucE proteins or peptides) without appreciable loss of
their biological utility or activity.
Polypeptides
Further embodiments of the invention include polypep-
tides, which comprise amino acid sequences at least 95%
identical, and more preferably at least 96%, 97%, 98% or
99% identical, to any of the amino acid sequences of the
polypeptides described above.
As a practical matter, whether any particular polypeptide is
at least 95%, 96%, 97%, 98% or 99% identical to, for
instance, the amino acid sequence shown in SEQ ID NOs:2
and 4 can be determined conventionally using known com-
puter programs such as the Bestfit program (Wisconsin
Sequence Analysis Package, Version 8 for Unix, Genetics
Computer Group, University Research Park 575 Science
Drive, Madison, Wis. 53711). Bestfit uses the local homology
algorithm of Smith and Waterman, Advances in Applied
Mathematics 2:482-489 (1981), to find the best segment of
homology between two sequences. When using Bestfit or any
other sequence alignment program to determine whether a
particular sequence is, for instance, 95% identical to a refer-
ence sequence according to the present invention, the param-
eters are set, of course, such that the percentage of identity is
calculated over the full length of the reference amino acid
sequence and that gaps in homology of up to 5% of the total
number of amino acids in the reference sequence are allowed.
Even though the invention has been described with a cer-
5 tain degree of particularity, it is evident that many alterna-
tives, modifications, and variations will be apparent to those
skilled in the art in light of the foregoing disclosure. Accord-
ingly, it is intended that all such alternatives, modifications,
and variations which fall within the spirit and the scope of the
10 invention be embraced by the defined claims.
The following examples are included for purposes of illus-
tration only and are not intended to limit the scope of the
present invention, which is defined by the appended claims. It
should be appreciated by those of skill in the art that the
15 techniques disclosed in the examples which follow, represent
techniques discovered by the inventors to function well in the
practice of the invention, and thus can be considered to con-
stitute preferred modes for its practice. However, those of
skill in the art should, in light of the present disclosure,
20 appreciate that many changes can be made in the specific
embodiments which are disclosed and still obtain a like or
similar result without departing from the spirit and scope of
the invention.
25 Antibodies
Further embodiments of the invention include MucE and
A1gW monoclonal antibodies and methods of using MucE
and A1gW antibodies for the detection and diagnosis of
mucoid P. aeruginosa in biological specimens. The methods
30 comprise reacting a specimen suspected of containing
mucoid P. aeruginosa with a MucE or A1gW monoclonal
antibody or fragment thereof, separating the specimen from
unbound antibody, and detecting the presence of immune
complexes formed between the monoclonal antibody and the
35 MucE or A1gW protein, as compared to non-mucoid control
cells and therefrom determining the presence of mucoid P.
aeruginosa. Novel hybrid cell lines are also provided which
produce the monoclonal antibodies capable of specifically
binding to the MucE or A1gW protein expressed in P. aerugi-
40 nosa. When the monoclonal antibodies are labeled and com-
bined with a solubilizing reagent, a specific and rapid direct
test for mucoid P. aeruginosa is achieved.
The monoclonal antibodies of this invention can be pre-
pared by immortalizing the expression of nucleic acid
45 sequences which code for antibodies specific for MucE or
A1gW of P. aeruginosa. This may be accomplished by intro-
ducing such sequences, typically cDNA encoding for the
antibody, into a host capable of cultivation and culture. The
immortalized cell line may be a mammalian cell line that has
50 been transformed through oncogenesis, by transfection,
mutation, or the like. Such cells include myeloma lines, lym-
phoma lines, or other cell lines capable of supporting the
expression and secretion of the antibody in vitro. The anti-
body may be a naturally occurring immunoglobulin of a
55 mammal other than human, produced by transformation of a
lymphocyte, by means of a virus or by fusion of the lympho-
cyte with a neoplastic cell, e.g., a myeloma, to produce a
hybrid cell line. Typically, the lymphoid cell will be obtained
from an animal immunized against MucE or a fragment
60 thereof containing an epitopic site.
Monoclonal antibody technology was pioneered by the
work of Kohler and Milstein, Nature 256:495 (1975). Mono-
clonal antibodies can now be produced in virtually unlimited
quantities consistently and with a high degree of purity. These
65 qualities facilitate the reproducibility and standardization of
performance of diagnostic tests which are required in hospi-
tals and other clinical settings.
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Immunization protocols are well known and can vary con-
siderably yet remain effective. See Golding, Monoclonal
Antibodies: Principles and Practice, (1983) which is incorpo-
rated herein by reference. Immunogenic amounts of antigenic
MucE preparations are injected, generally at concentrations
in the range of 1 ug to 20 mg/kg of host. Administration of the
antigenic preparations may be one or a plurality of times,
usually at one to four week intervals. Immunized animals are
monitored for production of antibody to the desired antigens,
the spleens are then removed and splenic B lymphocytes
isolated and transformed or fused with a myeloma cell line.
The transformation or fusion can be carried out in conven-
tional ways, the fusion technique being described in an exten-
sive number of patents, e.g., U.S. Pat. Nos. 4,172,124; 4,350,
683; 4,363,799; 4,381,292; and 4,423,147. See also Kennett
et al., Monoclonal Antibodies (1980) and references therein.
The biological sample suspected of containing P. aerugi-
nosa is combined withtheprimary antibody under conditions
conducive to immune complex formation. If the test is a
one-step immunofluorescence assay, the primary antibody
will be labeled. Typically, the specimen is first fixed or
adhered to a glass slide by heat and/or ethanol treatment,
although other fixatives or adherents are known by those
skilled in the art. The specimen is then contacted with the
solubilizing agent for a sufficient period, usually from 1 to 30
minutes and more usually about 10 minutes, and the solubi-
lizer is then washed from the slide. Alternatively, as described
above, the solubilizing agent and the primary antibody may
be combined and added as one step. The primary antibody
should be incubated with the specimen for approximately 30
minutes at room temperature, although the conditions may be
varied somewhat. The slide is rinsed to remove unbound
antibody. If the primary antibody has been labeled with FITC,
the reacted sample may be viewed under a fluorescence
microscope equipped with standard fluorescein filters (exci-
tation=490 mu; emission-520 mu) and a 40x oil immersion
lens. The quantitation of fluorescence is based on visual
observation of the brightness or relative contrast of the spe-
cifically stained antigen. Appropriate positive and negative
controls make interpretation more accurate. A counterstain,
such as Evans blue, may be employed to more easily visualize
the fluorescent organisms.
The antibodies of the invention may be a chimeric antibody
or fragment thereof, a humanized antibody or fragment
thereof, a single chain antibody; or a Fab fragment.
For use in diagnostic assays, the antibodies of the present
invention may be directly labeled. A wide variety of labels
may be employed, such as radionuclides, fluorescence,
enzymes, enzyme substrates, enzyme cofactors, enzyme
inhibitors, ligands (particularly haptens), etc. When unla-
beled, the antibodies may find use in agglutination assays. In
addition, unlabeled antibodies can be used in combination
with other labeled antibodies (second antibodies) that are
reactive with the monoclonal antibody, such as antibodies
specific for the immunoglobulin. Numerous types of immu-
noassays are available and are well known to those skilled in
the art.
Immunofluorescence staining methods can be divided into
two categories, direct and indirect. In the direct staining
method, a fluorophore is conjugated to an antibody (the "pri-
mary antibody") which is capable of binding directly to the
cellular antigen of interest. In the indirect staining mode, the
primary antibody is not fluorescently labeled; rather, its bind-
ing is visualized by the binding of a fluorescently labeled
second-step antibody, which second-step antibody is capable
of binding to the primary antibody. Typically, the second-step
antibody is an anti-immunoglobulin antibody. In some
18
instances the second-step antibody is unlabeled and a third-
step antibody which is capable of binding the second-step
antibody is fluorescently labeled.
Indirect immunofluorescence is sometimes advantageous
5 in that it can be more sensitive than direct immunofluores-
cence because for each molecule of the primary antibody
which is bound, several molecules of the labeled second-step
antibody can bind. However, it is well known that indirect
to immunofluorescence is more prone to nonspecific staining
than direct immunofluorescence, that is, staining which is not
due to the specific antigen-antibody interaction of interest
(Johnson et al., in Handbook of Experimental Immunology,
D. M. Weir, ed., Blackwell Publications Oxford (1979); and
15 Selected Methods in Cellular Immunology, Mishell et al., ed.,
W. H. Freeman, San Francisco (1980)). In addition, the mul-
tiple steps involved in performing the indirect tests makes
them slow, laborintensive, and more susceptibleto technician
error.
20 Various immunoassays known in the art can be used to
detect binding of MucE or A1gW to antibodies, including but
not limited to, competitive and non-competitive assay sys-
tems using techniques such as radioimmunoassays, ELISA
(enzyme linked immunosorbent assay), "sandwich" immu-
25 noassays, immunoradiometric assays, gel diffusion precipi-
tation reactions, immunodiffusion assays, in situ immunoas-
says (using colloidal gold, enzyme or radioisotope labels, for
example), western blots, precipitation reactions, agglutina-
tion assays (e.g., gel agglutination assays, hemagglutination
3o assays), complement fixation assays, immunofluorescence
assays, protein  assays, and immunoelectrophoresis assays,
etc.
Kits can also be supplied for use with the subj ect antibodies
in the detection of mucoid P. aeruginosa in specimens,
35 wherein the kits comprise compartments containing a MucE
and/or A1gW monoclonal antibody capable of reacting with
essentially all serotypes and immunotypes of P. aeruginosa,
and labels and necessary reagents for providing a detectable
signal. Thus, the monoclonal antibody composition of the
40 present invention may be provided, usually in a lyophilized
form, either alone or in conjunction with additional antibod-
ies specific for other antigens of P. aeruginosa. The antibod-
ies, which may be conjugated to a label, are included in the
kits with buffers, such as Tris, phosphate, carbonate, etc.,
45 stabilizers, biocides, inert proteins, e.g., bovine serum albu-
min, or the like. Generally, these materials will be present in
less than about 5% weight based on the amount of active
antibody, and usually present in a total amount of at least
about 0.001% weight based on the antibody concentration.
50 Frequently, it will be desirable to include an inert extender or
excipient to dilute the active ingredients, where the excipient
may be present in from about 1% to 99% weight of the total
composition. Where a second antibody capable of binding to
the monoclonal antibody is employed, this will usually be
55 present in a separate vial. The second antibody may be con-
jugated to a label and formulated in a manner analogous to the
antibody formulations described above.
Cystic Fibrosis (CF) Risk Assessment
60 Further embodiments of the invention include methods for
Cystic Fibrosis (CF) disease assessment in an individual
which comprise detecting the presence or absence of MucE
and/orA1gW in a sample from an individual. Further embodi-
ments include methods for Cystic Fibrosis (CF) disease
65 assessment in an individual which comprise detecting the
presence or absence of MucE orA1gW antibodies in a sample
from an individual.
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Additional embodiments include methods for treating P.
aeruginosa biofilms in Cystic Fibrosis (CF) disease in an
individual which comprise the steps of detecting the presence
of MucE and/or A1gW in a sample from an individual; and
selecting a therapy regimen for the individual based on the
presence of MucE and/or A1gW. The P. aeruginosa biofilms
in Cystic Fibrosis (CF) disease are treated by the therapy
regimen. Also contemplated are methods for treating P.
aeruginosa biofilms in Cystic Fibrosis (CF) disease in an
individual which comprise the steps of detecting the presence
of MucE and/or A1gW antibodies in a sample from an indi-
vidual; and selecting a therapy regimen for the individual
based on the presence of MucE and/orA1gW antibodies. The
P. aeruginosa biofilms in Cystic Fibrosis (CF) disease are
treated by the therapy regimen.
As used herein, "individual' is intended to refer to a
human, including but not limited to, children and adults. One
skilled in the art will recognize the various biological samples
available for detecting the presence or absence of MucE or
A1gW in an individual, any of which may be used herein.
Samples include, but are not limited to, airway surface liquid,
sputa, or combinations thereof, human blood, wound exu-
date, respiratory secretions, human tissues (e.g., lung) or a
laboratory culture thereof, and urine. Moreover, one skilled in
the art will recognize the various samples available for detect-
ing the presence or absence of MucE orA1gW antibodies in an
individual, any of which may be used herein. Samples
include, but are not limited to, airway surface liquid, sputa, or
combinations thereof, human blood, wound exudate, respira-
tory secretions, human tissues (e.g., lung) or a laboratory
culture thereof, urine, and other body fluids, or combinations
thereof.
As used herein, "assessment' is intended to refer to the
prognosis, monitoring, delaying progression, delaying early
death, staging, predicting progression, predicting response to
therapy regimen, tailoring response to a therapy regimen, of
Cystic Fibrosis disease based upon the presence or absence of
MucE, A1gW, MucE antibodies, or A1gW antibodies in a
biological sample.
As used herein, "therapy regimen" is intended to refer to a
procedure for delaying progression, or delaying early death
associated with Cystic Fibrosis disease and/or Pseudomonas
aeruginosa in a Cystic Fibrosis individual. In one embodi-
ment, the therapy regimen comprises administration of ago-
nists and/or antagonists of MucE and/or A1gW. In another
embodiment, the therapy regimen comprises agonists and/or
antagonists of Pseudomonas aeruginosa.
One skilled in the art will appreciate the various known
direct and/or indirect techniques for detecting the presence or
absence of MucE or A1gW, any of which may be used herein.
These techniques include, but are not limited to, amino acid
sequencing, antibodies, Western blots, 2-dimensional gel
electrophoresis, immunohistochemistry, autoradiography, or
combinations thereof.
All references cited in the Examples are incorporated
herein by reference in their entireties.
EXAMPLES
Materials and Methods
The following materials and methods apply generally to all
the examples disclosed herein. Specific materials and meth-
ods are disclosed in each example, as necessary.
The practice of the present invention will employ, unless
otherwise indicated, conventional techniques of cell biology,
cell culture, molecular biology (including PCR), vaccinol-
20
ogy, microbiology, recombinant DNA, and immunology,
which are within the skill of the art. Such techniques are
explained fully in the literature. See, for example, Molecular
Cloning A Laboratory Manual, 2d Ed., Sambrook et al., ed.,
5 Cold Spring Harbor Laboratory Press (1989); DNA Cloning,
Volumes I and II, D. N. Glover ed., (1985); Oligonucleotide
Synthesis, M. J. Gait ed., (1984); Mullis et al. U.S. Pat. No.
4,683,195; Nucleic Acid Hybridization, B. D. Flames & S. J.
10 Higgins eds. (1984); Transcription And Translation, B. D.
Flames & S. J. Higgins, eds. (1984); Freshney, R. L, Culture
OfAnimal Cells, Alan R. Liss, Inc. (1987); Immobilized Cells
And Enzymes, IRL Press (1986); Perbal, B., A Practical
Guide To Molecular Cloning (1984); the treatise, Methods In
15 Enzymology, Academic Press, Inc., N.Y.; Gene Transfer Vec-
tors For Mammalian Cells, J. H. Miller and M. P. Calos eds.,
Cold Spring Harbor Laboratory (1987); Methods In Enzymol-
ogy, Vols. 154 and 155, Wu et al. eds.; Immunochemical
Methods In Cell And Molecular Biology, Mayer and Walker,
20 eds., Academic Press, London, (1987); and in Ausubel et al.,
Current Protocols in Molecular Biology, John Wiley and
Sons, Baltimore, Md. (1989). Each of the references cited in
this paragraph is incorporated herein by reference in its
25 
entirety.
Bacterial Strains, Plasmids, Transposons and Growth Condi-
tions
P. aeruginosa strains were grown at 37° C. in Lennox broth
30 (LB), on LB agar or Pseudomonas Isolation Agar (PIA,
DIFCO) plates. When required, PIA plates were supple-
mented with carbenicillin, tetracycline, or gentamicin at a
concentration of 300 µg/ml. E. coli strains were grown in LB
broth, or LB agar supplemented with carbenicillin (100
35 µg/ml), tetracycline (15 µg/ml), gentamicin (13 µg/ml), or
kanamycin (40 µg/ml), when required.
Transposon Mutagenesis
A standard Pseudomonas conjugation protocol was fol-
40 lowed with the following modifications. E. coli SM10 Xpir
carrying pFAC and P. aeruginosa strains were grown in 2 ml
LB broth overnight at 37° C. and 42° C., respectively. The cell
density of the cultures was measured by optical density at 600
nm and adjusted to a ratio of 1:1, which was equivalent to
45 8x10$ cells for matings. The mixed cultures were incubated
on LB plates for 6 h at 37° C. The cells were harvested and
washed in LB broth. The final cell mixtures in a volume of 1
ml were spread on 8 PIA plates (50 ml each) supplemented
with gentamicin. The conjugal pairs were incubated at 37° C.
50 for 24 h for selection and screening exconjugants with a
mucoid colony morphology. Such mutants were isolated and
purified a minimum of 3 times. Mutants were frozen in 10%
skim milk in a —80° C. freezer.
55 DNA Manipulations.
Two steps ofpolymerase chain reaction (PCR)-based clon-
ing were used for general cloning purposes. First, the target
genes were amplified by high-fidelity PCR using the appro-
60 priate primer sets containing the built-in restriction sites fol-
lowed by cloning into pCR4-TOPO. The DNA fragments
were digested by restriction enzymes, gel-purified, and trans-
ferred to the shuttle vector pUCP20. All recombinant plas-
mids were sequenced to verify the absence of mutations with
65 M13 universal forward and reverse primers using an ABI
3130 Genetic Analyzer at the Marshall University School of
Medicine Genomics Core Facility. PCR reactions were per-
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formed with MasterAmpTM Taq DNA Polymerase (Epicen-
tre) in 50 l EasyStart PCR tubes (Molecular BioProducts) as 	
-continued
previously described (Head, N. E., and H. Yu, Infect. Immun.
72:133-44 (2004)).	 gcgcgcgtaa tacactcact atagggcgaa ttggaggatc
cggtctaaca aagaaaacac attttttgtg aaa
A multiple cloning site (MCS) was identified immediately
outside the 3' end of the gentamicin cassette within the trans-
poson. To map the insertion site, an iPCR protocol was devel-
10 oped to utilize this convenient MCS. Pseudomonas genomic
DNA was purified using a QIAamp genomic DNA kit. The
DNA concentration was measured using the NanoDrop®
ND-1000 spectrophotometer (NanoDrop Technologies). Two
µg DNA was digested by restriction enzymes Sall or PstI at
i5 37° C. overnight followed by gel purification. The frag-
mented DNA was ligated to form the circularly closed DNA
using the Fast-LinkTM DNA ligation kit (Epicentre). A vol-
ume of 1 ld ligated DNA was used as template for PCR using
20 GM5OUT and GM3OUT according to the condition as fol-
lows, 94° C. for 1 min, 34 cycles consisting of 94° C. for 1
min, 58° C. for 2 min, and 72° C. for 2 min, and a final
extension step consisting of 72° C. for 8 min. After PCR, the
products were analyzed on a I% agarose gel. The PCR prod-
25 ucts were purified using the QIAquick PCR purification kits
and sequenced using GM50UT as described above.
Alginate and Protein Assays
The alginate assay was based on a previously published
30 method (Knutson, C. A., and A. Jeans, Anal. Biochem.
24:470-481 (1968)) with the following modifications. P.
aeruginosa and mutants were grown on 50 ml PIA plates in
triplicate for a period of 72 h. At various time points, bacterial
growth was removed from plates and re-suspended in 40 ml
35 phosphate-buffered saline (PBS; pH 7.4). The optical density
at 600 nm (OD ... ) was recorded. The alginate standard curve
was made using D-mannuronic acid lactone (Sigma) in the
range of 0-100 µg/ml. To measure the protein concentration,
40 
the cells in PBS were lysed in 1:1 ratio with 1 M NaOH for 15
min. The protein assay was performed using the Bio-Rad D,
Protein Assay kit. The range for protein standard (bovine
serum albumin) curve was from 0.2 to 1.2 mg/ml.
(3-Galactosidase Activity Assay
45
The assay was based on the method as originally described
by Miller (In Experiments in Molecular Genetics, J. H.
Miller, ed., Cold Spring Harbor Laboratory, Cold Spring Har-
bor, N.Y. (1972), pp. 352-355) with the following modifica-
50 tion. The cells of NHl-3 were grown on PIA plates in tripli-
cate for 24 h at 37' C. The cells were harvested in PBS and cell
density was measured by OD 60,. Samples were assayed after
SDS/chloroform permeabilization of the cells.
55 Alkaline Phosphatase A-Fusion Assay
The entire open reading frame and different portion of
mucE were translationally fused with the E. coli phoA gene
with deletion of the sequence encoding the N-terminal signal
sequence. These mucE-phoA fusions were cloned into
60 pUCP20 vector for alkaline phosphatase A-fusion assay as
previously described (Lewenza, S. et al., Genome Res.
15:321-329 (2005); Manoil, C. et al., J. Bacterol. 172:515-
518 (1990)) and the transformants were plated on the LB plate
containing 40 µg/ml BCIP. The construct pUCP20-phoA
65 expressing full-length PhoA was used as a positive control
and the pUCP20-phoA expressing the truncated PhoA with-
out N-terminal signal leader sequence as a negative control.
Inverse PCR (iPCR)
The mariner transposon and its junction region in pFAC
were sequenced. The sequence of the junction region includ-
ing the inverted repeats inpFAC (SEQID NO: 8) is as follows:
accacacccg ccgcgcttaa tgcgccgcta cagggcgcgt
cccattcgcc actcaaccaa gtcattctga gaatagtgta
tgcggcgacc gagttgctct tgcccggcgt caatacggga
taataccgcg ccacataaca ggttggctga taagtccccg
gtctaacaaa gaaaaacaca tttttttgtg aaaattcgtt
tttattattc aacatagttc ccttcaagag cgatacccct
cgaattgacg cgtcaattct cgaattgaca taagcctgtt
cggttcgtaa actgtaatgc aagtagcgta tgcgctcacg
caactggtcc agaaccttga ccgaacgcag cggtggtaac
ggcgcagtgg cggttttcat ggcttgttat gactgttttt
ttgtacagtc tatgcctcgg gcatccaagc agcaagcgcg
ttacgccgtg ggtcgatgtt tgatgttatg gagcagcaac
gatgttacgc agcagcaacg atgttacgca gcagggcagt
cgccctaaaa caaagttagg tggctcaagt atgggcatca
ttcgcacatg taggctcggc cctgaccaag tcaaatccat
gcgggctgct cttgatcttt tcggtcgtga gttcggagac
gtagccacct actcccaaca tcagccggac tccgattacc
tcgggaactt gctccgtagt aagacattca tcgcgcttgc
tgccttcgac caagaagcgg ttgttggcgc tctcgcggct
tacgttctgc ccaggtttga gcagccgcgt agtgagatct
atatctatga tctcgcagtc tccggcgagc accggaggca
gggcattgcc accgcgctca tcaatctcct caagcatgag
gccaacgcgc ttggtgctta tgtgatctac gtgcaagcag
attacggtga cgatcccgca gtggctctct atacaaagtt
gggcatacgg gaagaagtga tgcactttga tatcgaccca
agtaccgcca cctaacaatt cgttcaagcc gagatcggct
tcccggccga cgcgtcctcg gtaccgggcc ccccctcgag
gtcgacggta tcgataagct tgatatcgaa ttcctgcagc
ccgggaatca tttgaaggtt ggtactatat aaaaataata
tgcatttaat actagcgacg ccatctatgt gtcagaccgg
ggacttatca gccaacctgt tagcagaact ttaaaagtgc
tcatcattgg aaaaaggctg cgcaactgtt gggaagggcg
atcggtgcgg gcctcttcgc tattacgcca gctggcgaaa
gggggatgtg ctgcaaggcg attaagttgg gtaacgccag
ggttttccca gtcacgacgt tgtaaaacga cggccagtga
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RNA Isolation and RT-PCR
P. aeruginosa strains PAO1, VE2 and VE3 were grown on
50 ml PIA plates for 24 h at 37° C. The cells were harvested
in 40 ml PBS and re-suspended based on OD 600 to produce a
cell population of 109 to 10 10 . Total RNA was isolated using
a RiboPureTM-Bacteria Kit (Ambion) followed by DNase
treatment as supplied. The quality of RNA was evaluated on
an Agilent 2100 bioanalyzer. RT-PCR was performed using a
One-Step RT-PCR kit (Qiagen). One µg bacterial RNA was
reverse-transcribed into cDNA at 50° C. for 30 min followed
by PCR amplification: 94° C. for 15 min, 34 cycles consisting
of 94° C. for 1 min, 58° C. for 2 min, and 72° C. for 2 min. The
PCR products were analyzed on 1% agarose gel, and the
intensity of bands was analyzed on a Typhoon 8600 Variable
Mode Imager (Molecular Dynamics) withthe ImageQuant (v.
5.2) Software.
Monoclonal Antibodies
The A1gU and MucB monoclonal antibodies used in the
Examples are from previously published sources (Boucher et
al., J. Bacteriol. 178:511-523 (1996); Schurr et al., J. Bacte-
riol. 178:4997-5004 (1996)) with a low level of cross-reac-
tivity. The specificities of these antibodies are appropriate
because the a1gU and mucB negative strains failed to display
the respective A1gU and MucB proteins (FIG. 8). Further-
more, two non-specific proteins of 50 kDa and 75 kDa from
MucB and A1gU blots respectively were used as convenient
internal controls to normalize the protein levels.
Southern Hybridization
A 754 by PCR product was amplified from accl of
pUCP30T using GM-F and GM-R primers, which was puri-
fied via gel extraction and labeled with digoxygenin as
described by the manufacturer (Roche Molecular Biochemi-
cals). Agarose gels were soaked in 0.25 N HCl for 30 min,
rinsed in H2O, soaked in 1.5 M NaCI/0.5 M NaOH for 30 min
and 1.5 M NaCl/0.5 M Tris-Cl, pH 8.0 for 30 min. A blotting
apparatus (BIO-RAD Vacuum Blotter) was used with a filter
paper wick, a Hybond-N+ membrane (Amersham Pharmacia
Biotech), and transferred with l OxSSC transfer buffer for 2 h.
After transfer, the membrane was rinsed in transfer buffer and
UV cro ss-linked. Hybridization was done using the DIG High
Prime DNA Labeling and Detection Starter Kit II (Roche
Applied Science) and labeled probe described above.
Western Blot Analysis.
Forty µg of total protein was prepared by bead-beating 3x
for 1 min with 5 min intervals on ice. The proteins were mixed
with 2xSDS-PAGE sample buffer. A Precision Plus Protein
Standard (Bio-Rad) was used as molecular mass ranging
from 10 to 250 kD. Protein and standard were loaded into a
Criterion pre-cast gel of linear gradient (10-15% Tris-HCI
gel) (Bio-Bad) and was run in a Criterion Cell (Bio-Bad) at
60V for 4 h. The transfer onto a PVDF membrane was done in
a Criterion Blotter (Bio-Rad) with CAPS buffer at 50V for 1
h. Primary antibodies were obtained using standard tech-
niques. Horseradish Peroxidase-labeled secondary antibod-
ies, goat anti-mouse IgG (H+L) and goat anti-rabbit IgG
(H+L), were obtained from Peirce Biotechnologies and
Kirkegaard & Perry Laboratories, respectively. Primary anti-
bodies were diluted 1:1000 and secondary antibodies 1:5000
in TBS/Tween before application. ECL Western Blotting
Detection System (Amersham Biosciences) was used to
detect the protein of interest. X-ray film was exposed, and
developed on an Alphatek AX390SE developer. The protein
intensity was analyzed using a ChemiDoc XRS system (Bio-
Rad) and Quantity One software (Bio-Bad). These results
24
were normalized against an internal protein within each
sample. The relative expression level for each protein was
then compared.
5 Statistical Analysis
Analysis of alginate production (3-galactosidase activity
was done with one-way analysis of variance (ANOVA) fol-
lowed by pairwise multiple comparisons with Holm-Sidak
method. Analysis of normalized protein intensity was carried
10 out with the means of each group in comparison with that of
PAOI using t test assuming unequal variance or ANOVA if
multiple groups were compared. All analyses were performed
with SigmaStat (v. 3.1, Systat Software) and SigmaPlot (v.
9.0, Systat Software) software.
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Example 1
Mariner-Based Transposon Mutagenesis Approach to
Identify Mucoid Mutants in P. aeruginosa
20
To investigate alginate regulation in P. aeruginosa, the
versatile Tcl/mariner himarl transposon carried on pFAC
(GenBank Accession number DQ366300), a Pseudomonas
suicide plasmid, was used to mutagenize the non-mucoid
25 strains of P. aeruginosa coupled with a genetic screen for
mucoid mutants.
The transposition efficiency of this transposon is high and
has been shown to cause high-density insertions in P. aerugi-
nosa (Wong, S. M. and Mekalanos, J. 7., Proc Nad Acad Sci
30 US 97:10191-10196 (2000)). Moreover, this transposon can
knockout, knockdown or induce expression of the target gene
depending on the nature of its insertion. The mariner trans-
poson himarl can jump onto the TA dinucleotides in non-
essential genes. These sites are abundant in the genomes of P.
35 aeruginosa strains. Based on the two completed genomes,
there are 94,404 and 100,229 such sites in PAOI (Stover et al.,
Nature 406:959-964 (2000)) and PA14 respectively, which
gives rise to 17-18 per ORE. In addition, pFAC can cause
increased or reduced expression of the target gene by insert-
40 ing into the intergenic region.
Four non-mucoid strains were subject to transposon
mutagenesis. Only three regions were targeted in this back-
ground: i) 6x in the a1gU promoter region, ii)1 x in mucA, and
iii) 3 x in the intergenic region between a1gU and mucA (Table
45 1). The a1gU promoter mutants caused increased expression
of A1gU while the mucA and the a1gU-mucA intergenic
mutants affected the activity of A1gU. These results indicate
that A1gU has a key role in alginate overproduction in
PAO579NM.
50 A total of 370,000 clones were screened from 13 conjuga-
tions (Table 1). Eighty-five mucoid mutants were isolated
with 90% carrying single insertions as verified by Southern
blot analysis (data not shown). To map the site of transposon
insertions, iPCR was performed with 90% of PCR reactions
55 producing single products. The iPCR results displayed a
100% correlation with Southern blots. The iPCR products
were used as templates for DNA sequencing. Seventy-eight
mutants with single insertions were mapped. We next created
the criteria of differentiating the independent mutational
60 events. Independent and non-sibling mutants were defined as
those carrying a transposon at different sites, or at the same
sites but were obtained through different matings. Using
these criteria, a collection of 45 independent mucoid mutants
was obtained and classified in 9 different functional groups
65 (Table 1). The mutagenesis approach used here was at a
saturating level because multiple insertions at the same sites
were repeatedly targeted (FIG. 5).
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TABLE 
Transposon mutagenesis analysis of alginate regulators
in four non-mucoid strains of P. aeruginosa
PAOI PA0579NM PA14	 FRD2	 Sum	 Freq
# matings 4 3 3 3 13
# mutants screened 81,280 88,800 126,000 75,000 371,080
# mucoid obtained 32 18 31 4 85
# independent mutants 21 10 11 3 45
mutation freq 3.9 x 10-4 2.0 x 10-4 2.5 x 10-4 5.3 x 10-5
Induction°
PA0762-algU promoter 5 (23.8) 6 (60.0) 8 (72.7) 3 (100.0) 22 49
PA4033-mucE 1 (4.8) 1 (9.1) 2 4
PA4082-cupB5 1 (4.8) 1 2
Knockdown 
PA0762-algU 2 (9.5) 3 (30.0) 5 11
PA0973-oprL 1 (4.8) 1 2
Knockout`
PA0763-mucA 1 (10.0) 1 2
PA0764-mucB 1 (4.8) 1 (9.1) 2 4
PA0766-mucD 9(42.9) 1 (9.1) 10 22
PA5484-kinB 1 (4.8) 1 2
,,b 
"The number of mutants obtained from each strain ofP aeruginosa is shown. Number inside a bracket denotes the
percentage of a mutation in the total number of mutants within a strain.
Similar to another himarl transposon vector of the same
lineage but constructed for M. tuberculosis studies (Rubin, E.
7., et al., Proc Natl Acad Sci USA 96:1645-1650 (1999)), the
transposon end in pFAC has no termination sequences. There-
fore, three types of mutations can be caused by the transposon
in thi s vector depending on how and where it is inserted on the
genome. As shown in Table 1, when inserted in the a1gU,
mucE or cupB5 promoter region, the transposon used its d'
promoter (P,m) (Wohlleben, W., et al., Mol Gen Genet 217:
202-208 (1989)) to direct the expression of the downstream
genes. Reduced (knockdown) expression occurred when the
transposon was inserted in the intergenic region of algUmucA
or immediately downstream of oprL with P, m in the opposite
direction with regard to the upstream a1gU or oprL. When the
transposon was within the coding sequences, this produced
stop codons away from insertion sites due to frameshifl muta-
tions, producing gene knockouts for mucA, mucB, mucD and
kinB.
The mucoid phenotype poises a great demand for energy
from the cells. The amount of alginate in mucoid mutants was
initially lower than that of the wild-type strain PAOI (FIG.
6A-8A), suggesting that mucoid mutants may grow slower
than the non-mucoid counterparts to compensate for the
energy demand.
Example 2
The Majority of Insertions are within
algUmucABCD and Result in Upregulation of A1gU
While all pFAC insertions were within five clusters (data
not shown), the most frequent sites (49%) were in the a1gU
promoters with the transposons situated in the induction con-
figuration. Since the algUmucABC genes are co-transcribed
(DeVries, C. A. & Ohman, D. E., JBacteriol 176:6677-6687
(1994); Firoved, A. M. & Deretic, V., JBacteriol 185:1071-
1081 (2003)), the levels ofA1gU and MucB were measured in
these mutants. VEl, one of the representative promoter
mutants as shown in FIG. 5, was grown on PIA plates for
quantification of alginate and the protein levels of A1gU and
MucB.
As the results show, compared to PAOL VEl produced
increased amounts of alginate from 24 to 72 h in concurrence
with increased levels of A1gU and MucB (FIG. 6). The level
30 
of A1gU was higher than that of MucB (P-0.005). A1gU and
MucB reached the steady-state level at 4 h and remained so
for the rest of the time points. The a1gU mutants in
PA0579NM, PA14 and FRD2 were mucoid and displayed the
same trend as VEI regarding alginate production and protein35 levels ofA1gU and MucB. These results indicate that the a1gU
promoter mutations were gain-of-function and associated
with an elevated level of A1gU.
Twenty eight percent of mucoid mutants had insertions in
40 the coding regions of mucA, mucB and mucD (Table 1). The
Alg' phenotype of the mucD- mutants (DRS, VE19, VE14 23
and VE12) was complemented to Alg by mucD or mucBCD
in trans. VE3 and VI, the equivalent of a triple knockout of
mucA-B-C- in PAOI and PA0579NM respectively, were
45 complemented to Alg by mucA, but not by mucBC or
mucBCD, in trans. The Alg' phenotype in mucB - mutants of
PAOI (VE8) and PA14 (DRI) was complemented to Alg by
mucB, mucBC and mucBCD, in trans. These results suggest
that the insertions in mucA, mucB and mucD are loss-of-
50 function (null) mutations.
Example 3
mucE and cupB5 Encode Two Novel Positive
55	 Regulators of Alginate
Alginate is regulated by a signal transduction pathway.
While ample information is available on the interaction
between the sigma factor A1gU and trans-inner membrane
6o anti-sigma factor MucA, it is unclear what and how periplas-
mic signals activate the A1gU pathway leading to alginate
overproduction. MucE and CupB5 identified here are two
candidates for such signals. VE2 and DR4 had two identical
insertions 16 bps upstream of ATG of PA4033 in PAOI and
65 PA 14, respectively (data not shown). The transposon in both
mutants was in the induction configuration (Table 1). PA4033
belongs to a class of unclassified open reading frames (ORE)
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in the annotated genome of PAOI, and encodes a hypothetical
peptide (89 aa) with a predicted molecular mass of 9.5 kDa.	
-continued
The protein has a leader sequence of 36 as with the mature	 AATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCG
MULE protein exported to periplasm. In E. Coll, the 6E path-	 GGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGA
way is activated via a similar signal transduction system in 5
which an outer membrane porin, OmpC serves as an inducing 	 ACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGA
signal. The carboxy-terminal signal of MULE (WVF) has a	 ACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAG
three consensus as sequence as does OmpC (YQF) (Walsh, N.
P., et al., Cell 113:61-71 (2003)) and CupBS (NIW).	 10 GGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAG
The results show that alginate production in VE2 was 	 CGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGT
increased after 24 h (FIG. 7A) in association with the
increased levels of AIgU and MucB compared with PAOI at 	 CGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAG
all time points (FIG. 7A vs. FIG. 613). The wild-type and 	 GGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTC
mucoid mutation alleles of PA4033 plus its upstream region 15
were cloned into pUCP20. The resultant plasmid was named 	 CTGGCCTTTTGCTGGCCTTTTGCTCACATAAGCTAGCTTATCGGCCAGCC
pUCP20-Gm-MucE (5622 bp) and has the following nucle-
otide sequence(SEQ ID NO: 9):
	
	
TCGCAGAGCAGGATTCCCGTTGAGCACCGCCAGGTGCGAATAAGGGACAG
TGAAGAAGGAACACCCGCTCGCGGGTGGGCCTACTTCACCTATCCTGCCC
20GACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATA GGCTGACGCCGTTGGATACACCAAGGAAAGTCTACACGAACCCTTTGGCA
ATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGG AAATCCTGTATATCGTGCGAAAAAGGATGGATATACCGAAAAAATCGCTA
AACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCA TAATGACCCCGAAGCAGGGTTATGCAGCGGAAAGTATACCTTAAGGAATC
TGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGT 25 CCCATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTAC
ATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATT CGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCA
TTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATG GCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCT
CTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAAC 30 CTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCC
AGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGAT CGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCTCA
GAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACG CTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTG
CCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTG 35 TGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCA
GTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGT TGATTACGAATTCGAGCTCGGTACCCTAGCCTGATTCCAAATAGCCATTA
AAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCA AGCGGGACGAAGAGCCCGTGAGCCAGCGCCAGCCTGACCTAACAGGTTGG
ACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTG CTGATAAGTCCCCGGTCTAACAAAGAAAAACACATTTTTTTGTGAAAATT40
CACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCT CGTTTTTATTATTCAACATAGTTCCCTTCAAGAGCGATACCCCTCGAATT
GAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAA GACGCGTCAATTCTCGAATTGACATAAGCCTGTTCGGTTCGTAAACTGTA
TGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCT ATGCAAGTAGCGTATGCGCTCACGCAACTGGTCCAGAACCTTGACCGAAC
45
TCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACC GCAGCGGTGGTAACGGCGCAGTGGCGGTTTTCATGGCTTGTTATGACTGT
ACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTG
GAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGAT
GGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAAC
TATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTA
AGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGAT
TTTTTTGTACAGTCTATGCCTCGGGCATCCAAGCAGCAAGCGCGTTACGC
CGTGGGTCGATGTTTGATGTTATGGAGCAGCAACGATGTTACGCAGCAGC
50
AACGATGTTACGCAGCAGGGCAGTCGCCCTAAAACAAAGTTAGGTGGCTC
AAGTATGGGCATCATTCGCACATGTAGGCTCGGCCCTGACCAAGTCAAAT
CCATGCGGGCTGCTCTTGATCTTTTCGGTCGTGAGTTCGGAGACGTAGCC
55
TTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGA 	 ACCTACTCCCAACATCAGCCGGACTCCGATTACCTCGGGAACTTGCTCCG
TAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGT
CAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTG
CGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGT
TTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCT
TCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTA
GGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCT
TAGTAAGACATTCATCGCGCTTGCTGCCTTCGACCAAGAAGCGGTTGTTG
GCGCTCTCGCGGCTTACGTTCTGCCCAGGTTTGAGCAGCCGCGTAGTGAG
60 ATCTATATCTATGATCTCGCAGTCTCCGGCGAGCACCGGAGGCAGGGCAT
TGCCACCGCGCTCATCAATCTCCTCAAGCATGAGGCCAACGCGCTTGGTG
CTTATGTGATCTACGTGCAAGCAGATTACGGTGACGATCCCGCAGTGGCT
65 CTCTATACAAAGTTGGGCATACGGGAAGAAGTGATGCACTTTGATATCGA
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-continued	 -continued
CCCAAGTACCGCCACCTAACAATTCGTTCAAGCCGAGATCGGCTTCCCGG 	 AGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGCCCCGACACCCGCC
CCGACGCGTCCTCGGTACCGGGCCCCCCCTCGAGGTCGACGGTATCGATA 	 AACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTT
5
AGCTTGATATCGAATTCCTGCAGCCCGGGAATCATTTGAAGGTTGGTACT 	 ACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCA
ATATAAAAATAATATGCATTTAATACTAGCGACGCCATCTATGTGTCAGA
CCGGGGACTTATCAGCCAACCTGTTATCAAGGAGTCGTAGCCATGGGTTT
CCGGCCAGTTAGCCAACGTTTGCGTGACATCAACCTGCAGGCCCTCGGCA
AGTTTTCCTGCCTTGCCCTGGTCCTCGGCCTGGAATCGGTAAGCCATCCG
GCCGGCCCGGTCCAGGCCCCCTCGTTCAGCCAGGGCACCGCCAGCCCGTC
CTTCGCTACTCCGCTCGGCCTCGACGGCCCGGCCCGCGCCAGGGCCGAGA
TGTGGAACGTCGGCCTGTCCGGCGCCGTCAGCGTGCGTGACGAGTTGCGC
TGGGTGTTTTGAACGCGAAGCTTAGGGGATCCTCTAGAGTCGACCTGCAG
GCATGCAAGCTTGGCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAA
ACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCC
AGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTT
GCGCAGCCTGAAAGGCAGGCCGGGCCGTGGTGGCCACGGCCTCTAGGCCA
GATCCAGCGGCATCTGGGTTAGTCGAGCGCGGGCCGCTTCCCATGTCTCA
CCAGGGCGAGCCTGTTTCGCGATCTCAGCATCTGAAATCTTCCCGGCCTT
GCGCTTCGCTGGGGCCTTACCCACCGCCTTGGCGGGCTTCTTCGGTCCAA
AACTGAACAACAGATGTGTGACCTTGCGCCCGGTCTTTCGCTGCGCCCAC
TCCACCTGTAGCGGGCTGTGCTCGTTGATCTGCGTCACGGCTGGATCAAG
CACTCGCAACTTGAAGTCCTTGATCGAGGGATACCGGCCTTCCAGTTGAA
ACCACTTTCGCAGCTGGTCAATTTCTATTTCGCGCTGGCCGATGCTGTCC
CATTGCATGAGCAGCTCGTAAAGCCTGATCGCGTGGGTGCTGTCCATCTT
GGCCACGTCAGCCAAGGCGTATTTGGTGAACTGTTTGGTGAGTTCCGTCA
GGTACGGCAGCATGTCTTTGGTGAACCTGAGTTCTACACGGCCCTCACCC
TCCCGGTAGATGATTGTTTGCACCCAGCCGGTAATCATCACACTCGGTCT
TTTCCCCTTGCCATTGGGCTCTTGGGTTAACCGGACTTCCCGCCGTTTCA
GGCGCAGGGCCGCTTCTTTGAGCTGGTTGTAGGAAGATTCGATAGGGACA
CCCGCCATCGTCGCTATGTCCTCCGCCGTCACTGAATACATCACTTCATC
GGTGACAGGCTCGCTCCTCTTCACCTGGCTAATACAGGCCAGAACGATCC
GCTGTTCCTGAACACTGAGGCGATACGCGGCCTCGACCAGGGCATTGCTT
TTGTAAACCATTGGGGGTGAGGCCACGTTCGACATTCCTTGTGTATAAGG
GGACACTGTATCTGCGTCCCACAATACAACAAATCCGTCCCTTTACAACA
ACAAATCCGTCCCTTCTTAACAACAAATCCGTCCCTTAATGGCAACAAAT
CCGTCCCTTTTTAAACTCTACAGGCCACGGATTACGTGGCCTGTAGACGT
CCTAAAAGGTTTAAAAGGGAAAAGGAAGAAAAGGGTGGAAACGCAAAAAA
CGCACCACTACGTGGCCCCGTTGGGGCCGCATTTGTGCCCCTGAAGGGGC
GGGGGAGGCGTCTGGGCAATCCCCGTTTTACCAGTCCCCTATCGCCGCCT
GAGAGGGCGCAGGAAGCGAGTAATCAGGGTATCGAGGCGGATTCACCCTT
GGCGTCCAACCAGCGGCACCAGCGGCGCCTGAGAGGTATGGTGCACTCTC
CCGTCATCACCGAAACGCGCGA
The PA4033 (VE2) but not wild-type PA4033 allele caused
10 mucoid conversion in PAO1 and PA14 in association with an
elevated level ofA1gU in comparison with the parent (data not
shown). Because the insertional mutation was dominant over
the wild-type allele, we suspected that VE2 was overproduc-
ing the mucE product. Using RT-PCR, we determined that the
15 levels of mucE and a1gU mRNA were 7-fold and 1.2-fold
higher in VE2 (PAO1 mucE"') than in PAO1 respectively
(FIG. 713). Because of the positive effect on alginate regula-
tion, PA4033 was named mucE.
We also tested whether introduction of pUCP20-Gm"-
20 
mucE or pUCP20-PG.-mucE plasmids could cause mucoid
conversion in other non-mucoid P. aeruginosa strains. We
observed the emergence of a mucoid phenotype in the envi-
ronmental isolate ERC-1 and non-mucoid clinical CF isolates
including CF149 (Head, N. H. et al., Infect. Immun. 72:133-
25 144 (2004)) and early colonizing strains (C0746C, C0126C,
C0686C, C1207C, C3715C, C4009C, C7406C and C8403C)
(data not shown). Therefore, the extracytoplasmic stress sig-
nals may play an important role in the initial lung colonization
30 
and mucoid conversion of P. aeruginosa.
Induction of MucE initiates a regulatory cascade causing
an increased level of A1gU. It appears that induction of A1gU
is the major pathway that governs alginate overproduction.
The mutants that operate via this pathway include VE1 (algU
35 promoter mutants), VE2 (mucE +Oe) and VE22 (cupB5 +Oe)
and VE13 (kinB-). One common feature is that an elevated
level of MucB did not seem to match with that ofA1gU (FIGS.
6A-8A). As the algUmucA-D genes are an operon, this sug-
gests that the level of MucA in these mutants may not be the
40 same as that of A1gU. The excess A1gU could escape from the
antagonistic interaction with MucA, thus causing mucoid
conversion.
Another mutant, VE22, which had a dominant effect on
alginate overproduction, carried an insertion at 96 by before
45 ATG of cupB5 (PA4082) (Table 1). The cupB5 gene encodes
a probable adhesive protein (1,018 aa) with a predicted
molecular mass of 100 kDa. This protein has a signal peptide
of 53 aa, suggesting that the mature protein is bound for the
extracellular milieu. The protein shares consensus motifs of
50 the filamentous hemagglutinin and IgAl -specific metalloen-
dopeptidases (GLUG) at the N- and C-terminus, respectively.
The cupB5 gene sits within a genetic cluster encoding fim-
brial subunits and CupB5, which have been proposed to be the
chaperone/usher pathway involved in biofilm formation (Val-
55 let, I., et al., Proc Nad Acad Sci USA 98:6911-6916 (2001)).
Induction of cupB5 in VE22 caused upregulation ofA1gU and
MucB (FIG. 813).
Example 4
60
KinB is a Negative Regulator of Alginate in PAO1
As a sensor-kinase, KinB is responsible for responding to
some environmental signals and phosphorylating a response
65 regulator, A1gB, via signal transduction. One mutant, VE13,
displayed a stable mucoid phenotype (Table 1). The mutation
of VE13 was mapped to 788 bps after ATG of kinB. This
US 7,781,166 B2
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insertion caused a frameshift mutation with a stop codon
created at 54 bps after the insertion site. To ensure that inac-	
-continued
tivation of kinB was causal for the phenotype, PAOI kinBwas	 gtgcggttcg tgcacgacgc ccaggaagcc caggacgtag
cloned into pUCP20. Introduction of wild-type kinB in trans
into VE13 reversed the phenotype from Alg' to Alg- . Algi-	 5	
cgcaggaagc cttcatcaag gcataccgtg cgctcggcaa
nate production inVE13 was significantly higher than that in 	 tttccgcggc gatagtgctt tttatacctg gctgtatcgg
PAOI, which was associated with the increased amount of
AIgU	 (P-0.005) while the level	 of MucB remained	 atcgccatca acaccgcgaa gaaccacctg gtcgctcgcg
unchanged (P-0.07) compared with PAOI (FIGS. 8A and	 ggcgtcggcc accggacagc gatgtgaccg cagaggatgc
6A).	 10
The results show that the kinase activity inhibits overpro-	 ggagttcttc gagggcgacc acgccctgaa ggacatcgag
duction of alginate, thereby formally establishing the role of
KinB as a negative regulator of alginate. A1gB is a well-
tcgccggaac gggcgatgtt gcgggatgag atcgaggcca
known transcriptional activator for alginate biosynthesis. 	 ccgtgcacca gaccatccag cagttgcccg aggatttgcg
VE13 is a kinB null mutant of PAOI, and theAlg' phenotype 15
has been complemented to Alg	 by pUCP-kinB in trans.	 cacggccctg accctgcgcg agttcgaagg tttgagttac
Inactivation of kinB in PAOI increased the levels of AIgU	 gaagatatcg ccaccgtgat gcagtgtccg gtggggacgg
(FIG. 8A), suggesting that KinB may inhibit the expression of
algU via an AlgB-independent fashion. Alternatively, since 	 tgtccggtgg ggacggtacg gtcgcggatc ttccgcgctc
A1gB in VE13 is probably in an unphosphorylated or under- 20
phosphorylated state, it is possible that this form of A1gB
gtgaagcaat cgacaaagct ctgcagcctt tgttgcgaga
serves as the transcriptional activator for alginate.	 agcctgacac agcggcaaat gccaagagag gtta
Example 5	 VE3-NM2	 (SEQ ID NO:11) :
cttggcagac gattcgctgg gacgctcgaa gctcctccag
25
Reduced Expression of oprL Causes Mucoid 	 gttcgaagag gagctttcat gctaacccag gaacaggatc
Conversion in PAOI
agcaactggt tgaacgggta cagcgcggag acaagcgggc
One mutant, VE24, had an insertion at the stop codon ( 	 tttcgatctg ctggtactga aataccagca caagatactg
TAA) of oprL (PA0973) in the knockdown configuration. The 30
oprL gene encodes a homolog of the peptidoglycan associ-	 ggattgatcg tgcggttcgt gcacgacgcc caggaagccc
ated lipoprotein precursor (168 aa) with a predicted molecu-
larmass of 18 kDa. OprL has a leader sequence of 24 aa which aggacgtagc gcaggaagcc ttcatcaagg cataccgtgc
probably directs the mature protein to the outer membrane. 	 gctcggcaat ttccgcggcg atagtgcttt ttatacctgg
Reduced expression of oprL in VE24 caused mucoid conver- 35
sion in PAOI, and was associated with a reduced level of 	 ctgtatcgga tcgccatcaa caccgcgaag aaccacctgg
AIgU and MUCB (FIG. 813).	 tcgctcgcgg gcgtcggcca ccggacagcg atgtgaccgc
Example 6	 agaggatgcg gagttcttcg agggcgacca cgccctgaag
40
Nonmucoid Revertants inAlgU-Hyperactive 	 gacatcgagt cgccggaacg ggcgatgttg cgggatgaga
Mutants were Caused by Suppressor Mutations 	 tcgaggccac cgtgcaccag accatccagc agttgcccga
Inactivating algU
ggatttgcgc acggccctga ccctctgcgc gagttcgaag
Eleven percent of insertions were in the intergenic region 45	 gtttgagtta cgaagatatc gccaccgtga tgcagtgtcc
between a1gU and mucA in the knockdown configuration
(Table 1). The mutants of this category were hyper mucoid. 	 ggtggggacg gtacggtcgc ggatcttccg cgctcgtgaa
The level ofA1gU in VE3 was slightly reduced compared with
that in PAOI (FIG. 8B). The abundance of algU mRNA in 	 gcaatcgaca aagctctgca gcctttgttg cgagaagcct
VE3 was 84% of that in PAOI based on RT-PCR (FIG. 7B). 50	 gacacagcgg caaatgccaa gagaggta
Four random spontaneous non-mucoid revertants of VE3,
PAOI-VE3-NMI-4, were isolated (GenBank accessionnum- 	 VE3-NM3 (SEQ ID NO:12) :
hers DQ352563, DQ352564, DQ352565, and DQ352566). 	 tatcttggca agacgattcg ctgggacgct cgaagctcct
Sequencing the algU gene in VE3-NMI, -NM2, -NM3 and 	 ccaggttcga agaggagctt tcatgctaac ccaggaacag
-NM4 revealed that all carried a completely inactivated algU 55
gene due to tandem duplications or a nonsense mutation. The 	 gatcagcaac tggttgaacg ggtacagcgc ggagacaagc
nucleotide sequences of these four algU mutants are: 	 gggctttcga tctgctggta ctgaaatacc agcacaagat
actgggattg atcgtgcggt tcgtgcacga cgcccaggaa
VE3-NM1	 (SEQ ID NO:10):
cgattcgctg ggacgctcga agctcctcca ggttcgaaga	 60	 gcccaggacg tagcgcagga agccttcatc aaggcatacc
ggagctttca tgctaaccca ggaacaggat cagcaactgg	 gtgcgctcgg caatttccgc ggcgatagtg ctttttatac
ttgaacgggt acagcgcgga gacaagcggg ctttcgatct 	 ctgactgtat cggatcgcca tcaacaccgc gaagaaccac
gctggtactg aaataccagc acaagatact gggattgatc	 65	 ctggtcgctc gcgggcgtcg gccaccggac agcgatgtga
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ccgcagagga tgcggagttc ttcgagggcg accacgccct
gaaggacatc gagtcgccgg aacgggcgat gttgcgggat
gagatcgagg ccaccgtgca ccagaccatc cagcagttgc
ccgaggattt gcgcacggcc ctgaccctgc gcgagttcga
aggtttgagt tacgaagata tcgccaccgt gatgcagtgt
ccggtgggga cggtacggtc gcggatcttc cgcgctcgtg
aagcaatcga caaagctctg cagcctttgt tgcgagaagc
ctgacacagc ggcaaatgcc aagagagta
VE3-NM4 (SEQ ID NO:13):
gattcgctgg gacgctcgaa gctcctccag gttcgaagag
gagctttcat gctaacccag gaacaggatc agcaactggt
tgaacgggta cagcgcggag acaagcgggc tttcgatctg
ctggtactga aataccagca caagatactg ggattgatcg
tgcggttcgt gcacgacgcc caggaagccc aggacgtagc
gcaggaagcc ttcatcaagg cataccgtgc gctcggcaat
ttccgcggcg atagtgcttt ttatacctgg ctgtatcgga
tcgccatcaa caccgcgaag aaccacctgg tcgctcgcgg
gcgtcggcca ccggacagcg atgtgaccgc agaggatgcg
gagttcttcg agggcgacca cgccctgaag gacatcgagt
cgccggaacg ggcgatgttg cgggatgaga tcgaggccac
cgtgcaccag accatccagc agttgcccga ggatttgcgc
acggccctga ccctgcgcga gttcgaaggt ttgagttacg
aagatatcgc caccgtgatg cagtgtccgg tggggacggt
gtccggtggg gacggtacgg tcgcggatct tccgcgctcg
tgaagcaatc gacaaagctc tgcagccttt gttgcgagaa
gcctgacaca gcggcaaatg ccaagagagg to
These mutations resulted in the disappearance ofA1gU and
MucB in these mutants (FIG. 813). The suppressor mutants
were complemented to Alg' by a1gU in trans. The comple-
mented mutants, which restored the mucoid phenotype,
caused the re-appearance of A1gU (FIG. 813). We also mea-
sured the A1gU-dependent P  promoter activity by fusing the
PaigUPi to the lacZ gene on the chromosome (DeVries, C.
A. & Ohman, D. E., J Bacteriol 176:6677-6687 (1994);
Schurr, M. 7., et al., J Bacteriol 176:3375-3382 (1995)).
Assay of the (3-galactosidase activity indicated that the
Paigupi activity was 2348±156 units in NHl (algU') and
16.0±5.5 units in NH3 (algU-) while that of the promoterless
control in NH2 was 146±34 units (P=1.2x10 -5) (data not
shown).
PA0579 is a relatively unstable mucoid mutant of PAOI
origin with an undefined muc-23 mutation. A spontaneous
non-mucoid revertant, PA0579NM, was isolated which had
an unknown suppressor mutation. The algUmucA alleles in
PA0579 and PA0579NM were sequenced but no mutations
were detected. To discern the pathway that regulated the
mucoid phenotype in this strain, PA0579NM was
mutagenized to screen for mucoid mutants. Three sites, the
a1gU promoter, the algUmucA intergenic region and mucA,
were targeted that reversed the phenotype to Alg' (Table 1).
34
The highest frequency of mutations (60% within the strain)
occurred in the a1gU promoters causing increased levels of
A1gU and MucB in the same fashion as in VE1 in FIG. 5A
(data not shown).
5
The results show that inactivation of mucA and mucB did
not cause a marked induction in the amounts of A1gU and
MucB to the same extent as the kinB, mucE and cupB5
mutants (FIG. 8B vs. 6A-8A). This supports the notion that
io the mucAB and oprL genes negatively regulate the activity of
A1gU (Firoved, A. M. & Deretic, V., JBacteriol 185:1071-
1081 (2003); Mathee, K., et al., JBacteriol 179:3711-3720
(1997)).
15	 Example 7
Upregulation of A1gU (A1gT) Causes Mucoid
Conversion
20
The mucoid phenotype in clinical isolates of P. aeruginosa
is unstable, and non-mucoid revertants arise spontaneously in
the laboratory. Suppressor mutations in a1gT were the main
cause of mucoid suppression in P. aeruginosa (DeVries, C.
25 A. & Ohman, D. E., J Bacteriol 176:6677-6687 (1994);
Schurr, M. 7., et al., J Bacteriol 176:3375-3382 (1994)).
FRD2 is a CF isolate which has a suppressor mutation in
a1gT18 (DeVries, C. A. & Ohman, D. E., JBacteriol 176:
30 6677-6687 (1994)). Three rare mucoid mutants were identi-
fied in FRD2 (Table 1). They all had an insertion in front of
a1gU, in the same manner as the a1gU promoter mutants in
PAO1 (VE1), PA14, and PA0579NM, which resulted in
increased transcription of the algTl8mucA22mucBC operon
35 as confirmed by Western blots (FIG. 813).
The rare FRD2 mucoid mutants coupled with the upregu-
lation ofA1gU support the notion thatAlgU is the only sigma
factor controlling the expression of algD in P. aeruginosa
(FIG. 8). The results indicate that a suppressor nonmucoid
40 mutant (FRD2) can revert back to a mucoid phenotype
(FRD2-VE1) in P. aeruginosa. This observation may help to
explain why the a1gU suppressors are prevalent in clinical
isolates.
45 Analysis of the suppressor mutations in a1gU indicate that
A1gU is required for alginate overproduction but is not an
essential protein in P. aeruginosa.
Example 8
50
The Carboxyl Terminus of MucE Affects Mucoid
Induction
The carboxyl-terminal signal of MucE (WVF) has a simi-
55 lar three consensus as sequence as OmpC (YQF) (Walsh et
al., 2003). Searching for this motif in the known outer mem-
brane protein database from PAO1 did not identify any obvi-
ous E. coli OmpC homologs, indicating that mucE encodes a
60 protein specific for induction of alginate. Other protein sig-
nals with such a function also exist. The C-terminal Cup135
carries the three amino acid motif NIW. NIW and WVF are
not interchangeable in MucE (unpublished observation),
indicating that MucE and Cup135 work on different effector
65 proteins in the periplasm. Table II shows the effect of altering
the carboxyl terminus of MucE on mucoid induction in P.
aeruginosa.
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TABLE II	 TABLE III
Alteration of C-terminal signal moiety of MucE and mucoidy induction	 MucE-mediated induction of mucoidy in the mucA'
in Pseudomonas aeruginosa PAO1.	 5	 wild type P. aeruginosa is via AlgW.
Carboxyl
terminal
sequences
Mucoidy
induction
Outer membrane proteins with
the same C-terminal peptide
-WVF M MucE
(Wild-type)
-YVF M OprP, OprQ
-LVF M MucE orthologue (P. fluoresces)
-WIF M MucE orthologue (P. syringae)
-WVW M
-WQF NM*
-YQF NM* OptS, HasR, OmpC and OmpF ofE. coli.
-WLF NM
-DRF NM AlgE
-YYF NM Strongest signal in E. coli
-YKF NM OprH (PA1178)
-FQF NM AlgI
-WWW NM
-WVA NM
-WVY NM
-ELR NM
(AWVF)
-RWV NM
(AF)
M: mucoid.; NM: Non-mucoid;
*Slightly mucoid after 1 day of incubation
The results in Table II show that the last three carboxyl-
terminal amino acids of MucE, WVF, are critical for the
ability of MucE to induce mucoid induction.
Similarly, the WFV signal induced mucoidy in P. fluore-
scens. The WVF and YVF carboxyl terminal sequences sig-
nificantly induced mucoidy, while theYQF carboxyl terminal
sequence did not (data not shown). The envelope signal is
well conserved among Pseudomonads. Therefore, P. fluore-
scens is an alternative producer when alginate will be used for
human consumption.
Example 9
MucE Interacts with A1gW Resulting in Alginate
Overproduction
A1gW (GenBank accession number (U29172) is a periplas-
mic serine protease in P. aeruginosa. Inactivation of algW on
the chromosome of PAOI -VE2 causes this strain to become
nonmucoid (Boucher, J. C., et al., J. Bacteriol. 178:511-523
(1996)). Revertion back to the mucoid state occurs when a
functional copy of algW is brought into the cells. Similarly,
the disruption of algW in PAOI (PAOlAalgW) prevents
mucoid induction even when plasmid-borne mucE (pUCP20-
Gm''-mucE) was in a state of overexpression. MucE is found
to interact with A1gW causing alginate overproduction by
increasing the expression and/or activity of A1gU.
Normally, A1gW is inactive because the functional domain
(the trypsin domain) is covered with a PDZ domain of its own.
Interaction between MucE and AlgW results in the release of
the PDZ domain of A1gW. This interaction occurs via the
carboxyl terminus of MucE, specifically the terminal amino
acids WVF, resulting in the activation of A1gW. Activated
A1gW degrades the carboxyl terminus of anti-sigma factor
MucA. This action causes the release of A1gU into the cyto-
plasm, thereby activating alginate biosynthesis (see FIG. 9).
A1gU is the sigma factor that drives alginate biosynthesis.
Therefore, MucE is an inducing signal for alginate overpro-
duction and the periplasmic target of MucE is A1gW (see
Table III).
Bacterial
strains	 Genotype	 Phenotype
PAOI	 Wild type	 NM
VE2	 PAOI over-expressing mucE	 M
10 VE2 algal KO	 VE2 algW knockout 	 NM
VE2 algal KO +	 VE2 algW KO + pUCP20 algW M
pUCP20alg W
The nucleotide sequence of algW (SEQ ID NO: 14) is as
15 follows:
ATGCCCAAGGCCCTGCGTTTCCTCGGCTGGCCCGTGCTGGTCGGCGTGCT
20 GCTGGCCCTGCTGATCATCCAGCACAACCCCGAGCTGGTCGGCCTGCCAC
GCCAGGAGGTGCACGTCGAGCAGGCGCCTCTGCTCAGCCGCCTGCAGGAA
GGCCCGGTGTCCTATGCCAACGCGGTGAGTCGAGCGGCTCCGGCAGTGGC
CAACCTGTACACCACCAAGATGGTCAGCAAGCCCTCCCACCCCCTGTTCG
25
ACGACCCGATGTTCCGCCGCTTCTTCGGCGACAACCTGCCGCAACAGAAG
CGCATGGAGTCGAGCCTCGGCTCGGCGGTGATCATGAGCGCGGAAGGCTA
CCTGCTGACCAACAACCACGTGACCGCTGGCGCCGACCAGATCATCGTGG
30
CCTTGCGCGACGGCCGCGAAACCATCGCCCAGTTGGTCGGCAGCGACCCG
GAAACCGACCTGGCCGTGCTGAAGATCGACCTTAAGAACCTGCCGGCGAT
GACCCTCGGCCGCTCCGACGGCATTCGCACCGGCGACGTCTGCCTCGCCA
35
TCGGCAACCCGTTCGGCGTCGGCCAGACCGTGACCATGGGCATCATCAGC
GCCACCGGACGCAACCAGCTCGGCCTGAACACCTACGAAGACTTCATCCA
GACCGACGCGGCGATCAACCCCGGCAACTCCGGCGGCGCGCTGGTGGACG
40 CTGCCGGCAACCTGATCGGCATCAACACGGCGATCTTCTCCAAGTCCGGC
GGCTCCCAGGGTATCGGCTTCGCCATCCCGACCAAGCTGGCCCTGGAGGT
CATGCAGTCGATCATCGAGCACGGCCAGGTGATCCGCGGCTGGCTCGGCG
45 TCGAGGTCAAGGCGCTGACCCCGGAACTGGCGGAGTCGCTGGGCCTCGGC
GAAACCGCCGGGATCGTCGTCGCCGGCGTCTATCGCGACGGTCCGGCGGC
ACGCGGCGGCCTGCTGCCGGGCGATGTGATCCTGACCATCGACAAGCAGG
50 AAGCCAGCGACGGCCGCCGCTCGATGAACCAGGTGGCGCGCACCCGTCCG
GGACAGAAGATCAGCATCGTGGTGCTGCGCAACGGACAGAAGGTCAACCT
GACCGCCGAGGTCGGCCTGCGTCCGCCGCCGGCACCGGCTCCACAGCAGA
55 AACAGGACGGCGGCGAGTGA
The amino acid sequence of A1gW (SEQ ID NO: 15) is as
follows:
60 MPKALRFLGWPVLVGVLLALLIIQHNPELVGLPRQEVHVEQAPLLSRLQE
GPVSYANAVSRAAPAVANLYTTKMVSKPSHPLFDDPMFRRFFGDNLPQQK
RMESSLGSAVIMSAEGYLLTNNHVTAGADQIIVALRDGRETIAQLVGSDP
65 ETDLAVLKIDLKNLPAMTLGRSDGIRTGDVCLAIGNPFGVGQTVTMGIIS
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ATGRNQLGLNTYEDFIQTDAAINPGNSGGALVDAAGNLIGINTAIFSKSG
GSQGIGFAIPTKLALEVMQSIIEHGQVIRGWLGVEVKALTPELAESLGLG
ETAGIVVAGVYRDGPAARGGLLPGDVILTIDKQEASDGRRSMNQVARTRP
GQKISIVVLRNGQKVNLTAEVGLRPPPAPAPQQKQDGGE
38
shown) was seen. These results indicate that MucP is required
for MucE activation ofA1gU activity.
Example 12
5
MucE-Induced Mucoidy does not Require the Prc
Protease
The homolog ofA1gW is DegS inE. coli (see also FIG. 12).
The interaction between DegS and OmpC, an outer mem-
brane porin protein, has been shown to activate the signal
transduction pathway for the activation of RpoE, the A1gU
homolog in E. coli. It has been shown that interaction between
OmpC and DegS in the periplasm activates the signal trans-
duction pathway that controls the expression and/or activity
of RpoE, a homolog of A1gU (Walsh, N. P., et al., Cell 113:
61-71 (2003)).
The results suggest that MucE functions upstream of the
anti-sigma factor MucA.
Example 10
The MucE Gene Encodes a Small Periplasmic or
Outer Membrane Protein
The mucE gene is predicted to encode a polypeptide of 89
amino acids with a probable transmembrane helix and a
cleavable N-terminal signal sequence. (Stover, C. K., et al.,
Nature 406:959-964 (2000)). Homologues of MucE are
found in other species of p seudomonads capable of producing
alginate (FIG. 11). We confirmed that mucE encodes a protein
by detecting an approximately 10 kD protein in Western blots
of cell extracts of E. coli and P. aeruginosa expressing His-
tagged MucE (FIG. 13). PseudoCAP and Signal IP servers
predicted that MucE is likely to be located in the periplasm.
To test the localization of MucE, we constructed a series of
deletions of mucE-phoA translational fusions. We observed
phosphatase activity when phoA was fused to sequence cor-
responding to the full-length MucE or the N-terminus after
P36 but not after A25. The MucE C-terminus-PhoA fusion
did not show apparent phosphatase activity (FIG. 14). These
results indicate that MucE is a small protein of about 9.5 kDa
located in the periplasm or outer membrane, with an N-ter-
minal signal sequence that is required for translocation across
the cytoplasmic membrane.
Example 11
MucP is Essential for MucE-Induced Conversion to
Mucoidy
In E. coli, the degradation of RseA requires another pro-
tease called RseP (also known as YaeL) to cleave the anti-
sigma factor RseA after it is cleaved by DegS (Alba, B. M., et
al., Genes Dev 16:2156-2168 (2002); Kanehara, K., et al.,
Embo J 22:6389-6398 (2003)). The P. aeruginosa genome
also contains a homolog of RseP (PA3649, designated as
MucP) (FIG. 15). The role of MucP in the degradation of
MucA and activation of A1gU activity was examined. Inacti-
vation of mucP in PAOI VE2 caused a loss of mucoidy. Fur-
thermore, the plasmid pUCP20 (pUCP20-mucP) restored the
mucoid phenotype in PAOI VE2AmucP. Similarly, disruption
of mucP in PAOI prevented mucoid conversion when a high
level of MucE was present from plasmid pUC20-Gmr-mucE.
In addition, a higher level of MucA and a lower level of A1gU
in PAOI VE2AmucP as compared to PAOI VE2 (data not
10 The gene prc (PA3257) was recently identified as a regu-
lator of alginate synthesis in P. aeruginosa and is predicted to
encode a PDZ domain-containing periplasmic protease simi-
lar to a E. coli protease called Prc or Tsp (Reiling S. A., et al.,
Microbiology 151:2251-2261 (2005)). Prc appears to act to
15 promote mucoidy in mucA mutants by degrading truncated
forms of MucA found in mucoid mucA mutants (Reiling S.
A., et al., Microbiology 151:2251-2261 (2005)). To test
whether Prc plays a role in the activation of alginate produc-
tion mediated by MucE, MucE was overexpressed in a strain
20 lacking Prc and examined for mucoidy. Cells of the prc null
mutant PAOI-184 (prc::tetR) carrying either MucE overex-
pression plasmid pUCP20-Gmr-mucE or pUCP20PGm-
mucE were as mucoid as PAOI cells carrying pUCP20-Gmr-
25 mucE or pUCP20 PGm-mucE. These results suggest that
Prc is not required for mucoidy induced by MucE and is
consistent with Prc only acting against truncated forms of
MucA.
30	 Example 13
MucD Eliminates Signal Proteins that Activate A1gW
and Other Proteases to Cleave MucA
35 The mucD gene (PA0766) is a member of the a1gU
mucABCD operon and is predicted to encode a serine pro-
tease similar to HtrA in E. coli (Boucher, C. 7., et al., J.
Bacteriol. 178:511-523 (1996)). MucD appears to be a nega-
40 tive regulator of mucoidy andAlgU activity (Boucher, C. 7., et
al., J. Bacteriol. 178:511-523 (1996)). The mariner transpo-
son library screen confirmed this result because several
mucoid mutants were isolated that had transposons inserted
within the coding region of mucD. HtrA in E. coli has been
45 hypothesized to regulate the cTE stress response system by
removing misfolded proteins in the periplasm that can acti-
vate the DegS protease via the degradation of the anti-sigma
factor RseA (Alba, B. M., et al., Genes Deu 16:2156-2168
(2002); Kanehara, K., et al., Embo J. 22:6389-6398 (2003)).
50 Therefore, it was determined whether MucD ofP.. aeruginosa
acted in a similar manner as HtrA of E. coli. To test this,
overexpression of MucD in a strain overexpressing MucE
was examined. Overexpression of mucD from the plasmid
55 
pUCP20-mucD partially suppressed the mucoid phenotype
of the mucE-overexpressing strain PAOI VE2. This result is
consistent with the notion that MucD can aid in the elimina-
tion of mis-folded OMPs including MucE. In addition, dis-
ruption of mucP in the mucoid mucD mutant PAOIVE19
60 caused the loss of the mucoid phenotype. The mucoid phe-
notype of PAOI VE19AmucP was restored when mucP was in
trans. Loss of the mucoid phenotype from the mucD mutant
PAOIVE19 after the disruption of algW was not observed.
The results suggest that MucD can act to remove misfolded
65 proteins that activate proteases for degradation of MucA and
that at least under certain conditions other proteases indepen-
dent of A1gW can also initiate the cleavage of MucA.
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SEQUENCE LISTING
<160> NUMBER OF SEQ ID NOS: 37
<210> SEQ ID NO 1
<211> LENGTH:	 270
<212> TYPE: DNA
<213> ORGANISM: Pseudomonas aeruginosa
<400> SEQUENCE:	 1
atgggtttcc ggccagttag ccaacgtttg cgtgacatca acctgcaggc cctcggcaag 60
ttttcctgcc ttgccctggt cctcggcctg gaatcggtaa gccatccggc cggcccggtc 120
caggccccct cgttcagcca gggcaccgcc agcccgtcct tcgctactcc gctcggcctc 180
gacggcccgg cccgcgccag ggccgagatg tggaacgtcg gcctgtccgg cgccgtcagc 240
gtgcgtgacg agttgcgctg ggtgttttga 270
<210> SEQ ID NO 2
<211> LENGTH: 89
<212> TYPE: PRT
<213> ORGANISM: Pseudomonas aeruginosa
<400> SEQUENCE: 2
Met Gly Phe Arg Pro Val Ser Gin Arg Leu Arg Asp Ile Asn Leu Gin
1	 5	 10	 15
Ala Leu Gly Lys Phe Ser Cys Leu Ala Leu Val Leu Gly Leu Glu Ser
20	 25	 30
Val Ser His Pro Ala Gly Pro Val Gin Ala Pro Ser Phe Ser Gin Gly
35	 40	 45
Thr Ala Ser Pro Ser Phe Ala Thr Pro Leu Gly Leu Asp Gly Pro Ala
50	 55	 60
Arg Ala Arg Ala Glu Met Trp Asn Val Gly Leu Ser Gly Ala Val Ser
65	 70	 75	 80
Val Arg Asp Glu Leu Arg Trp Val Phe
85
<210> SEQ ID NO 3
<211> LENGTH:	 288
<212> TYPE: DNA
<213> ORGANISM: Pseudomonas fluorescens
<400> SEQUENCE: 3
atggggaacc tgctcaggaa aggccaggtc gcgcttgtca gaatattcag cggcgatgat 60
ccggtgcgtc ttctcagttt gatgctggcg gcttatctgg gaatcagtgc ctgtaccgtg 120
ccagcgtcca cagcgggctg ctgtcagccc tccggcatag ggcaataccc ggcgtctgcc 180
ctgcccgctg gcagtgactc caacctgacc ctggacgccg agcccgtgat cggtcggaca 240
gcgctaccca cgaacctgca gccaccggcc ccgcgctggg tgttctag 288
<210> SEQ ID NO 4
<211> LENGTH: 95
<212> TYPE: PRT
<213> ORGANISM: Pseudomonas fluorescens
<400> SEQUENCE: 4
Met Gly Asn Leu Leu Arg Lys Gly Gin Val Ala Leu Val Arg Ile Phe
1	 5	 10	 15
Ser Gly Asp Asp Pro Val Arg Leu Leu Ser Leu Met Leu Ala Ala Tyr
20	 25	 30
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Leu Gly Ile Ser Ala Cys Thr Val Pro Ala Ser Thr Ala Gly Cys Cys
35	 40	 45
Gln Pro Ser Gly Ile Gly Gln Tyr Pro Ala Ser Ala Leu Pro Ala Gly
50	 55	 60
Ser Asp Ser Asn Leu Thr Leu Asp Ala Glu Pro Val Ile Gly Arg Thr
65	 70	 75	 80
Ala Leu Pro Thr Asn Leu Gln Pro Pro Ala Pro Arg Trp Val Phe
85	 90	 95
<210> SEQ ID NO 5
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic complementary oligonucleotide
sequence designed to form hybridized complexes
<400> SEQUENCE: 5
tcaaaacacc cagcgcaact cgtcacg	 27
<210> SEQ ID NO 6
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic complementary oligonucleotide
sequence designed to form hybridized complexes
<400> SEQUENCE: 6
agtagcgaag gacgggctgg cggt 	 24
<210> SEQ ID NO 7
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic complementary oligonucleotide
sequence designed to form hybridized complexes
<400> SEQUENCE: 7
ttggctaact ggccggaaac ccat 	 24
<210> SEQ ID NO 8
<211> LENGTH: 1473
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic sequence of mariner transposon's
junction region
<400> SEQUENCE: 8
accacacccg ccgcgcttaa tgcgccgcta cagggcgcgt cccattcgcc actcaaccaa 	 60
gtcattctga gaatagtgta tgcggcgacc gagttgctct tgcccggcgt caatacggga 	 120
taataccgcg ccacataaca ggttggctga taagtccccg gtctaacaaa gaaaaacaca 	 180
tttttttgtg aaaattcgtt tttattattc aacatagttc ccttcaagag cgatacccct 	 240
cgaattgacg cgtcaattct cgaattgaca taagcctgtt cggttcgtaa actgtaatgc 	 300
aagtagcgta tgcgctcacg caactggtcc agaaccttga ccgaacgcag cggtggtaac 	 360
ggcgcagtgg cggttttcat ggcttgttat gactgttttt ttgtacagtc tatgcctcgg 	 420
gcatccaagc agcaagcgcg ttacgccgtg ggtcgatgtt tgatgttatg gagcagcaac 	 480
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gatgttacgc agcagcaacg atgttacgca gcagggcagt cgccctaaaa caaagttagg 	 540
tggctcaagt atgggcatca ttcgcacatg taggctcggc cctgaccaag tcaaatccat 	 600
gcgggctgct cttgatcttt tcggtcgtga gttcggagac gtagccacct actcccaaca 	 660
tcagccggac tccgattacc tcgggaactt gctccgtagt aagacattca tcgcgcttgc 	 720
tgccttcgac caagaagcgg ttgttggcgc tctcgcggct tacgttctgc ccaggtttga 	 780
gcagccgcgt agtgagatct atatctatga tctcgcagtc tccggcgagc accggaggca 	 840
gggcattgcc accgcgctca tcaatctcct caagcatgag gccaacgcgc ttggtgctta 	 900
tgtgatctac gtgcaagcag attacggtga cgatcccgca gtggctctct atacaaagtt 	 960
gggcatacgg gaagaagtga tgcactttga tatcgaccca agtaccgcca cctaacaatt 	 1020
cgttcaagcc gagatcggct tcccggccga cgcgtcctcg gtaccgggcc ccccctcgag 	 1080
gtcgacggta tcgataagct tgatatcgaa ttcctgcagc ccgggaatca tttgaaggtt 	 1140
ggtactatat aaaaataata tgcatttaat actagcgacg ccatctatgt gtcagaccgg 	 1200
ggacttatca gccaacctgt tagcagaact ttaaaagtgc tcatcattgg aaaaaggctg 	 1260
cgcaactgtt gggaagggcg atcggtgcgg gcctcttcgc tattacgcca gctggcgaaa 	 1320
gggggatgtg ctgcaaggcg attaagttgg gtaacgccag ggttttccca gtcacgacgt 	 1380
tgtaaaacga cggccagtga gcgcgcgtaa tacactcact atagggcgaa ttggaggatc 	 1440
cggtctaaca aagaaaacac attttttgtg aaa	 1473
<210> SEQ ID NO 9
<211> LENGTH: 5622
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic sequence of pUCP20-Gm-MucE plasmid
<400> SEQUENCE: 9
gacgaaaggg cctcgtgata cgcctatttt tataggttaa tgtcatgata ataatggttt 	 60
cttagacgtc aggtggcact tttcggggaa atgtgcgcgg aacccctatt tgtttatttt 	 120
tctaaataca ttcaaatatg tatccgctca tgagacaata accctgataa atgcttcaat 	 180
aatattgaaa aaggaagagt atgagtattc aacatttccg tgtcgccctt attccctttt 	 240
ttgcggcatt ttgccttcct gtttttgctc acccagaaac gctggtgaaa gtaaaagatg 	 300
ctgaagatca gttgggtgca cgagtgggtt acatcgaact ggatctcaac agcggtaaga 	 360
tccttgagag ttttcgcccc gaagaacgtt ttccaatgat gagcactttt aaagttctgc 	 420
tatgtggcgc ggtattatcc cgtattgacg ccgggcaaga gcaactcggt cgccgcatac 	 480
actattctca gaatgacttg gttgagtact caccagtcac agaaaagcat cttacggatg 	 540
gcatgacagt aagagaatta tgcagtgctg ccataaccat gagtgataac actgcggcca 	 600
acttacttct gacaacgatc ggaggaccga aggagctaac cgcttttttg cacaacatgg 	 660
gggatcatgt aactcgcctt gatcgttggg aaccggagct gaatgaagcc ataccaaacg 	 720
acgagcgtga caccacgatg cctgtagcaa tggcaacaac gttgcgcaaa ctattaactg 	 780
gcgaactact tactctagct tcccggcaac aattaataga ctggatggag gcggataaag 	 840
ttgcaggacc acttctgcgc tcggcccttc cggctggctg gtttattgct gataaatctg 	 900
gagccggtga gcgtgggtct cgcggtatca ttgcagcact ggggccagat ggtaagccct 	 960
cccgtatcgt agttatctac acgacgggga gtcaggcaac tatggatgaa cgaaatagac 	 1020
agatcgctga gataggtgcc tcactgatta agcattggta actgtcagac caagtttact 	 1080
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catatatact ttagattgat ttaaaacttc atttttaatt taaaaggatc taggtgaaga 	 1140
tcctttttga taatctcatg accaaaatcc cttaacgtga gttttcgttc cactgagcgt 	 1200
cagaccccgt agaaaagatc aaaggatctt cttgagatcc tttttttctg cgcgtaatct 	 1260
gctgcttgca aacaaaaaaa ccaccgctac cagcggtggt ttgtttgccg gatcaagagc 	 1320
taccaactct ttttccgaag gtaactggct tcagcagagc gcagatacca aatactgtcc 	 1380
ttctagtgta gccgtagtta ggccaccact tcaagaactc tgtagcaccg cctacatacc 	 1440
tcgctctgct aatcctgtta ccagtggctg ctgccagtgg cgataagtcg tgtcttaccg 	 1500
ggttggactc aagacgatag ttaccggata aggcgcagcg gtcgggctga acggggggtt 	 1560
cgtgcacaca gcccagcttg gagcgaacga cctacaccga actgagatac ctacagcgtg 	 1620
agctatgaga aagcgccacg cttcccgaag ggagaaaggc ggacaggtat ccggtaagcg 	 1680
gcagggtcgg aacaggagag cgcacgaggg agcttccagg gggaaacgcc tggtatcttt 	 1740
atagtcctgt cgggtttcgc cacctctgac ttgagcgtcg atttttgtga tgctcgtcag 	 1800
gggggcggag cctatggaaa aacgccagca acgcggcctt tttacggttc ctggcctttt 	 1860
gctggccttt tgctcacata agctagctta tcggccagcc tcgcagagca ggattcccgt 	 1920
tgagcaccgc caggtgcgaa taagggacag tgaagaagga acacccgctc gcgggtgggc 	 1980
ctacttcacc tatcctgccc ggctgacgcc gttggataca ccaaggaaag tctacacgaa 	 2040
ccctttggca aaatcctgta tatcgtgcga aaaaggatgg atataccgaa aaaatcgcta 	 2100
taatgacccc gaagcagggt tatgcagcgg aaagtatacc ttaaggaatc cccatgttct 	 2160
ttcctgcgtt atcccctgat tctgtggata accgtattac cgcctttgag tgagctgata 	 2220
ccgctcgccg cagccgaacg accgagcgca gcgagtcagt gagcgaggaa gcggaagagc 	 2280
gcccaatacg caaaccgcct ctccccgcgc gttggccgat tcattaatgc agctggcacg 	 2340
acaggtttcc cgactggaaa gcgggcagtg agcgcaacgc aattaatgtg agttagctca 2400
ctcattaggc accccaggct ttacacttta tgcttccggc tcgtatgttg tgtggaattg 	 2460
tgagcggata acaatttcac acaggaaaca gctatgacca tgattacgaa ttcgagctcg 	 2520
gtaccctagc ctgattccaa atagccatta agcgggacga agagcccgtg agccagcgcc 	 2580
agcctgacct aacaggttgg ctgataagtc cccggtctaa caaagaaaaa cacatttttt 	 2640
tgtgaaaatt cgtttttatt attcaacata gttcccttca agagcgatac ccctcgaatt 	 2700
gacgcgtcaa ttctcgaatt gacataagcc tgttcggttc gtaaactgta atgcaagtag 	 2760
cgtatgcgct cacgcaactg gtccagaacc ttgaccgaac gcagcggtgg taacggcgca 	 2820
gtggcggttt tcatggcttg ttatgactgt ttttttgtac agtctatgcc tcgggcatcc 	 2880
aagcagcaag cgcgttacgc cgtgggtcga tgtttgatgt tatggagcag caacgatgtt 	 2940
acgcagcagc aacgatgtta cgcagcaggg cagtcgccct aaaacaaagt taggtggctc 	 3000
aagtatgggc atcattcgca catgtaggct cggccctgac caagtcaaat ccatgcgggc 	 3060
tgctcttgat cttttcggtc gtgagttcgg agacgtagcc acctactccc aacatcagcc 	 3120
ggactccgat tacctcggga acttgctccg tagtaagaca ttcatcgcgc ttgctgcctt 	 3180
cgaccaagaa gcggttgttg gcgctctcgc ggcttacgtt ctgcccaggt ttgagcagcc 	 3240
gcgtagtgag atctatatct atgatctcgc agtctccggc gagcaccgga ggcagggcat 	 3300
tgccaccgcg ctcatcaatc tcctcaagca tgaggccaac gcgcttggtg cttatgtgat 	 3360
ctacgtgcaa gcagattacg gtgacgatcc cgcagtggct ctctatacaa agttgggcat 	 3420
US 7,781,166 B2
47	 48
-continued
acgggaagaa gtgatgcact ttgatatcga cccaagtacc gccacctaac aattcgttca 	 3480
agccgagatc ggcttcccgg ccgacgcgtc ctcggtaccg ggccccccct cgaggtcgac 	 3540
ggtatcgata agcttgatat cgaattcctg cagcccggga atcatttgaa ggttggtact 	 3600
atataaaaat aatatgcatt taatactagc gacgccatct atgtgtcaga ccggggactt 	 3660
atcagccaac ctgttatcaa ggagtcgtag ccatgggttt ccggccagtt agccaacgtt 	 3720
tgcgtgacat caacctgcag gccctcggca agttttcctg ccttgccctg gtcctcggcc 	 3780
tggaatcggt aagccatccg gccggcccgg tccaggcccc ctcgttcagc cagggcaccg 	 3840
ccagcccgtc cttcgctact ccgctcggcc tcgacggccc ggcccgcgcc agggccgaga 	 3900
tgtggaacgt cggcctgtcc ggcgccgtca gcgtgcgtga cgagttgcgc tgggtgtttt 	 3960
gaacgcgaag cttaggggat cctctagagt cgacctgcag gcatgcaagc ttggcactgg 4020
ccgtcgtttt acaacgtcgt gactgggaaa accctggcgt tacccaactt aatcgccttg 	 4080
cagcacatcc ccctttcgcc agctggcgta atagcgaaga ggcccgcacc gatcgccctt 	 4140
cccaacagtt gcgcagcctg aaaggcaggc cgggccgtgg tggccacggc ctctaggcca 4200
gatccagcgg catctgggtt agtcgagcgc gggccgcttc ccatgtctca ccagggcgag 	 4260
cctgtttcgc gatctcagca tctgaaatct tcccggcctt gcgcttcgct ggggccttac 	 4320
ccaccgcctt ggcgggcttc ttcggtccaa aactgaacaa cagatgtgtg accttgcgcc 	 4380
cggtctttcg ctgcgcccac tccacctgta gcgggctgtg ctcgttgatc tgcgtcacgg 	 4440
ctggatcaag cactcgcaac ttgaagtcct tgatcgaggg ataccggcct tccagttgaa 	 4500
accactttcg cagctggtca atttctattt cgcgctggcc gatgctgtcc cattgcatga 	 4560
gcagctcgta aagcctgatc gcgtgggtgc tgtccatctt ggccacgtca gccaaggcgt 	 4620
atttggtgaa ctgtttggtg agttccgtca ggtacggcag catgtctttg gtgaacctga 	 4680
gttctacacg gccctcaccc tcccggtaga tgattgtttg cacccagccg gtaatcatca 	 4740
cactcggtct tttccccttg ccattgggct cttgggttaa ccggacttcc cgccgtttca 	 4800
ggcgcagggc cgcttctttg agctggttgt aggaagattc gatagggaca cccgccatcg 4860
tcgctatgtc ctccgccgtc actgaataca tcacttcatc ggtgacaggc tcgctcctct 	 4920
tcacctggct aatacaggcc agaacgatcc gctgttcctg aacactgagg cgatacgcgg 	 4980
cctcgaccag ggcattgctt ttgtaaacca ttgggggtga ggccacgttc gacattcctt 	 5040
gtgtataagg ggacactgta tctgcgtccc acaatacaac aaatccgtcc ctttacaaca 	 5100
acaaatccgt cccttcttaa caacaaatcc gtcccttaat ggcaacaaat ccgtcccttt 	 5160
ttaaactcta caggccacgg attacgtggc ctgtagacgt cctaaaaggt ttaaaaggga 	 5220
aaaggaagaa aagggtggaa acgcaaaaaa cgcaccacta cgtggccccg ttggggccgc 	 5280
atttgtgccc ctgaaggggc gggggaggcg tctgggcaat ccccgtttta ccagtcccct 	 5340
atcgccgcct gagagggcgc aggaagcgag taatcagggt atcgaggcgg attcaccctt 	 5400
ggcgtccaac cagcggcacc agcggcgcct gagaggtatg gtgcactctc agtacaatct 	 5460
gctctgatgc cgcatagtta agccagcccc gacacccgcc aacacccgct gacgcgccct 	 5520
gacgggcttg tctgctcccg gcatccgctt acagacaagc tgtgaccgtc tccgggagct 	 5580
gcatgtgtca gaggttttca ccgtcatcac cgaaacgcgc ga 	 5622
<210> SEQ ID NO 10
<211> LENGTH: 674
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
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<220> FEATURE:
<223> OTHER INFORMATION: Synthetic sequence of algU mutant, VE3-NM1
<400> SEQUENCE: 10
cgattcgctg ggacgctcga agctcctcca ggttcgaaga ggagctttca tgctaaccca 	 60
ggaacaggat cagcaactgg ttgaacgggt acagcgcgga gacaagcggg ctttcgatct 	 120
gctggtactg aaataccagc acaagatact gggattgatc gtgcggttcg tgcacgacgc 	 180
ccaggaagcc caggacgtag cgcaggaagc cttcatcaag gcataccgtg cgctcggcaa 	 240
tttccgcggc gatagtgctt tttatacctg gctgtatcgg atcgccatca acaccgcgaa 	 300
gaaccacctg gtcgctcgcg ggcgtcggcc accggacagc gatgtgaccg cagaggatgc 	 360
ggagttcttc gagggcgacc acgccctgaa ggacatcgag tcgccggaac gggcgatgtt 	 420
gcgggatgag atcgaggcca ccgtgcacca gaccatccag cagttgcccg aggatttgcg 	 480
cacggccctg accctgcgcg agttcgaagg tttgagttac gaagatatcg ccaccgtgat 	 540
gcagtgtccg gtggggacgg tgtccggtgg ggacggtacg gtcgcggatc ttccgcgctc 	 600
gtgaagcaat cgacaaagct ctgcagcctt tgttgcgaga agcctgacac agcggcaaat 	 660
gccaagagag gtta	 674
<210> SEQ ID NO 11
<211> LENGTH: 668
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic sequence of algU mutant, VE3-NM2
<400> SEQUENCE: 11
cttggcagac gattcgctgg gacgctcgaa gctcctccag gttcgaagag gagctttcat 	 60
gctaacccag gaacaggatc agcaactggt tgaacgggta cagcgcggag acaagcgggc 	 120
tttcgatctg ctggtactga aataccagca caagatactg ggattgatcg tgcggttcgt 	 180
gcacgacgcc caggaagccc aggacgtagc gcaggaagcc ttcatcaagg cataccgtgc 	 240
gctcggcaat ttccgcggcg atagtgcttt ttatacctgg ctgtatcgga tcgccatcaa 	 300
caccgcgaag aaccacctgg tcgctcgcgg gcgtcggcca ccggacagcg atgtgaccgc 	 360
agaggatgcg gagttcttcg agggcgacca cgccctgaag gacatcgagt cgccggaacg 	 420
ggcgatgttg cgggatgaga tcgaggccac cgtgcaccag accatccagc agttgcccga 	 480
ggatttgcgc acggccctga ccctctgcgc gagttcgaag gtttgagtta cgaagatatc 	 540
gccaccgtga tgcagtgtcc ggtggggacg gtacggtcgc ggatcttccg cgctcgtgaa 	 600
gcaatcgaca aagctctgca gcctttgttg cgagaagcct gacacagcgg caaatgccaa 	 660
gagaggta	 668
<210> SEQ ID NO 12
<211> LENGTH: 669
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic sequence of algU mutant, VE3-NM3
<400> SEQUENCE: 12
tatcttggca agacgattcg ctgggacgct cgaagctcct ccaggttcga agaggagctt 60
tcatgctaac ccaggaacag gatcagcaac tggttgaacg ggtacagcgc ggagacaagc 120
gggctttcga tctgctggta ctgaaatacc agcacaagat actgggattg atcgtgcggt 180
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tcgtgcacga cgcccaggaa gcccaggacg tagcgcagga agccttcatc aaggcatacc 240
gtgcgctcgg caatttccgc ggcgatagtg ctttttatac ctgactgtat cggatcgcca 300
tcaacaccgc gaagaaccac ctggtcgctc gcgggcgtcg gccaccggac agcgatgtga 360
ccgcagagga tgcggagttc ttcgagggcg accacgccct gaaggacatc gagtcgccgg 420
aacgggcgat gttgcgggat gagatcgagg ccaccgtgca ccagaccatc cagcagttgc 480
ccgaggattt gcgcacggcc ctgaccctgc gcgagttcga aggtttgagt tacgaagata 540
tcgccaccgt gatgcagtgt ccggtgggga cggtacggtc gcggatcttc cgcgctcgtg 600
aagcaatcga caaagctctg cagcctttgt tgcgagaagc ctgacacagc ggcaaatgcc 660
aagagagta 669
<210> SEQ ID NO 13
<211> LENGTH: 672
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic sequence of algU mutant, VE3-NM4
<400> SEQUENCE: 13
gattcgctgg gacgctcgaa gctcctccag gttcgaagag gagctttcat gctaacccag 	 60
gaacaggatc agcaactggt tgaacgggta cagcgcggag acaagcgggc tttcgatctg 	 120
ctggtactga aataccagca caagatactg ggattgatcg tgcggttcgt gcacgacgcc 	 180
caggaagccc aggacgtagc gcaggaagcc ttcatcaagg cataccgtgc gctcggcaat 	 240
ttccgcggcg atagtgcttt ttatacctgg ctgtatcgga tcgccatcaa caccgcgaag 	 300
aaccacctgg tcgctcgcgg gcgtcggcca ccggacagcg atgtgaccgc agaggatgcg 	 360
gagttcttcg agggcgacca cgccctgaag gacatcgagt cgccggaacg ggcgatgttg 	 420
cgggatgaga tcgaggccac cgtgcaccag accatccagc agttgcccga ggatttgcgc 	 480
acggccctga ccctgcgcga gttcgaaggt ttgagttacg aagatatcgc caccgtgatg 	 540
cagtgtccgg tggggacggt gtccggtggg gacggtacgg tcgcggatct tccgcgctcg 	 600
tgaagcaatc gacaaagctc tgcagccttt gttgcgagaa gcctgacaca gcggcaaatg 	 660
ccaagagagg to	 672
<210> SEQ ID NO 14
<211> LENGTH:	 1170
<212> TYPE: DNA
<213> ORGANISM: Pseudomonas aeruginosa
<400> SEQUENCE:	 14
atgcccaagg ccctgcgttt cctcggctgg cccgtgctgg tcggcgtgct gctggccctg 60
ctgatcatcc agcacaaccc cgagctggtc ggcctgccac gccaggaggt gcacgtcgag 120
caggcgcctc tgctcagccg cctgcaggaa ggcccggtgt cctatgccaa cgcggtgagt 180
cgagcggctc cggcagtggc caacctgtac accaccaaga tggtcagcaa gccctcccac 240
cccctgttcg acgacccgat gttccgccgc ttcttcggcg acaacctgcc gcaacagaag 300
cgcatggagt cgagcctcgg ctcggcggtg atcatgagcg cggaaggcta cctgctgacc 360
aacaaccacg tgaccgctgg cgccgaccag atcatcgtgg ccttgcgcga cggccgcgaa 420
accatcgccc agttggtcgg cagcgacccg gaaaccgacc tggccgtgct gaagatcgac 480
cttaagaacc tgccggcgat gaccctcggc cgctccgacg gcattcgcac cggcgacgtc 540
tgcctcgcca tcggcaaccc gttcggcgtc ggccagaccg tgaccatggg catcatcagc 600
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gccaccggac gcaaccagct cggcctgaac acctacgaag acttcatcca gaccgacgcg 	 660
gcgatcaacc ccggcaactc cggcggcgcg ctggtggacg ctgccggcaa cctgatcggc 	 720
atcaacacgg cgatcttctc caagtccggc ggctcccagg gtatcggctt cgccatcccg 	 780
accaagctgg ccctggaggt catgcagtcg atcatcgagc acggccaggt gatccgcggc 	 840
tggctcggcg tcgaggtcaa ggcgctgacc ccggaactgg cggagtcgct gggcctcggc 	 900
gaaaccgccg ggatcgtcgt cgccggcgtc tatcgcgacg gtccggcggc acgcggcggc 	 960
ctgctgccgg gcgatgtgat cctgaccatc gacaagcagg aagccagcga cggccgccgc 	 1020
tcgatgaacc aggtggcgcg cacccgtccg ggacagaaga tcagcatcgt ggtgctgcgc 	 1080
aacggacaga aggtcaacct gaccgccgag gtcggcctgc gtccgccgcc ggcaccggct 	 1140
ccacagcaga aacaggacgg cggcgagtga	 1170
<210> SEQ ID NO 15
<211> LENGTH: 389
<212> TYPE: PRT
<213> ORGANISM: Pseudomonas aeruginosa
<400> SEQUENCE: 15
Met Pro Lys Ala Leu Arg Phe Leu Gly Trp Pro Val Leu Val Gly Val
1	 5	 10	 15
Leu Leu Ala Leu Leu Ile Ile Gin His Asn Pro Glu Leu Val Gly Leu
20	 25	 30
Pro Arg Gin Glu Val His Val Glu Gin Ala Pro Leu Leu Ser Arg Leu
35	 40	 45
Gin Glu Gly Pro Val Ser Tyr Ala Asn Ala Val Ser Arg Ala Ala Pro
50	 55	 60
Ala Val Ala Asn Leu Tyr Thr Thr Lys Met Val Ser Lys Pro Ser His
65	 70	 75	 80
Pro Leu Phe Asp Asp Pro Met Phe Arg Arg Phe Phe Gly Asp Asn Leu
85	 90	 95
Pro Gin Gin Lys Arg Met Glu Ser Ser Leu Gly Ser Ala Val Ile Met
100	 105	 110
Ser Ala Glu Gly Tyr Leu Leu Thr Asn Asn His Val Thr Ala Gly Ala
115	 120	 125
Asp Gin Ile Ile Val Ala Leu Arg Asp Gly Arg Glu Thr Ile Ala Gin
130	 135	 140
Leu Val Gly Ser Asp Pro Glu Thr Asp Leu Ala Val Leu Lys Ile Asp
145	 150	 155	 160
Leu Lys Asn Leu Pro Ala Met Thr Leu Gly Arg Ser Asp Gly Ile Arg
165	 170	 175
Thr Gly Asp Val Cys Leu Ala Ile Gly Asn Pro Phe Gly Val Gly Gin
180	 185	 190
Thr Val Thr Met Gly Ile Ile Ser Ala Thr Gly Arg Asn Gin Leu Gly
195	 200	 205
Leu Asn Thr Tyr Glu Asp Phe Ile Gin Thr Asp Ala Ala Ile Asn Pro
210	 215	 220
Gly Asn Ser Gly Gly Ala Leu Val Asp Ala Ala Gly Asn Leu Ile Gly
225	 230	 235	 240
Ile Asn Thr Ala Ile Phe Ser Lys Ser Gly Gly Ser Gin Gly Ile Gly
245	 250	 255
Phe Ala Ile Pro Thr Lys Leu Ala Leu Glu Val Met Gin Ser Ile Ile
260	 265	 270
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Glu His Gly Gln Val Ile Arg Gly Trp Leu Gly Val Glu Val Lys Ala
275	 280	 285
Leu Thr Pro Glu Leu Ala Glu Ser Leu Gly Leu Gly Glu Thr Ala Gly
290	 295	 300
Ile Val Val Ala Gly Val Tyr Arg Asp Gly Pro Ala Ala Arg Gly Gly
305	 310	 315	 320
Leu Leu Pro Gly Asp Val Ile Leu Thr Ile Asp Lys Gln Glu Ala Ser
325	 330	 335
Asp Gly Arg Arg Ser Met Asn Gln Val Ala Arg Thr Arg Pro Gly Gln
340	 345	 350
Lys Ile Ser Ile Val Val Leu Arg Asn Gly Gln Lys Val Asn Leu Thr
355	 360	 365
Ala Glu Val Gly Leu Arg Pro Pro Pro Ala Pro Ala Pro Gln Gln Lys
370	 375	 380
Gln Asp Gly Gly Glu
385
<210> SEQ ID NO 16
<211> LENGTH:	 547
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic algU promoter region
<400> SEQUENCE:	 16
agtaggtcga gccctgcgac agttcgccct tgctgaggac ggcgatgcgc aggtgttccg 60
gaagggtcaa ggccagactc aggccggcgg cgccgctgcc gatgaccagt acatcgtgtt 120
gataatgttg gctcatgccc gcatttcccc gtggtggagc cctagtatat agaagggcct 180
ggcggcacaa tagcgcaccc ccgctgccgg tccggcggat gagctgcggg cctgtcatcg 240
gcaggcgtca tcagagcggg gcgatgtagt gctggaactt tcttagacgc atcggttcca 300
aagcaggatg cctgaagacc tcgtccggtt ggcctaccca gcggcacaga ggccgggccc 360
tgagcccgat gcaatccatt ttcgcggggc ccggacacga tgtccggggc cgcacgtcac 420
gagcgaggaa aaaactcgtg acgcatgctt ggaggggaga acttttgcaa gaagcccgag 480
tctatcttgg caagacgatt cgctgggacg ctcgaagctc ctccaggttc gaagaggagc 540
tttcatg 547
<210> SEQ ID NO 17
<211> LENGTH: 306
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic mucE gene
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (18)..(18)
<223> OTHER INFORMATION: n is a, c, g, or t
<400> SEQUENCE: 17
agcgccagcc tgacctanta tcaaggagtc gtagccatgg gtttccggcc agttagccaa 	 60
cgtttgcgtg acatcaacct gcaggccctc ggcaagtttt cctgccttgc cctggtcctc 	 120
ggcctggaat cggtaagcca tccggccggc ccggtccagg ccccctcgtt cagccagggc 180
accgccagcc cgtccttcgc tactccgctc ggcctcgacg gcccggcccg cgccagggcc 240
gagatgtgga acgtcggcct gtccggcgcc gtcagcgtgc gtgacgagtt gcgctgggtg 300
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ttttga	 306
<210> SEQ ID NO 18
<211> LENGTH: 450
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic E. coli orthologue RseP peptide
<400> SEQUENCE: 18
Met Leu Ser Phe Leu Trp Asp Leu Ala Ser Phe Ile Val Ala Leu Gly
1	 5	 10	 15
Val Leu Ile Thr Val His Glu Phe Gly His Phe Trp Val Ala Arg Arg
20	 25	 30
Cys Gly Val Arg Val Glu Arg Phe Ser Ile Gly Phe Gly Lys Ala Leu
35	 40	 45
Trp Arg Arg Thr Asp Lys Leu Gly Thr Glu Tyr Val Ile Ala Leu Ile
50	 55	 60
Pro Leu Gly Gly Tyr Val Lys Met Leu Asp Glu Arg Ala Glu Pro Val
65	 70	 75	 80
Val Pro Glu Leu Arg His His Ala Phe Asn Asn Lys Ser Val Gly Gin
85	 90	 95
Arg Ala Ala Ile Ile Ala Ala Gly Pro Val Ala Asn Phe Ile Phe Ala
100	 105	 110
Ile Phe Ala Tyr Trp Leu Val Phe Ile Ile Gly Val Pro Gly Val Arg
115	 120	 125
Pro Val Val Gly Glu Ile Ala Ala Asn Ser Ile Ala Ala Glu Ala Gin
130	 135	 140
Ile Ala Pro Gly Thr Glu Leu Lys Ala Val Asp Gly Ile Glu Thr Pro
145	 150	 155	 160
Asp Trp Asp Ala Val Arg Leu Gin Leu Val Asp Lys Ile Gly Asp Glu
165	 170	 175
Ser Thr Thr Ile Thr Val Ala Pro Phe Gly Ser Asp Gin Arg Arg Asp
180	 185	 190
Val Lys Leu Asp Leu Arg His Trp Ala Phe Glu Pro Asp Lys Glu Asp
195	 200	 205
Pro Val Ser Ser Leu Gly Ile Arg Pro Arg Gly Pro Gin Ile Glu Pro
210	 215	 220
Val Leu Glu Asn Val Gin Pro Asn Ser Ala Ala Ser Lys Ala Gly Leu
225	 230	 235	 240
Gin Ala Gly Asp Arg Ile Val Lys Val Asp Gly Gin Pro Leu Thr Gin
245	 250	 255
Trp Val Thr Phe Val Met Leu Val Arg Asp Asn Pro Gly Lys Ser Leu
260	 265	 270
Ala Leu Glu Ile Glu Arg Gin Gly Ser Pro Leu Ser Leu Thr Leu Ile
275	 280	 285
Pro Glu Ser Lys Pro Gly Asn Gly Lys Ala Ile Gly Phe Val Gly Ile
290	 295	 300
Glu Pro Lys Val Ile Pro Leu Pro Asp Glu Tyr Lys Val Val Arg Gin
305	 310	 315	 320
Tyr Gly Pro Phe Asn Ala Ile Val Glu Ala Thr Asp Lys Thr Trp Gin
325	 330	 335
Leu Met Lys Leu Thr Val Ser Met Leu Gly Lys Leu Ile Thr Gly Asp
340	 345	 350
Val Lys Leu Asn Asn Leu Ser Gly Pro Ile Ser Ile Ala Lys Gly Ala
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355	 360	 365
Gly Met Thr Ala Glu Leu Gly Val Val Tyr Tyr Leu Pro Phe Leu Ala
370	 375	 380
Leu Ile Ser Val Asn Leu Gly Ile Ile Asn Leu Phe Pro Leu Pro Val
385	 390	 395	 400
Leu Asp Gly Gly His Leu Leu Phe Leu Ala Ile Glu Lys Ile Lys Gly
405	 410	 415
Gly Pro Val Ser Glu Arg Val Gin Asp Phe Cys Tyr Arg Ile Gly Ser
420	 425	 430
Ile Leu Leu Val Leu Leu Met Gly Leu Ala Leu Phe Asn Asp Phe Ser
435	 440	 445
Arg Leu
450
<210> SEQ ID NO 19
<211> LENGTH: 450
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic MucP peptide
<400> SEQUENCE: 19
Met Ser Ala Leu Tyr Met Ile Val Gly Thr Leu Val Ala Leu Gly Val
1	 5	 10	 15
Leu Val Thr Phe His Glu Phe Gly His Phe Trp Val Ala Arg Arg Cys
20	 25	 30
Gly Val Lys Val Leu Arg Phe Ser Val Gly Phe Gly Thr Pro Leu Val
35	 40	 45
Arg Trp His Asp Arg His Gly Thr Glu Phe Val Val Ala Ala Ile Pro
50	 55	 60
Leu Gly Gly Tyr Val Lys Met Leu Asp Glu Arg Glu Ala Glu Val Pro
65	 70	 75	 80
Ala His Leu Leu Glu Gin Ser Phe Asn Arg Lys Thr Val Arg Gin Arg
85	 90	 95
Ile Ala Ile Val Ala Ala Gly Pro Ile Ala Asn Phe Leu Leu Ala Ile
100	 105	 110
Leu Phe Phe Trp Val Val Ala Leu Leu Gly Ser Gin Gin Val Arg Pro
115	 120	 125
Val Ile Gly Ser Val Ala Pro Glu Ser Leu Ala Ala Gin Ala Gly Leu
130	 135	 140
Glu Ala Gly Gin Glu Leu Leu Ala Val Asp Gly Glu Pro Val Thr Gly
145	 150	 155	 160
Trp Asn Gly Val Asn Leu Gin Leu Val Arg Arg Leu Gly Glu Ser Gly
165	 170	 175
Thr Leu Glu Val Arg Val Gin Glu Lys Gly Ser Asn Val Asp Ser Thr
180	 185	 190
His Gin Val Arg Leu Asp Gly Trp Leu Lys Gly Glu Asp Asn Pro Asp
195	 200	 205
Pro Ile Ala Ser Leu Gly Ile Arg Pro Trp Arg Pro Ala Leu Pro Pro
210	 215	 220
Val Leu Ala Glu Leu Asp Pro Lys Gly Pro Ala Gin Ala Ala Gly Leu
225	 230	 235	 240
Lys Leu Gly Asp Arg Leu Gin Ser Ile Asp Gly Ile Ala Val Asp Asp
245	 250	 255
Trp Gin Gin Val Val Asp Ser Val Arg Ala Arg Pro Gly Gin Arg Val
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260	 265	 270
Gin Leu Lys Val Leu Arg Asp Gly Glu Val Leu Asp Val Ala Leu Glu
275	 280	 285
Leu Ala Val Arg Gly Glu Gly Lys Ala Arg Ser Gly Tyr Met Gly Ala
290	 295	 300
Gly Val Ala Gly Thr Glu Trp Pro Ala Glu Met Leu Arg Glu Val Ser
305	 310	 315	 320
Tyr Gly Pro Leu Glu Ala Val Gly Gin Ala Leu Ser Arg Thr Trp Thr
325	 330	 335
Met Ser Leu Leu Thr Leu Asp Ser Ile Lys Lys Met Leu Leu Gly Glu
340	 345	 350
Leu Ser Val Lys Asn Leu Ser Gly Pro Ile Thr Ile Ala Lys Val Ala
355	 360	 365
Gly Ala Ser Ala Gin Ser Gly Val Gly Asp Phe Leu Asn Phe Leu Ala
370	 375	 380
Tyr Leu Ser Ile Ser Leu Gly Val Leu Asn Leu Leu Pro Ile Pro Val
385	 390	 395	 400
Leu Asp Gly Gly His Leu Leu Phe Tyr Leu Val Glu Trp Val Arg Gly
405	 410	 415
Arg Pro Leu Ser Glu Arg Val Gin Ala Trp Gly Met Gin Ile Gly Ile
420	 425	 430
Ser Leu Val Val Gly Val Met Leu Leu Ala Leu Val Asn Asp Leu Ser
435	 440	 445
Arg Leu
450
<210> SEQ ID NO 20
<211> LENGTH: 89
<212> TYPE: PRT
<213> ORGANISM: Pseudomonas aeruginosa
<400> SEQUENCE: 20
Met Gly Phe Arg Pro Val Ser Gin Arg Leu Arg Asp Ile Asn Leu Gin
1	 5	 10	 15
Ala Leu Gly Lys Phe Ser Cys Leu Ala Leu Val Leu Gly Leu Glu Ser
20	 25	 30
Val Ser His Pro Ala Gly Pro Val Gin Ala Pro Ser Phe Ser Gin Gly
35	 40	 45
Thr Ala Ser Pro Ser Phe Ala Thr Pro Leu Gly Leu Asp Gly Pro Ala
50	 55	 60
Arg Ala Arg Ala Glu Met Trp Asn Val Gly Leu Ser Gly Ala Val Ser
65	 70	 75	 80
Val Arg Asp Glu Leu Arg Trp Val Phe
85
<210> SEQ ID NO 21
<211> LENGTH: 89
<212> TYPE: PRT
<213> ORGANISM: Pseudomonas aeruginosa
<400> SEQUENCE: 21
Met Gly Phe Arg Pro Val Ser Gin Arg Leu Arg Asp Ile Asn Leu Gin
1	 5	 10	 15
Ala Leu Gly Lys Phe Ser Cys Leu Ala Leu Val Leu Gly Leu Glu Ser
20	 25	 30
Val Ser His Pro Ala Gly Pro Val Gin Ala Pro Ser Phe Ser Gin Gly
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35	 40	 45
Thr Ala Ser Pro Ser Phe Ala Thr Pro Leu Gly Leu Asp Gly Pro Ala
50	 55	 60
Arg Ala Arg Ala Glu Met Trp Asn Val Gly Leu Ser Gly Ala Val Ser
65	 70	 75	 80
Val Arg Asp Glu Leu Arg Trp Val Phe
85
<210> SEQ ID NO 22
<211> LENGTH: 89
<212> TYPE: PRT
<213> ORGANISM: Pseudomonas aeruginosa
<400> SEQUENCE: 22
Met Gly Phe Arg Pro Val Ser Gin Arg Leu Arg Asp Ile Asn Leu Gin
1	 5	 10	 15
Ala Leu Gly Lys Phe Ser Cys Leu Ala Leu Val Leu Gly Leu Glu Ser
20	 25	 30
Val Ser His Pro Ala Gly Pro Val Gin Ala Pro Ser Phe Ser Gin Gly
35	 40	 45
Thr Ala Ser Pro Ser Phe Ala Thr Pro Leu Gly Leu Asp Gly Pro Ala
50	 55	 60
Arg Ala Arg Ala Glu Met Trp Asn Val Gly Leu Ser Gly Ala Val Ser
65	 70	 75	 80
Val Arg Asp Glu Leu Arg Trp Val Phe
85
<210> SEQ ID NO 23
<211> LENGTH: 89
<212> TYPE: PRT
<213> ORGANISM: Pseudomonas aeruginosa
<400> SEQUENCE: 23
Met Gly Phe Arg Pro Val Ser Gin Arg Leu Arg Asp Ile Asn Leu Gin
1	 5	 10	 15
Ala Leu Gly Lys Phe Ser Cys Leu Ala Leu Val Leu Gly Leu Glu Ser
20	 25	 30
Val Ser His Pro Ala Gly Pro Val Gin Ala Pro Ser Phe Ser Gin Gly
35	 40	 45
Thr Ala Ser Pro Ser Phe Ala Thr Pro Leu Gly Leu Asp Gly Pro Ala
50	 55	 60
Arg Ala Arg Ala Glu Met Trp Asn Val Gly Leu Ser Gly Ala Val Ser
65	 70	 75	 80
Val Arg Asp Glu Leu Arg Trp Val Phe
85
<210> SEQ ID NO 24
<211> LENGTH: 79
<212> TYPE: PRT
<213> ORGANISM: Pseudomonas fluorescens
<400> SEQUENCE: 24
Met Asn Ser Ala Leu Leu Leu Leu Asn Ala Ile Ala Ile Ala Val Leu
1	 5	 10	 15
Ala Ala Phe His Phe Gin Pro Ala Asp Asp Ala Ala Pro Gly Gly Thr
20	 25	 30
Ser Phe Ala His Tyr Gin Gin Arg Leu Ala Pro Gin Leu Ala Val Met
35	 40	 45
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Asn Thr Gin Ile Glu Pro Gly Ser Val Thr Arg Val Thr Gin Gly Lys
50	 55	 60
Ala Ser Gin Gin Pro Ala Ala Ala Pro Thr Glu Arg Trp Val Phe
65	 70	 75
<210> SEQ ID NO 25
<211> LENGTH: 75
<212> TYPE: PRT
<213> ORGANISM: Pseudomonas fluorescens
<400> SEQUENCE: 25
Met Asn Ser Ala Leu Val Phe Ala Asn Ala Ile Ala Leu Ala Val Leu
1	 5	 10	 15
Met Gly Phe His Leu Val Pro Glu Asp Asn Glu Lys Val Ala Gly Arg
20	 25	 30
Met Pro His Tyr Leu Gin Val Gin Lys Ala Pro Gin Trp Ala Val Leu
35	 40	 45
Ser Asp Gin Ser Phe Ala Pro Gin Ala Val Ser Gin Ser Glu Gin Ala
50	 55	 60
Leu Pro Ala His Ser Thr Glu Arg Leu Val Phe
65	 70	 75
<210> SEQ ID NO 26
<211> LENGTH: 79
<212> TYPE: PRT
<213> ORGANISM: Pseudomonas syringae
<400> SEQUENCE: 26
Met Asn Lys Thr Leu Ser Val Leu Asn Ala Ala Ala Leu Val Ala Leu
1	 5	 10	 15
Val Ala Phe His Phe His Asp Ser Gly Ala Ser Asp Thr Gin Val Asn
20	 25	 30
Ala Pro Ala Pro Val His His Gin Ile Ser His Ala Pro Gin Leu Ala
35	 40	 45
Ile Met Thr Asp Arg Ile Ala Ser Ala Ala Val Leu Ala Asn Asp Asp
50	 55	 60
Asp Asp Ser Leu Gin Met Pro Arg Ala Glu Gin Arg Trp Ile Phe
65	 70	 75
<210> SEQ ID NO 27
<211> LENGTH: 79
<212> TYPE: PRT
<213> ORGANISM: Pseudomonas syringae
<400> SEQUENCE: 27
Met Asn Lys Thr Leu Ser Ala Leu Asn Ala Ala Ala Leu Val Ala Leu
1	 5	 10	 15
Val Ala Phe His Phe Gin Asp Ser Gly Ala Lys Asp Thr Gin Val Thr
20	 25	 30
Ala Pro Ala Pro Val His His Gin Ile Ser His Ala Pro Gin Leu Ala
35	 40	 45
Ile Met Thr Asp Arg Val Ala Ser Ala Ala Val Leu Ala Thr Asp Asp
50	 55	 60
Asp Ala Ser Val Gin Met Pro Arg Ala Glu Gin Arg Trp Val Phe
65	 70	 75
<210> SEQ ID NO 28
<211> LENGTH: 79
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<212> TYPE: PRT
<213> ORGANISM: Pseudomonas syringae
<400> SEQUENCE: 28
Met Asn Lys Thr Leu Ser Ala Leu Asn Ala Ala Ala Leu Val Ala Leu
1	 5	 10	 15
Val Ala Phe His Phe Gin Asp Ser Gly Ile Lys Asp Ala Gin Ala Ile
20	 25	 30
Thr Pro Ala Pro Val His His Gin Ile Ser Gin Ala Pro Lys Leu Ala
35	 40	 45
Ile Met Thr Asp Arg Val Ala Ser Ala Ala Met Leu Ala Asn Asp Asp
50	 55	 60
Asp Glu Ser Leu Gin Phe Pro Arg Ala Glu Gin Arg Trp Val Phe
65	 70	 75
<210> SEQ ID NO 29
<211> LENGTH: 389
<212> TYPE: PRT
<213> ORGANISM: Pseudomonas aeruginosa
<400> SEQUENCE: 29
Met Pro Lys Ala Leu Arg Phe Leu Gly Trp Pro Val Leu Val Gly Val
1	 5	 10	 15
Leu Leu Ala Leu Leu Ile Ile Gin His Asn Pro Glu Leu Val Gly Leu
20	 25	 30
Pro Arg Gin Glu Val His Val Glu Gin Ala Pro Leu Leu Ser Arg Leu
35	 40	 45
Gin Glu Gly Pro Val Ser Tyr Ala Asn Ala Val Ser Arg Ala Ala Pro
50	 55	 60
Ala Val Ala Asn Leu Tyr Thr Thr Lys Met Val Ser Lys Pro Ser His
65	 70	 75	 80
Pro Leu Phe Asp Asp Pro Met Phe Arg Arg Phe Phe Gly Asp Asn Leu
85	 90	 95
Pro Gin Gin Lys Arg Met Glu Ser Ser Leu Gly Ser Ala Val Ile Met
100	 105	 110
Ser Ala Glu Gly Tyr Leu Leu Thr Asn Asn His Val Thr Ala Gly Ala
115	 120	 125
Asp Gin Ile Ile Val Ala Leu Arg Asp Gly Arg Glu Thr Ile Ala Gin
130	 135	 140
Leu Val Gly Ser Asp Pro Glu Thr Asp Leu Ala Val Leu Lys Ile Asp
145	 150	 155	 160
Leu Lys Asn Leu Pro Ala Met Thr Leu Gly Arg Ser Asp Gly Ile Arg
165	 170	 175
Thr Gly Asp Val Cys Leu Ala Ile Gly Asn Pro Phe Gly Val Gly Gin
180	 185	 190
Thr Val Thr Met Gly Ile Ile Ser Ala Thr Gly Arg Asn Gin Leu Gly
195	 200	 205
Leu Asn Thr Tyr Glu Asp Phe Ile Gin Thr Asp Ala Ala Ile Asn Phe
210	 215	 220
Gly Asn Ser Gly Gly Ala Leu Val Asp Ala Ala Gly Asn Leu Ile Gly
225	 230	 235	 240
Ile Asn Thr Ala Ile Phe Ser Lys Ser Gly Gly Ser Gin Gly Ile Gly
245	 250	 255
Phe Ala Ile Pro Thr Lys Leu Ala Leu Glu Val Met Gin Ser Ile Ile
260	 265	 270
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Glu His Gly Gin Val Ile Arg Gly Trp Leu Gly Val Glu Val Lys Ala
275	 280	 285
Leu Thr Pro Glu Leu Ala Glu Ser Leu Gly Leu Gly Glu Thr Ala Gly
290	 295	 300
Ile Val Val Ala Gly Val Tyr Arg Asp Gly Pro Ala Ala Arg Gly Gly
305	 310	 315	 320
Leu Leu Pro Gly Asp Val Ile Leu Thr Ile Asp Lys Gin Glu Ala Ser
325	 330	 335
Asp Gly Arg Arg Ser Met Asn Gin Val Ala Arg Thr Arg Pro Gly Gin
340	 345	 350
Lys Ile Ser Ile Val Val Leu Arg Asn Gly Gin Lys Val Asn Leu Thr
355	 360	 365
Ala Glu Val Gly Leu Arg Pro Pro Pro Ala Pro Ala Pro Gin Gin Lys
370	 375	 380
Gin Asp Gly Gly Glu
385
<210> SEQ ID NO 30
<211> LENGTH: 389
<212> TYPE: PRT
<213> ORGANISM: Pseudomonas aeruginosa
<400> SEQUENCE: 30
Met Pro Lys Ala Leu Arg Phe Leu Gly Trp Pro Val Leu Val Gly Val
1	 5	 10	 15
Leu Leu Ala Leu Leu Ile Ile Gin His Asn Pro Glu Leu Val Gly Leu
20	 25	 30
Pro Arg Gin Glu Val His Val Glu Gin Ala Pro Leu Leu Ser Arg Leu
35	 40	 45
Gin Glu Gly Pro Val Ser Tyr Ala Asn Ala Val Ser Arg Ala Ala Pro
50	 55	 60
Ala Val Ala Asn Leu Tyr Thr Thr Lys Met Val Ser Lys Pro Ser His
65	 70	 75	 80
Pro Leu Phe Asp Asp Pro Met Phe Arg Arg Phe Phe Gly Asp Asn Leu
85	 90	 95
Pro Gin Gin Lys Arg Met Glu Ser Ser Leu Gly Ser Ala Val Ile Met
100	 105	 110
Ser Ala Glu Gly Tyr Leu Leu Thr Asn Asn His Val Thr Ala Gly Ala
115	 120	 125
Asp Gin Ile Ile Val Ala Leu Arg Asp Gly Arg Glu Thr Ile Ala Gin
130	 135	 140
Leu Val Gly Ser Asp Pro Glu Thr Asp Leu Ala Val Leu Lys Ile Asp
145	 150	 155	 160
Leu Lys Asn Leu Pro Ala Met Thr Leu Gly Arg Ser Asp Gly Ile Arg
165	 170	 175
Thr Gly Asp Val Cys Leu Ala Ile Gly Asn Pro Phe Gly Val Gly Gin
180	 185	 190
Thr Val Thr Met Gly Ile Ile Ser Ala Thr Gly Arg Asn Gin Leu Gly
195	 200	 205
Leu Asn Thr Tyr Glu Asp Phe Ile Gin Thr Asp Ala Ala Ile Asn Phe
210	 215	 220
Gly Asn Ser Gly Gly Ala Leu Val Asp Ala Ala Gly Asn Leu Ile Gly
225	 230	 235	 240
Ile Asn Thr Ala Ile Phe Ser Lys Ser Gly Gly Ser Gin Gly Ile Gly
245	 250	 255
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Phe Ala Ile Pro Thr Lys Leu Ala Leu Glu Val Met Gin Ser Ile Ile
260	 265	 270
Glu His Gly Gin Val Ile Arg Gly Trp Leu Gly Val Glu Val Lys Ala
275	 280	 285
Leu Thr Pro Glu Leu Ala Glu Ser Leu Gly Leu Gly Glu Thr Ala Gly
290	 295	 300
Ile Val Val Ala Gly Val Tyr Arg Asp Gly Pro Ala Ala Arg Gly Gly
305	 310	 315	 320
Leu Leu Pro Gly Asp Val Ile Leu Thr Ile Asp Lys Gin Glu Ala Ser
325	 330	 335
Asp Gly Arg Arg Ser Met Asn Gin Val Ala Arg Thr Arg Pro Gly Gin
340	 345	 350
Lys Ile Ser Ile Val Val Leu Arg Asn Gly Gin Lys Val Asn Leu Thr
355	 360	 365
Ala Glu Val Gly Leu Arg Pro Pro Pro Ala Pro Ala Pro Gin Gin Lys
370	 375	 380
Gin Asp Gly Gly Glu
385
<210> SEQ ID NO 31
<211> LENGTH: 389
<212> TYPE: PRT
<213> ORGANISM: Pseudomonas aeruginosa
<400> SEQUENCE: 31
Met Pro Lys Ala Leu Arg Phe Leu Gly Trp Pro Val Leu Val Gly Val
1	 5	 10	 15
Leu Leu Ala Leu Leu Ile Ile Gin His Asn Pro Glu Leu Val Gly Leu
20	 25	 30
Pro Arg Gin Glu Val His Val Glu Gin Ala Pro Leu Leu Ser Arg Leu
35	 40	 45
Gin Glu Gly Pro Val Ser Tyr Ala Asn Ala Val Ser Arg Ala Ala Pro
50	 55	 60
Ala Val Ala Asn Leu Tyr Thr Thr Lys Met Val Ser Lys Pro Ser His
65	 70	 75	 80
Pro Leu Phe Asp Asp Pro Met Phe Arg Arg Phe Phe Gly Asp Asn Leu
85	 90	 95
Pro Gin Gin Lys Arg Met Glu Ser Ser Leu Gly Ser Ala Val Ile Met
100	 105	 110
Ser Ala Glu Gly Tyr Leu Leu Thr Asn Asn His Val Thr Ala Gly Ala
115	 120	 125
Asp Gin Ile Ile Val Ala Leu Arg Asp Gly Arg Glu Thr Ile Ala Gin
130	 135	 140
Leu Val Gly Ser Asp Pro Glu Thr Asp Leu Ala Val Leu Lys Ile Asp
145	 150	 155	 160
Leu Lys Asn Leu Pro Ala Met Thr Leu Gly Arg Ser Asp Gly Ile Arg
165	 170	 175
Thr Gly Asp Val Cys Leu Ala Ile Gly Asn Pro Phe Gly Val Gly Gin
180	 185	 190
Thr Val Thr Met Gly Ile Ile Ser Ala Thr Gly Arg Asn Gin Leu Gly
195	 200	 205
Leu Asn Thr Tyr Glu Asp Phe Ile Gin Thr Asp Ala Ala Ile Asn Phe
210	 215	 220
Gly Asn Ser Gly Gly Ala Leu Val Asp Ala Ala Gly Asn Leu Ile Gly
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225	 230	 235	 240
Ile Asn Thr Ala Ile Phe Ser Lys Ser Gly Gly Ser Gin Gly Ile Gly
245	 250	 255
Phe Ala Ile Pro Thr Lys Leu Ala Leu Glu Val Met Gin Ser Ile Ile
260	 265	 270
Glu His Gly Gin Val Ile Arg Gly Trp Leu Gly Val Glu Val Lys Ala
275	 280	 285
Leu Thr Pro Glu Leu Ala Glu Ser Leu Gly Leu Gly Glu Thr Ala Gly
290	 295	 300
Ile Val Val Ala Gly Val Tyr Arg Asp Gly Pro Ala Ala Arg Gly Gly
305	 310	 315	 320
Leu Leu Pro Gly Asp Val Ile Leu Thr Ile Asp Lys Gin Glu Ala Ser
325	 330	 335
Asp Gly Arg Arg Ser Met Asn Gin Val Ala Arg Thr Arg Pro Gly Gin
340	 345	 350
Lys Ile Ser Ile Val Val Leu Arg Asn Gly Gin Lys Val Asn Leu Thr
355	 360	 365
Ala Glu Val Gly Leu Arg Pro Pro Pro Ala Pro Ala Pro Gin Gin Lys
370	 375	 380
Gin Asp Gly Gly Glu
385
<210> SEQ ID NO 32
<211> LENGTH: 389
<212> TYPE: PRT
<213> ORGANISM: Pseudomonas aeruginosa
<400> SEQUENCE: 32
Met Pro Lys Ala Leu Arg Phe Leu Gly Trp Pro Val Leu Val Gly Val
1	 5	 10	 15
Leu Leu Ala Leu Leu Ile Ile Gin His Asn Pro Glu Leu Val Gly Leu
20	 25	 30
Pro Arg Gin Glu Val His Val Glu Gin Ala Pro Leu Leu Ser Arg Leu
35	 40	 45
Gin Glu Gly Pro Val Ser Tyr Ala Asn Ala Val Ser Arg Ala Ala Pro
50	 55	 60
Ala Val Ala Asn Leu Tyr Thr Thr Lys Met Val Ser Lys Pro Ser His
65	 70	 75	 80
Pro Leu Phe Asp Asp Pro Met Phe Arg Arg Phe Phe Gly Asp Asn Leu
85	 90	 95
Pro Gin Gin Lys Arg Met Glu Ser Ser Leu Gly Ser Ala Val Ile Met
100	 105	 110
Ser Ala Glu Gly Tyr Leu Leu Thr Asn Asn His Val Thr Ala Gly Ala
115	 120	 125
Asp Gin Ile Ile Val Ala Leu Arg Asp Gly Arg Glu Thr Ile Ala Gin
130	 135	 140
Leu Val Gly Ser Asp Pro Glu Thr Asp Leu Ala Val Leu Lys Ile Asp
145	 150	 155	 160
Leu Lys Asn Leu Pro Ala Met Thr Leu Gly Arg Ser Asp Gly Ile Arg
165	 170	 175
Thr Gly Asp Val Cys Leu Ala Ile Gly Asn Pro Phe Gly Val Gly Gin
180	 185	 190
Thr Val Thr Met Gly Ile Ile Ser Ala Thr Gly Arg Asn Gin Leu Gly
195	 200	 205
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Leu Asn Thr Tyr Glu Asp Phe Ile Gin Thr Asp Ala Ala Ile Asn Phe
210	 215	 220
Gly Asn Ser Gly Gly Ala Leu Val Asp Ala Ala Gly Asn Leu Ile Gly
225	 230	 235	 240
Ile Asn Thr Ala Ile Phe Ser Lys Ser Gly Gly Ser Gin Gly Ile Gly
245	 250	 255
Phe Ala Ile Pro Thr Lys Leu Ala Leu Glu Val Met Gin Ser Ile Ile
260	 265	 270
Glu His Gly Gin Val Ile Arg Gly Trp Leu Gly Val Glu Val Lys Ala
275	 280	 285
Leu Thr Pro Glu Leu Ala Glu Ser Leu Gly Leu Gly Glu Thr Ala Gly
290	 295	 300
Ile Val Val Ala Gly Val Tyr Arg Asp Gly Pro Ala Ala Arg Gly Gly
305	 310	 315	 320
Leu Leu Pro Gly Asp Val Ile Leu Thr Ile Asp Lys Gin Glu Ala Ser
325	 330	 335
Asp Gly Arg Arg Ser Met Asn Gin Val Ala Arg Thr Arg Pro Gly Gin
340	 345	 350
Lys Ile Ser Ile Val Val Leu Arg Asn Gly Gin Lys Val Asn Leu Thr
355	 360	 365
Ala Glu Val Gly Leu Arg Pro Pro Pro Ala Pro Ala Pro Gin Gin Lys
370	 375	 380
Gin Asp Gly Gly Glu
385
<210> SEQ ID NO 33
<211> LENGTH: 384
<212> TYPE: PRT
<213> ORGANISM: Pseudomonas fluorescens
<400> SEQUENCE: 33
Met Leu Lys Ala Leu Arg Phe Phe Gly Trp Pro Leu Leu Ala Gly Val
1	 5	 10	 15
Leu Ile Ala Leu Leu Ile Ile Gin Arg Tyr Pro Gin Trp Val Gly Leu
20	 25	 30
Pro Ser Leu Asp Val Asn Leu Gin Gin Ala Pro Gin Thr Thr Ser Thr
35	 40	 45
Gin Gin Gly Pro Val Ser Tyr Ala Asp Ala Val Val Ile Ala Ala Pro
50	 55	 60
Ala Val Val Asn Leu Tyr Thr Thr Lys Val Ile Asn Lys Pro Ala His
65	 70	 75	 80
Pro Leu Phe Glu Asp Pro Gin Phe Arg Arg Phe Phe Gly Asp Asn Leu
85	 90	 95
Pro Lys Gin Gin Arg Met Glu Ser Ser Leu Gly Ser Gly Val Ile Met
100	 105	 110
Ser Pro Glu Gly Tyr Leu Leu Thr Asn Asn His Val Thr Ser Gly Ala
115	 120	 125
Glu Gin Ile Val Val Ala Leu Lys Asp Gly Arg Glu Thr Leu Ala Arg
130	 135	 140
Val Ile Gly Ser Asp Pro Glu Thr Asp Leu Ala Val Leu Lys Ile Asp
145	 150	 155	 160
Leu Lys Asn Leu Pro Ser Ile Thr Val Gly Arg Ser Glu Asn Val Arg
165	 170	 175
Val Gly Asp Val Ala Leu Ala Ile Gly Asn Pro Phe Gly Val Gly Gin
180	 185	 190
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Thr Val Thr Met Gly Ile Ile Ser Ala Thr Gly Arg Asn Gin Leu Gly
195	 200	 205
Leu Asn Asn Tyr Glu Asp Phe Ile Gin Thr Asp Ala Ala Ile Asn Pro
210	 215	 220
Gly Asn Ser Gly Gly Ala Leu Val Asp Ala Asn Gly Asn Leu Thr Gly
225	 230	 235	 240
Ile Asn Thr Ala Ile Phe Ser Lys Ser Gly Gly Ser Gin Gly Ile Gly
245	 250	 255
Phe Ala Ile Pro Ile Lys Leu Ala Met Glu Val Met Lys Ser Ile Ile
260	 265	 270
Glu His Gly Gin Val Ile Arg Gly Trp Leu Gly Ile Glu Val Gin Pro
275	 280	 285
Leu Thr Gin Glu Leu Ala Glu Ser Phe Gly Leu Ala Gly Arg Pro Gly
290	 295	 300
Ile Val Val Ala Gly Ile Phe Arg Asp Gly Pro Ala Gin Lys Ala Gly
305	 310	 315	 320
Met Gin Leu Gly Asp Val Ile Leu Ser Ile Asp Gly Glu Pro Ala Gly
325	 330	 335
Asp Gly Arg Arg Ser Met Asn Gin Val Ala Arg Ile Lys Pro Thr Asp
340	 345	 350
Lys Val Ser Ile Leu Val Met Arg Asn Gly Lys Glu Leu Lys Leu Thr
355	 360	 365
Ala Glu Ile Gly Leu Arg Pro Pro Pro Ala Pro Val Lys Glu Glu Glu
370	 375	 380
<210> SEQ ID NO 34
<211> LENGTH: 385
<212> TYPE: PRT
<213> ORGANISM: Pseudomonas fluorescens
<400> SEQUENCE: 34
Met Leu Lys Ala Leu Arg Phe Phe Gly Trp Pro Leu Leu Ala Gly Val
1	 5	 10	 15
Leu Ile Ala Leu Leu Ile Ile Gin Arg Tyr Pro Gin Trp Val Gly Leu
20	 25	 30
Pro Ser Leu Asp Val Asn Leu Gin Gin Ala Pro Gin Thr Thr Ser Val
35	 40	 45
Gin Gin Gly Pro Val Ser Tyr Ala Asp Ala Val Thr Ile Ala Ala Pro
50	 55	 60
Ser Val Val Asn Leu Tyr Thr Thr Lys Val Ile Asn Lys Pro Ser His
65	 70	 75	 80
Pro Leu Phe Glu Asp Pro Gin Phe Arg Arg Phe Phe Gly Asp Asn Ser
85	 90	 95
Pro Lys Gin Lys Arg Met Glu Ser Ser Leu Gly Ser Gly Val Ile Met
100	 105	 110
Ser Pro Glu Gly Tyr Ile Leu Thr Asn Asn His Val Thr Ser Gly Ala
115	 120	 125
Asp Gin Ile Val Val Ala Leu Lys Asp Gly Arg Glu Thr Leu Ala Arg
130	 135	 140
Val Ile Gly Ser Asp Pro Glu Thr Asp Leu Ala Val Leu Lys Ile Asp
145	 150	 155	 160
Leu Lys Asn Leu Pro Ala Ile Thr Val Gly Arg Ser Asp Asn Ile Arg
165	 170	 175
Ile Gly Asp Val Ala Leu Ala Ile Gly Asn Pro Phe Gly Val Gly Gin
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180	 185	 190
Thr Val Thr Met Gly Ile Ile Ser Ala Thr Gly Arg Asn Gin Leu Gly
195	 200	 205
Leu Asn Asn Tyr Glu Asp Phe Ile Gin Thr Asp Ala Ala Ile Asn Pro
210	 215	 220
Gly Asn Ser Gly Gly Ala Leu Val Asp Ala Asn Gly Asn Leu Thr Gly
225	 230	 235	 240
Ile Asn Thr Ala Ile Phe Ser Lys Ser Gly Gly Ser Gin Gly Ile Gly
245	 250	 255
Phe Ala Ile Pro Val Lys Leu Ala Met Glu Val Met Lys Ser Ile Ile
260	 265	 270
Glu His Gly Gin Val Ile Arg Gly Trp Leu Gly Ile Glu Val Gin Pro
275	 280	 285
Leu Thr Gin Glu Leu Ala Glu Ser Phe Gly Leu Ser Gly Arg Pro Gly
290	 295	 300
Ile Val Val Ala Gly Ile Phe Arg Asp Gly Pro Ala Gin Lys Ala Gly
305	 310	 315	 320
Leu Gin Leu Gly Asp Val Ile Leu Ser Ile Asp Gly Glu Pro Ala Gly
325	 330	 335
Asp Gly Arg Lys Ser Met Asn Gin Val Ala Arg Ile Lys Pro Thr Asp
340	 345	 350
Lys Val Thr Ile Gin Val Met Arg Asn Gly Lys Glu Leu Lys Leu Thr
355	 360	 365
Ala Glu Ile Gly Leu Arg Pro Pro Pro Ala Pro Val Lys Glu Lys Glu
370	 375	 380
Glu
385
<210> SEQ ID NO 35
<211> LENGTH: 386
<212> TYPE: PRT
<213> ORGANISM: Pseudomonas syringae
<400> SEQUENCE: 35
Met Phe Lys Ala Leu Arg Phe Phe Gly Trp Pro Leu Leu Ala Gly Val
1	 5	 10	 15
Leu Ile Ala Met Leu Ile Ile Gin Arg Tyr Pro Gin Trp Val Gly Leu
20	 25	 30
Pro Ser Leu Asp Val Asn Leu Gin Gin Ala Pro Gin Thr Thr Asn Val
35	 40	 45
Met Gin Gly Pro Ser Ser Tyr Ala Asp Ala Val Ile Ala Ala Ala Pro
50	 55	 60
Ala Val Val Asn Leu Tyr Thr Thr Lys Met Val Asn Lys Gly Asn Asn
65	 70	 75	 80
Pro Leu Phe Glu Asp Pro Gin Phe Arg Arg Phe Phe Gly Asp Asn Thr
85	 90	 95
Pro Lys Gin Lys Arg Met Glu Ser Ser Leu Gly Ser Gly Val Met Met
100	 105	 110
Ser Pro Glu Gly Tyr Ile Leu Thr Asn Asn His Val Thr Thr Gly Ala
115	 120	 125
Asp Gin Ile Val Val Ala Leu Lys Asp Gly Arg Glu Thr Ile Ala Arg
130	 135	 140
Val Ile Gly Asn Asp Pro Glu Thr Asp Leu Ala Val Leu Lys Ile Asp
145	 150	 155	 160
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Leu Lys Asn Leu Pro Ala Ile Thr Ile Ala Arg Ser Asp Gly Ile Arg
165	 170	 175
Ile Gly Asp Val Ala Leu Ala Ile Gly Asn Pro Phe Gly Val Gly Gin
180	 185	 190
Thr Val Thr Met Gly Ile Ile Ser Ala Thr Gly Arg Asn Gin Leu Gly
195	 200	 205
Leu Asn Thr Tyr Glu Asp Phe Ile Gin Thr Asp Ala Ala Ile Asn Pro
210	 215	 220
Gly Asn Ser Gly Gly Ala Leu Val Asp Ala Ser Gly Asn Leu Ile Gly
225	 230	 235	 240
Ile Asn Thr Ala Ile Phe Ser Lys Ser Gly Gly Ser Gin Gly Ile Gly
245	 250	 255
Phe Ala Ile Pro Thr Lys Leu Ala Met Asp Val Met Lys Ser Ile Ile
260	 265	 270
Glu His Gly Gin Val Ile Arg Gly Trp Leu Gly Ile Glu Val Gin Pro
275	 280	 285
Leu Thr Gin Glu Leu Ala Glu Ser Phe Gly Leu Lys Asp Arg Pro Gly
290	 295	 300
Ile Val Val Ala Gly Ile Phe Arg Asp Gly Pro Ala Gin Lys Ala Gly
305	 310	 315	 320
Leu Gin Leu Gly Asp Val Ile Leu Ser Ile Asn Gly Glu Pro Ala Gly
325	 330	 335
Asp Gly Arg Arg Ser Met Asn Gin Val Ala Arg Thr Lys Pro Lys Asp
340	 345	 350
Lys Ile Ala Ile Asp Val Met Arg Asn Gly Lys Glu Met Arg Leu Ser
355	 360	 365
Ala Glu Val Gly Leu Arg Pro Pro Pro Ala Pro Thr Pro Ala Ala Ala
370	 375	 380
Pro Glu
385
<210> SEQ ID NO 36
<211> LENGTH: 386
<212> TYPE: PRT
<213> ORGANISM: Pseudomonas syringae
<400> SEQUENCE: 36
Met Phe Lys Ala Leu Arg Phe Phe Gly Trp Pro Leu Leu Ala Gly Val
1	 5	 10	 15
Leu Ile Ala Leu Leu Ile Ile Gin Arg Tyr Pro Gin Trp Val Gly Leu
20	 25	 30
Pro Ser Met Asp Val Asn Leu Gin Gin Ala Pro Gin Thr Thr Asn Val
35	 40	 45
Met Gin Gly Pro Ser Ser Tyr Ala Asp Ala Val Ile Ala Ala Ala Pro
50	 55	 60
Ala Val Val Asn Leu Tyr Thr Thr Lys Met Val Asn Lys Gly Thr Asn
65	 70	 75	 80
Pro Leu Phe Glu Asp Pro Gin Phe Arg Arg Phe Phe Gly Asp Asn Thr
85	 90	 95
Pro Lys Gin Lys Arg Met Glu Ser Ser Leu Gly Ser Gly Val Met Met
100	 105	 110
Ser Pro Glu Gly Tyr Ile Leu Thr Asn Asn His Val Thr Thr Gly Ala
115	 120	 125
Asp Gin Ile Val Val Ala Leu Lys Asp Gly Arg Glu Thr Ile Ala Arg
130	 135	 140
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Val Ile Gly Asn Asp Pro Glu Thr Asp Leu Ala Val Leu Lys Ile Asp
145	 150	 155	 160
Leu Lys Asn Leu Pro Ala Ile Thr Ile Ala Arg Ser Asp Gly Ile Arg
165	 170	 175
Ile Gly Asp Val Ala Leu Ala Ile Gly Asn Pro Phe Gly Val Gly Gin
180	 185	 190
Thr Val Thr Met Gly Ile Ile Ser Ala Thr Gly Arg Asn Gin Leu Gly
195	 200	 205
Leu Asn Thr Tyr Glu Asp Phe Ile Gin Thr Asp Ala Ala Ile Asn Pro
210	 215	 220
Gly Asn Ser Gly Gly Ala Leu Val Asp Ala Ala Gly Asn Leu Ile Gly
225	 230	 235	 240
Ile Asn Thr Ala Ile Phe Ser Lys Ser Gly Gly Ser Gin Gly Ile Gly
245	 250	 255
Phe Ala Ile Pro Thr Lys Leu Ala Met Asp Val Met Lys Ser Ile Ile
260	 265	 270
Glu His Gly Gin Val Ile Arg Gly Trp Leu Gly Ile Glu Val Gin Pro
275	 280	 285
Leu Thr Pro Glu Leu Ala Glu Ser Phe Gly Leu Lys Asp Arg Pro Gly
290	 295	 300
Ile Val Val Ala Gly Ile Phe Arg Asp Gly Pro Ala Gin Lys Ala Gly
305	 310	 315	 320
Leu Arg Leu Gly Asp Val Ile Leu Ala Ile Asn Gly Glu Pro Ala Gly
325	 330	 335
Asp Gly Arg Arg Ser Met Asn Gin Val Ala Arg Thr Lys Pro Lys Asp
340	 345	 350
Lys Ile Ala Ile Asp Val Met Arg Asn Gly Lys Glu Met Arg Leu Ser
355	 360	 365
Ala Glu Val Gly Leu Arg Pro Pro Pro Ala Pro Thr Pro Ala Ala Ala
370	 375	 380
Pro Glu
385
<210> SEQ ID NO 37
<211> LENGTH: 386
<212> TYPE: PRT
<213> ORGANISM: Pseudomonas syringae
<400> SEQUENCE: 37
Met Phe Lys Ala Leu Arg Phe Phe Gly Trp Pro Leu Leu Ala Gly Val
1	 5	 10	 15
Leu Ile Ala Met Leu Ile Ile Gin Arg Tyr Pro Gin Trp Val Gly Leu
20	 25	 30
Pro Ser Leu Asp Val Asn Leu Gin Gin Ala Pro Gin Thr Thr Asn Val
35	 40	 45
Met Gin Gly Pro Ser Ser Tyr Ala Asp Ala Val Ile Ala Ala Ala Pro
50	 55	 60
Ala Val Val Asn Leu Tyr Thr Thr Lys Met Val Asn Lys Gly Asn Asn
65	 70	 75	 80
Pro Leu Phe Glu Asp Pro Gin Phe Arg Arg Phe Phe Gly Asp Asn Thr
85	 90	 95
Pro Lys Gin Lys Arg Met Glu Ser Ser Leu Gly Ser Gly Val Met Met
100	 105	 110
Ser Pro Glu Gly Tyr Ile Leu Thr Asn Asn His Val Thr Thr Gly Ala
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115	 120	 125
Asp Gln Ile Val Val Ala Leu Lys Asp Gly Arg Asp Thr Ile Ala Arg
130	 135	 140
Val Ile Gly Asn Asp Pro Glu Thr Asp Leu Ala Val Leu Lys Ile Asp
145	 150	 155	 160
Leu Lys Asn Leu Pro Ala Ile Thr Ile Ala Arg Ser Asp Ser Ile Arg
165	 170	 175
Ile Gly Asp Val Ala Leu Ala Ile Gly Asn Pro Phe Gly Val Gly Gln
180	 185	 190
Thr Val Thr Met Gly Ile Ile Ser Ala Thr Gly Arg Asn Gln Leu Gly
195	 200	 205
Leu Asn Thr Tyr Glu Asp Phe Ile Gln Thr Asp Ala Ala Ile Asn Pro
210	 215	 220
Gly Asn Ser Gly Gly Ala Leu Val Asp Ala Ser Gly Asn Leu Ile Gly
225	 230	 235	 240
Ile Asn Thr Ala Ile Phe Ser Lys Ser Gly Gly Ser Gln Gly Ile Gly
245	 250	 255
Phe Ala Ile Pro Thr Lys Leu Ala Met Asp Val Met Lys Ser Ile Ile
260	 265	 270
Glu His Gly Gln Val Ile Arg Gly Trp Leu Gly Ile Glu Val Gln Pro
275	 280	 285
Leu Thr Gln Glu Leu Ala Glu Ser Phe Gly Leu Lys Asp Arg Pro Gly
290	 295	 300
Ile Val Val Ala Gly Ile Phe Arg Asp Gly Pro Ala Gln Lys Ala Gly
305	 310	 315	 320
Leu Gln Leu Gly Asp Val Ile Leu Ser Ile Asn Gly Glu Pro Ala Gly
325	 330	 335
Asp Gly Arg Arg Ser Met Asn Gln Val Ala Arg Thr Lys Pro Lys Asp
340	 345	 350
Lys Ile Ala Ile Asp Val Met Arg Asn Gly Lys Glu Met Arg Leu Ser
355	 360	 365
Ala Glu Val Gly Leu Arg Pro Pro Pro Ala Pro Thr Pro Val Ala Ala
370	 375	 380
Pro Glu
385
What is claimed is: 	 5. The method of claim 2, wherein said probe comprises a
detectable label.
1. A method for detecting the emergence of mucoidy in a 6. Themethod of claim 5, whereinthe label is selectedfromPseudomonas bacterium obtained from a specimen, compris- 55
ing (a) obtaining the specimen from a patient; and (b) mea- the group consisting of: a radioactive label, an enzymatic
suring MucE expression, wherein an increase in MucE label, a fluorescent label, a biotinylated label, and a chemilu-
expression over baseline is indicative of the emergence of minescent label.
mucoidy, and wherein the MucE expressed is wild-type 7. The method of claim 1, wherein MucE expression is
MucE.	 60 measured with a MucE antibody or fragment thereof.
2. The method of claim 1, wherein MucE expression is 8. Themethodof claim 7, whereinthe antibody orfragment
measured with a nucleic acid probe for MucE.
thereof comprises a detectable label.3. The method of claim 2, wherein MucE expression is
measured via Northern Blot, RT-PCR, or real-time RT-PCR. 9. The method of claim 8, wherein the detectable label is
4. The method of claim 2, wherein said probe comprises at 65 selected from the group consisting of: a fluorophore, an
least 15 contiguous nucleotides of SEQ ID NO: 1 or the enzyme, a luminescent compound, a radioisotope, and a par-
complement thereof. ticle.
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10. The method of claim 7, wherein the antibody or frag-
ment thereof binds a MucE protein encoded by a polynucle-
otide encoding amino acids —36 to 53 of SEQ ID NO: 2.
11. The method of claim 7, wherein the antibody or frag-
ment thereof is used in an ELISA assay.
12. The method of claim 1, wherein said specimen is col-
lected from a human.
13. The method of claim 12, wherein the specimen is
selected from the group consisting of blood, sputum, wound
exudate, respiratory secretion, tissue or a laboratory culture
thereof, and urine.
14. The method of claim 12, wherein the human suffers
from Cystic Fibrosis.
15. The method of claim 1, wherein the Pseudomonas
bacterium is Pseudomonas aeruginosa.
16. The method of claim 1, wherein said detection occurs at
least 12 hours before a mucoid colony morphology emerges.
88
17. The method of claim 16, wherein said detection occurs
at least 24 hours before a mucoid colony morphology
emerges.
18. The method of claim 1, wherein said increase in MucE
5 expression over baseline is at least a six fold increase.
19. The method of claim 13, wherein the specimen is lung
tissue.
20. A method for detecting the emergence of mucoidy in a
10 Pseudomonas bacterium, comprising: (a) obtaining a
Pseudomonas bacterium suspected of conversion to
mucoidy; and (b) measuring MucE expression, wherein an
increase in MucE expression over baseline is indicative of the
emergence of mucoidy, and wherein the MucE expressed is
15 wild-type MucE.
